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Ras proteins are the most commonly mutated oncoproteins in cancer (~30%). Oncogenic, 
activating Ras mutations are known drivers of the deadliest human cancers, including lung, 
pancreatic and colorectal cancers. Ras proteins function as critical regulators of cellular growth 
by acting as molecular switches, cycling between active, GTP- and inactive, GDP-bound states. 
In their active form, Ras proteins signal through downstream pathways that regulate cellular 
growth, differentiation and apoptosis. Early attempts to target Ras proteins (farnesyltransferase 
inhibitors) were directed toward inhibiting key carboxyl (C)-terminal lipid post-translational 
modifications (PTMs), which are crucial for proper Ras localization and function at the cellular 
membrane. Despite their failure, FTIs represent the first direct targeting efforts of Ras proteins.  
 Promising new classes of anti-cancer drugs directed at targeting the dysregulation of 
PTM status in cancers (kinase inhibitors, histone deacetylase inhibitors, HDACi and 
methyltransferase inhibitors) have demonstrated multiple clinical successes in recent years. 
PTMs have been demonstrated to alter protein stability and localization as well as protein-protein 
interactions in several non-histone cancer-related proteins. While PTMs have been extensively 
studied in the C-terminus of Ras proteins, their role remains poorly understood in the core Ras 
guanine nucleotide binding domain (GTPase domain). Monoubiquitylation and acetylation 
within the core Ras GTPase domain have been demonstrated to modulate Ras protein activity, 
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signaling and tumorigenesis, suggesting that PTMs in this region are capable of regulating Ras 
behavior. Further, aberrant dysregulation in the balance of PTMs has been characterized in 
several cancer types, including the Ras-driven pancreatic cancer. It is therefore reasonable that 
Ras PTMs may present a novel avenue for therapeutic targeting in cancer. Despite more than 
three decades of research, Ras has remained an elusive target for cancer therapy. 
We have recently identified novel sites of PTMs in Ras proteins at highly conserved 
residues within the core GTPase domain. Herein, we present highly innovative and novel 
methods of generating both acetyl- and methyl-lysine in intact Ras proteins. With the combined 
use of biochemical, structural, cellular and computational data, we provide mechanistic insight 
into the regulation Ras proteins by PTMs and also provide rationale for novel therapeutic 
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Chapter 1 – Introduction to the Ras superfamily of GTPases and Ras proteins 
Ras Proteins as GTPases 
 Ras proteins are members of the larger Ras superfamily of guanine nucleotide binding 
proteins, which are classified by a highly conserved structural domain (1). The Ras subfamily 
contains approximately 40 members in humans (2)–(4). The three human Ras genes encode for 
four Ras proteins (HRas, NRas, KRas-4A and KRas-4B). Two Ras isoforms, KRas-4A and 
KRas-4B, arise from alternate RNA splice variations of the same Ras gene. KRas-4B (further 
referred to as KRas) is the predominant Ras isoform expressed in human cells and is the most 
commonly mutated Ras isoform (4),(5). These small (21 kDa) proteins are classified as 
guanosine triphosphatases, GTPases, as they bind GDP and GTP with high affinity and can 
slowly hydrolyze GTP to GDP. As the intrinsic rate of nucleotide dissociation and hydrolysis is 
slow (6), Ras proteins interact with modulatory factors to fine-tune their activation status in cells. 
GEFs, guanine nucleotide exchange factors, and GAPS, GTPase activating proteins, serve as 
modulatory proteins to further aid in maintaining the proper GTP/GDP balance of Ras proteins in 
vivo (7)–(9) (Figure 1.1). GEFs activate Ras proteins by facilitating the release of GDP primarily 
through a restructuring of the nucleotide binding site and displacement of a critical magnesium 
ion, allowing for the subsequent loading of GTP (10). GAPs play the opposite role of GEFs, 
aiding in the hydrolysis of GTP to GDP and thereby converting Ras proteins to an ‘off’ or 
inactive state (9). In particular, the critical ‘arginine finger’ in GAPs inserts itself into the Ras 
active site, stabilizing the catalytic glutamine 61 and allowing for proper coordination of a water 
molecule for nucleophilic attack at the γ-phosphate of GTP (11)–(13). In the unstimulated cell, 
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Ras proteins are predominately GDP-bound and inactive. After proper membrane localization, 
Ras proteins are capable of being activated. One mechanism of Ras activation involves upstream 
receptor tyrosine kinases (RTKs). Receptor activation via an external stimuli triggers 
phosphorylation of the internal portion of the receptor and subsequent recruitment of scaffolding 
and modulatory proteins to the cellular membrane, which in turn serves to activate Ras proteins 
at the membrane (14). When bound to GTP, Ras proteins assume a conformation that confers 
high affinity binding to downstream effector proteins (15),(16), initiating signaling through 
downstream pathways to regulate multiple aspects of cellular growth, differentiation and 
apoptosis (4),(17) (Figure 1.1).  
 
Figure 1.1. Ras Regulation and Effector Binding 
Ras proteins cycle between “off” and “on” states with the aid of the modulatory factors, GEFs (guanine 
nucleotide exchange factors) and GAPs (GTPase activating proteins), A. In their active form, Ras proteins 
display significantly higher affinity to their downstream effector proteins, which promotes binding and 
signaling through Ras-mediated signaling cascades (16), B. 
Ras History and Signaling in Cancer 
The discovery and report of the previously ‘unknown’ rat retroviruses in the 1960s and 
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1970s were the first glimpses into what we now know as Ras oncoproteins (18),(19). In hallmark 
discoveries in 1980s, Ras genes were discovered in human cancers and their role in driving 
oncogenic cancer cell transformation was first described (20)–(23). This has triggered decades of 
extensive research, aimed at therapeutically targeting and understanding Ras oncoproteins as 
drivers of human cancers. To date, no clinically effective anti-Ras therapies have been developed 
(24). 
Ras proteins are some of the most commonly mutated oncoproteins in human cancers 
(25). Oncogenic, gain-of-function mutations in Ras genes promote Ras protein hyper-activation 
and are present in approximately 30% of the most deadly human cancers, including melanoma, 
lung, pancreatic and colorectal cancers (5),(17),(26). While the ability of wild-type Ras proteins 
to serve as tumor suppressors is still in debate (27), ‘hotspot’ mutations in Ras proteins are 
known to be oncogenic drivers (4). These ‘hotspot’ mutations are located at three primary 
residues in the highly conserved Ras core GTPase domain: glycine (G) 12, glycine (G) 13, and 
glutamine (Q) 61 (Figure 1.2) (4),(5),(17). Mutations at these positions are known to activate 
Ras proteins by altering nucleotide binding and/or exchange directly or indirectly through 
altering the ability of GAPs to properly elicit their function (5),(17),(26),(28). Interestingly, Ras-
driven cancers display striking isoform- and mutation-specific preferences in each tissue type 
(5). For example, KRas proteins are mutated predominately at glycine 12 whereas NRas proteins 
harbor glutamine 61 mutations (4),(5),(29). HRas proteins on the other hand, have very similar 
mutation rates between the ‘hotspot’ G12, G13 and Q61 locations (Figure 1.2) (4),(5),(26). It 
has also been demonstrated that different Ras oncogenic mutations exhibit unique activity 
profiles (17),(28),(30),(31) and differentially affect clinical outcome (32). Historically, the 
majority of research on Ras proteins has been conducted on the HRas isoform (1). However, this 
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is the least frequently mutated Ras isoform in human cancers (~4%). This is followed by NRas, 
which is mutated in approximately 11% of human cancers. KRas proteins are by far the most 
mutated of the isoforms, revealing an almost 85% mutation rate in Ras-driven cancers 
(4),(5),(17). Ras-driven cancers also exhibit isoform preferences. Pancreatic ductal 
adenocarcinoma (PDAC) and colorectal cancers (CRC) are driven by oncogenic KRas proteins 
(nearly 100% of cases and ~86% of cases, respectively), whereas melanoma is driven by mutant 
NRas (~94% of cases) (4),(5),(26),(28). While HRas proteins are the least mutated of the Ras 
isoforms, they are known drivers of bladder urothelial carcinoma and head and neck squamous 
cell carcinoma (HNSCC) (4),(5),(26). Taken together, these data suggest a functionally unique 
role for each Ras isoform and mutation in cancer. Even though each of these mutations have a 
distinct mechanistic role in modulating Ras activity, the details of which are still under 
investigation, the outcome is similar in that they lead to a hyper-activated or constitutively 
activated form of Ras (17). This leads to aberrant downstream signaling to effector proteins and 
an upregulation of signaling through Ras-mediated pathways, resulting in dysregulation of 




Figure 1.2 Ras Mutations in Cancer. 
Ras proteins are oncogenic drivers in several of the deadliest cancers, including melanoma, lung (LAC), 
pancreatic (PDAC) and colorectal cancers (CRC). Strikingly, these cancers display tissue, mutation and 
isoform-specific preferences. 
Reprinted (adapted) with permission from Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016). RAS isoforms 
and mutations in cancer at a glance. Journal of Cell Science, 129(7), 1287–1292. Copyright 2016 Journal of 
Cell Science. 
 





Ras Structure and Dynamics 
The superfamily of Ras proteins are classified by a commonly conserved structural 
domain, the guanine-nucleotide binding domain, as Ras proteins bind GDP and GTP, which is 
critical to their activity (1). Ras isoforms are composed of a highly conserved core guanine 
nucleotide binding domain and a sequence divergent carboxy (C)-terminal hypervariable region 
(HVR). The C-terminal HVR is poorly conserved throughout the Ras isoforms (<10% sequence 
conservation) and undergoes isoform-specific post-translational modifications (PTMs) that 
facilitate proper membrane localization crucial for Ras activity (4),(5),(34). The core GTPase 
domain within N-, H- and KRas is highly similar (~90% sequence identity) and is composed of 
the effector and allosteric lobes. The effector lobe (residues 1-86) is strictly conserved and 
contains sites critical for nucleotide binding as well as for effector and regulator protein 
recognition (4),(26). Much less is known about the role of the allosteric lobe (residues 87-171) 
(4),(26). Ras proteins exhibit isoform-specific sequence differences within their allosteric lobe. 
While the effector lobe is 100% conserved between the Ras isoforms, the allosteric lobe contains 
several sequence differences between the Ras isoforms. Within their allosteric lobe, Ras proteins 
display less than 80% sequence homology (Figure 1.3A) (4),(5). Additionally, subsets of these 
sequence differences contain non-conservative substitutions. For example, -helix 3 in KRas is 
composed of charged, polar amino acids while in NRas this region is primarily nonpolar and not 
charged. This changes the entire electrostatic and solvent-exposed face of -helix 3. While the 
role of the allosteric lobe is poorly understood, this region may contribute to Ras isoform 
specificity and is postulated to play roles in effector recognition, regulator binding, membrane 




Figure 1.3. Ras Domain Architecture and Structure. 
A. Ras isoforms share a highly similar core GTPase domain but a highly dissimilar C-terminal hypervariable 
region (HVR). The effector lobe is strictly conserved between Ras isoforms and plays roles in 
effector/modulatory protein binding. The allosteric lobe houses isoform-specific sequence differences between 
Ras proteins, the roles of which are currently unknown. The c-terminal HVR is highly post-translationally 
modified, allowing for proper Ras location and activity at the cellular membrane. B. The Ras core GTPase 
domain (PDB 4LPK) is shown in cartoon representation. Core structural elements are labeled. The effector 
lobe is represented in grey and is the primary location of effector and regulatory protein interactions. The 
role of the allosteric lobe (teal) is more poorly understood and may contribute to Ras isoform-specificity. The 
highly dynamic switch regions are colored in red and blue for SWI and SWII, respectively. 
Structurally, the core GTPase domain is comprised of six -sheets and 5 -helices, taking 
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on a Rossmann-type fold of alternating -helices and -sheets (Figure 1.3B) (1). It is further 
divided into five different structural motifs (G1-G5). G1 contains the phosphate binding loop (P-
loop) that aids in coordinating the nucleotide within the Ras binding pocket. G2, more commonly 
termed ‘switch I’ (SWI, residues 32-38) is a highly dynamic region of Ras proteins that distinctly 
changes conformation upon nucleotide binding and exchange (41) (Figure 1.4). This region is 
also termed the ‘effector region’ as Ras effector proteins (such as the Raf kinases) are known to 
recognize and bind to Ras through this highly conserved region (Figure 1.5) (1),(41)–(43). G3 
comprises another highly dynamic region in Ras proteins, termed ‘switch II’ (SWII, residues 59-
67). Together with switch I, these regions describe the nucleotide-bound state of Ras (1). In an 
‘open’ conformation, Ras is GDP-bound and inactive. However, in a closed conformation, SWI 
and SWII residues aid in binding and coordinating the - and - phosphates of GTP, defining the 
active Ras conformation (Figure 1.4) (1),(41),(44),(45). G4 contains the critical NKXD motif in 
Ras proteins. These residues are essential in coordinating the binding of and providing specificity 
for the guanine-nucleotide base. Mutations at these residues greatly destabilize Ras nucleotide 
binding, resulting in increased protein activation (1),(46),(47). G5 is termed the SAK motif, 
where key interactions with the guanine nucleotide contribute to high affinity binding and 




Figure 1.4. Ras switch dynamics. 
Left, cartoon representation of the NMR structures of GDP-bound HRas (PDB 1CRP (48)). In the GDP-
bound form, Ras proteins exist in a more ‘open’ conformation, as seen by the increased conformational 
dynamics of SWII. Right, cartoon representation of the lowest energy NMR structures of GppNHp (GTP 
analogue)-bound HRasT35S (49). In the active, GTP-bound form the switch regions exist in a closed 
conformation, facilitating contacts with the - and -phosphates.                                                                                                                                       
Reprinted (adapted) with permission from Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., 
Nussinov, R., & Zhang, J. (2016). Ras Conformational Ensembles, Allostery, and Signaling. Chemical 
Reviews. https://doi.org/10.1021/acs.chemrev.5b00542. Copyright 2016 Chemical Reviews ACS. 
The ability to bind downstream effector proteins is also dependent upon the nucleotide-
bound state of Ras proteins. In the active, GTP-bound form, Ras proteins exhibit a significantly 
higher affinity to downstream effector proteins (15). Effector proteins such as the Raf kinases 
and PI3-kinases (phosphoinositide 3-kinase) bind Ras proteins within their Ras binding domain 
(RBD) through differential SWI and SWII residue engagement (Figure 1.5). These binding 
interfaces are often highly electrostatic in nature (42),(50),(51). Binding will also be a result of 
-strand pairing between Ras and the effector RBD (52). Effector binding and engagement will 
result in downstream signaling through Ras-mediated pathways. Ras effector proteins are not 
unique in their engagement of the switch regions. Ras GEFs and GAPs also interface with SWI 
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and SWII and the surrounding regions to engage with Ras proteins (13),(53),(54). 
 
Figure 1.5. Ras interactions with Raf and PI3K RBDs. 
Ras proteins interact with effector proteins primarily through the switch regions. Raf RBD (top figure, teal) 
interacts with Ras proteins (grey) through SWI (red) and β-strand pairing at the interaction interface (PDB 
4G0N (55)). Interactions shown are < 4.0 Å (56). PI3Kγ RBD (teal, bottom figure) also displays an interaction 
interface with β-strand pairing but engages both SWI (red) and SWII (blue) of Ras (grey) for binding (PDB 
1HE8 (50)). Binding interfaces in both models are shown as a surface. The switch regions are labeled 
accordingly. 
 Beyond effector and modulatory protein binding, the switch regions in Ras have been 
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implicated in an allosteric modulation mechanism. Several groups of inter-connected residues 
have been identified through computational simulations that propagate structural and dynamic 
changes upon effector binding from the N-terminus to the C-terminus of Ras (39). Results of 
these computational simulations indicate that the binding of effector proteins locked Ras in the 
active state, primarily due to the conformational restriction of SWI. Effector binding then 
stimulated conformational changes in unique residue groupings that stretch from the N- to C-
terminus of Ras (39),(40). While the dynamic switch regions are critical determinants of Ras 
activation state, their engagement in effector and regulatory protein binding can lead to larger 
global conformational and dynamic changes. These inside-out, allosteric structural changes are 
only beginning to be described in recent years and may serve to provide a more comprehensive 
understanding of Ras conformational and dynamic relationships alone and in complex with 
effector or regulatory proteins. 
Ras and Post-Translational Modifications 
Post-translational modifications (PTMs) in Ras have been primarily studied in the context 
of the C-terminal HVR, where they drive the differential localization of Ras isoforms (4),(37). It 
is well accepted that Ras proteins must be properly membrane localized to order to become 
activated. The C-terminus of Ras proteins are heavily post-translationally modified. The critical 
CAAX box and hypervariable regions are sites of post-translational lipid modifications (Figure 
1.3A). In all Ras proteins, the terminal cysteine (C) of the CAAX box is farnesylated followed 
by removal of the remaining –AAX by Rce1 (Ras and a-factor converting enzyme-1). This 
exposes the cysteine for carboxymethylation, and these actions promote weak membrane 
association (4),(57). Interestingly, the Ras isoforms display differential secondary processing 
within their C-terminal HVR that further enhances membrane association. HRas can additionally 
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be palmitoylated at two other sites, while NRas can be palmitoylated at one other site. The KRas-
4B HVR contains a polybasic lysine tail that is not further modified. This differential processing 
is thought to lead to isoform-specific trafficking at the cellular membrane (57)–(59).  Early 
attempts to target Ras proteins (farnesyltransferase inhibitors, FTIs) were directed toward 
inhibiting this key carboxyl (C)-terminal lipid modification, crucial for proper Ras localization 
and function at the cellular membrane. FTIs ultimately failed as NRas and KRas can undergo an 
alternative type of lipid modification (geranyl-geranylation) (60).  
Ras proteins are also post-translationally modified within their core GTPase domains (61) 
(Figure 1.6). However, the role of these PTMs has not been intensively studied. Importantly, 
PTMs in this region can directly regulate Ras activity. Monoubiquitylation has been identified at 
three sites within the core GTPase domain of Ras proteins: K104, K117 and K147 (62),(63). 
K147 is located in the conserved G5 box, which plays a role in the stabilization of the guanine 
nucleotide (1). Monoubiquitination at K147 has been demonstrated to up-regulate protein 
activity primarily through an insensitivity to GAP proteins, leading to persistent GTP-bound Ras 
(63). This was further verified in cellular studies where an amplified population of GTP-bound 
Ras was identified in RBD pulldown experiments (62). However, monoubiquitination at K147 
significantly impaired binding of activated Ras to the downstream effectors PI3Kγ, CRaf and 
RalGDS RBDs (64), which would seem to contradict the cellular findings. One possible 
explanation for increased RBD binding in cells could be due to an increased affinity of CRaf 
RBD to the GDP-bound from of monoubiquitinated Ras (64). Monoubiquitination of K117 in 
Ras also led to an activated phenotype in cells; however, this occurred through a unique 
mechanism (65). K117 is part of the NKxD motif and forms crucial interactions with the guanine 
nucleotide base (1),(46),(47). Mutations at K117 (K117R, K117N) have been demonstrated to 
 
 13 
increase rates of nucleotide exchange, in turn activating Ras proteins (46),(47),(66). These 
mutations have been demonstrated to promote tumorigenesis in human cancers and have also 
been identified in ‘Ras-opathies’ (developmental disorders characterized by Ras germline 
mutations). It was determined that monoubiquitination of K117 lead to increased guanine 
nucleotide dissociation rates, which served to activate Ras (65).   
Beyond ubiquitination, Ras proteins are also capable of being acetylated in the core 
GTPase domain at K104 (67)–(69). Lysine (K) 104 is a highly conserved residue in the Ras 
superfamily. Structurally, K104 is located in loop 7, following α-helix 3, in the Ras core G-
domain. In molecular dynamic simulations using an acetylation mimetic, glutamine (Q), Yang et 
al. identified that KQ mutation destabilized the α2 helix of SWII (67). They determined that 
the destabilization was primarily due to a disruption in the electrostatic interactions resulting 
from the KQ mutation (67). Given that these regions are critical for GEF-mediated nucleotide 
exchange, it was not surprising that K104Q mutation disrupted SOS-mediated exchange (67). 
Subsequent NMR studies using the same K104Q mutant indicated that the disruption of α2 was 
not as severe as predicted computationally, but partial helix disruption was able to be identified 
(69). In addition to the GEF defect, K104Q mutation in Ras also demonstrated a GAP defect 
(69). However, in cellular studies K104Q mutation in Ras did not significantly alter steady-state 
GTP levels, cellular growth or proliferation, leading to the conclusion that the GEF and GAP 
defects were compensatory in nature, and acetylation at K104 likely did not impact overall Ras 
activity (69). However, the validity of using canonical amino acids as a mimetic of PTMs is still 
under debate (70). Our lab and others were able to use a genetic approach to site specifically 
install Nε-acetyl-L-lysine into Ras proteins, generating natively acetylated lysine, and 
determined that natively acetylated Ras proteins exhibit much less of a harsh biochemical profile 
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than the acetylation mimetic, K104Q (68),(69). In fact natively acetylated Ras at K104 displayed 
no significant defects in intrinsic or GEF-mediated nucleotide exchange relative to wild-type 
protein, while K104A/R/Q all demonstrated both intrinsic and GEF-mediated exchange defects 
(68),(69). This work is described in detail in Chapter 4. Further, previous analysis using the 
acetylation mimetic K104Q identified HDAC6 and Sirt2 as the Ras deacetylates. However, these 
were not able to be verified when Ras proteins were natively acetylated at K104 (68). As PTMs 
are highly regulated in the cellular milieu, introduction of a foreign amino acid likely disrupts 
recognition sequences for regulatory/effector proteins, which is exemplified by these findings. 
Knyphausen et al. were able to identify the acetyltransferases responsible for acetylating Ras at 
K104 as CBP and p300 and also identified acetylation sites at K101, K128 and K147 using 
natively acetylated protein (68). In Chapter 2, we investigate the role of acetylation at a novel 










Figure 1.6. Ras proteins are extensively regulated by post-translational modifications. 
Here, a schematic of the Ras core G-domain is shown with Ras PTMs reported. On the top, HRas PTMs are 
identified, where KRas is on the bottom. We can see that Ras proteins are highly post-translationally 
modified both within their core G-domain and also their carboxy-terminal hypervariable regions. Several of 
these PTMs are known to regulate Ras activity. 
Reprinted (adapted) with permission from Ahearn, I. M., Haigis, K., Bar-Sagi, D., & Philips, M. R. (2012). 
Regulating the regulator: post-translational modification of RAS. Nature Reviews Molecular Cell Biology, 
13(1), 39–51. https://doi.org/10.1038/nrm3255. Copyright 2011, Springer Nature. 
Research in our lab and others has eluded to the identification of novel methylation sites 
within the core Ras G-domain. Several methylation sites have been identified, but their roles in 
regulating Ras activity are not clear (manuscripts submitted, data not shown). Aberrant 
methylation patterns have been described in several Ras-mediated signaling pathways and of Ras 
effector or modulatory proteins (71)–(75). Further, the Ras-driven cancer, pancreatic ductal 
adenocarcinoma (PDAC), displays strong dysregulation of crucial histone lysine 
methyltransferases (KMTs) and histone lysine demethylases (KDMs), which are responsible for 
modulating the methylation status in vivo (76). In fact, knockout of the KMT SMYD3 inhibited 
Ras-mediated tumorigenesis in mouse models for PDAC and lung cancer (77). MAP3K2 was 
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identified as a direct target of SMYD3 and its inhibition resulted in decreased MAPK signaling 
(73),(77). Taken together this data suggests that lysine methylation may be a novel therapeutic 
target in Ras-driven cancers. While the functional role of Ras methylation remains unclear, the 
role of methylation regulating other cancer-related proteins is well established. Lysine 
methylation (or acetylation) of the tumor suppressor gene p53, fine-tunes its overall activity in 
cancer (78),(79). Inhibitors of KMTs or KDMs present viable therapeutic opportunities in several 
cancer types (80). If Ras methylation contributes to aberrant growth control, methyltransferase 
inhibitors may represent a potential targeting mechanism. As most lysine PTMs in Ras occur at 
conserved sites involved in structural integrity or nucleotide binding (81), it is likely that these 
PTMs will alter the intrinsic function of the protein. In Chapter 5 I present novel methods to 
generate site-specifically methylated intact Ras proteins. This could be a crucial first step in 
understanding how methylation is capable of regulating Ras protein activity.  
Taken together, these data demonstrate the complexity by which Ras proteins are 
regulated by post-translational modifications. While our lab and others have demonstrated that 
Ras protein activity can be modulated by PTMs, namely acetylation and monoubiquitination, the 
mechanisms behind this regulation are complicated in nature. PTMs in the C-terminal HVR 
presented therapeutic opportunities in Ras proteins with farnesyltransferase inhibitors (60). This 
may also be the case with PTMs that occur in the core G-domain of Ras proteins. By 
understanding the distinct mechanisms by which PTMs elicit their activity in Ras proteins, we 
may develop novel therapeutic opportunities in Ras-driven cancers. 
Strategies to Therapeutically Target Ras Proteins: A Broad Overview 
 Early anti-Ras drug efforts were targeted at the C-terminal HVR of Ras proteins (FTIs, 
farnesyltransferase inhibitors). All Ras isoforms are farnesylated in their C-terminal CAAX box. 
 
 17 
Farnesylation of the C-terminal cysteine and subsequent proteolysis of -AAX leads to 
carboxymethylation of the terminal cysteine and facilitates proper Ras membrane localization, 
which is crucial for Ras activity (4),(57). FTIs were designed to inhibit the farnesyltransferase 
(FTase) responsible for acting on Ras proteins, thereby rendering them cytosolic and inactive 
(60). However, while FTIs were one of the first examples of rational drug design targeting Ras 
proteins, they were designed to be specific for the FTase and not for Ras itself. FTIs were 
successful at blocking the prenylation of HRas proteins, but this was not the case for N- or KRas 
proteins (60). It was soon discovered that in the presence of FTIs, N- and KRas could undergo 
alternative prenylation in the form of geranylgeranylation, allowing them to be effectively 
trafficked to the cellular membrane where they could be activated (4),(60),(82),(83). In recent 
years, the idea of blocking Ras membrane association has again become a topic of conversation. 
A salicylic acid derivative, Salirasib has been reported to dislodge prenylated Ras proteins from 
the cellular membrane. As a mimetic of farnesyl-cysteine, Salirasib has been reported to compete 
with farnesylated Ras binding sites at the cellular membrane (84)–(86). In cellular studies using 
human hepatocellular carcinoma cell lines, Salirasib was demonstrated to reduce Ras expression 
and activation and decreased phosphorylation of Akt, a readout of PI3-kinase pathway activation 
(85). In early preclinical trials in patient derived PDAC mouse xenograft studies, Salirasib in 
combination therapy demonstrated low overall toxicity, increased overall survival and decreased 
levels of signaling through both PI3-kinase and MAPK pathways as determined through western 
blotting (87). Unfortunately, in human phase 2 clinical trials of Salirasib in non-small cell lung 
cancer, low drug toxicity and good tolerance were noted but no increase in progression free 
survival was demonstrated (88). However, a more recent phase I clinical trial in Japanese 
patients with Ras positive solid tumors does indicate increased median progression-free survival 
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upon salirasib treatment (89). While these are preliminary studies, they bring to light the 
previous strategy of targeting Ras membrane localization as a potentially effective anti-Ras 
therapy.  
Since the failure of traditional FTIs, targeted Ras therapies are being pursued using both 
direct and indirect strategies. As Papke & Der outline, there are five general strategies for the 
development of anti-Ras therapeutics (83). These strategies include: 1) small molecules that bind 
directly to Ras proteins, disrupting interactions with regulatory/effector proteins, 2) inhibition of 
Ras membrane association/localization, 3) inhibition of Ras downstream effector signaling 
cascades, 4) inhibition of genes whose functions are crucial for mutant Ras (synthetic lethal 
interactions) and 5) inhibition of Ras-mediated metabolic processes (83),(86). Direct strategies to 
target Ras proteins have proven challenging as Ras proteins lack easily discernable druggable 
pockets on their surface, which greatly limits the efficacy of these approaches (24),(82). In recent 
years, potentially druggable novel pockets have been identified in Ras, and the hunt is on for 
specific and selective Ras therapeutics (24),(90),(91). One direct Ras targeting strategy that has 
garnered some initial successes has been the efforts to develop G12C-selective inhibitors. KRas 
G12C mutations have been identified in non-small cell lung cancer (NSCLC) and are associated 
with poor prognosis (92). Using the thiol of the cysteine mutation, G12C-selective inhibitors 
form covalent adducts with small molecules, thereby inhibiting GTP binding and rendering Ras 
inactive (83),(90),(93),(94). Currently there are 2 drugs that target Ras G12C in clinical trials for 
the treatment of G12C-specific Ras solid tumors. MRTX894 (clinical trial identifier 
NCT03785249) and AMG 510 (clinical trial identifier NCT03600883) are currently undergoing 
phase 1 and phase 2 clinical trials to determine safety and efficacy in human patients. These 
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drugs represent the first efforts for mutation-specific targeting of Ras proteins for the treatment 
of cancer. 
The most clinically successful inhibitors to date have been those that target downstream 
Ras effector signaling pathways. Arguably, the most important downstream Ras signaling 
cascade is the Ras/Raf/MEK/ERK (MAPK) cascade, responsible for regulating cellular 
proliferation (4),(82),(83),(95). However, given the multitude of Ras-regulated signaling 
pathways, targeting a specific pathway presents challenges due to significant pathway crosstalk 
and paradoxical activation (83). Initial efforts focused on developing direct inhibitors of Raf and 
MEK as a means to inhibit downstream ERK activation. However, this approach was not 
successful, as targeting BRaf led to paradoxical MAPK pathway activation due to compensatory 
CRaf activity (83). Since these initial findings, several generations of Raf, MEK and ERK-
specific inhibitors have been developed and have demonstrated varying levels of clinical success 
(83),(86). Pathway-specific inhibitors have also been developed for the PI3-kinase signaling 
cascade. However, there is contradicting evidence as to whether PI3K is a potent Ras effector or 
is its importance is situationally dependent (82). As monotherapies, inhibitors of the PI3K-AKT-
mTOR pathway have not demonstrated success in Ras-driven cancers (82),(83). While dual 
therapies targeting both MAPK and PI3K pathways seems promising, they have demonstrated 
limited clinical efficacy due to toxicity and drug-resistance concerns (83),(86).  
Very promising emerging classes of anti-cancer drugs directed at targeting the frequent 
dysregulation of PTM status in cancers (i.e. kinase inhibitors, methyltransferase inhibitors and 
histone deacetylase inhibitors, HDACi) have gained much interest in recent years. Kinase 
inhibitors, HDACi and methyltransferase inhibitors have shown multiple early and later phase 
clinical successes in the treatment of a myriad of non-solid tumor cancers (76),(96)–(99). 
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However, these drugs have not demonstrated successes as monotherapies in Ras-driven cancers. 
Ras proteins are known to be regulated by PTMs, and these PTMs has been demonstrated to 
modulate Ras activity (67)–(69). Recently, several labs have been able to demonstrate that 
HDACi are successful in Ras-driven cancers when administered as combination therapies (100)–
(102). In particular, the combination of a MEK inhibitor (trametinib, GSK1120212)+ PI3K 
inhibitor (belinostat, BEZ-235)+ HDAC inhibitor (TSA,SAHA or PDX101) resulted in >99% 
inhibition of cellular proliferation and dramatic induction of cellular apoptosis in pancreatic 
cancer cells (101). Additionally, a pan-HDAC inhibitor, Belinostat when combined with the 
MEK inhibitor, Trametinib functioned to synergistically decrease tumor formation in a mouse 
lung cancer xenograft model (102). This data suggests that HDACi may represent an untapped 
therapeutic potential in Ras-driven cancers. In addition to acetylation, methylation may also 
represent a therapeutically targetable PTM in Ras. It was recently discovered that there are 
significant alterations in methylation patterns and signaling in the Ras-driven cancer, PDAC 
(76). Additionally, the Ras-mediated MAPK signaling cascade has been demonstrated to be 
regulated by methylation. Methylation of MAP3K2 (MEKK2) by the methyltransferase SMYD3 
is linked to increases in MAPK signaling and promotes the formation of Ras-driven carcinomas 
in mouse models of PDAC and lung cancer (77). This effect was reversed in SMYD3 knock-out 
studies. This may suggest that lysine methylation is a tractable therapeutic target in Ras-driven 
cancers. HDACi and methyltransferase inhibitors have not been extensively studied in Ras-
driven cancers. This is due in part to the lack of clinical knowledge surrounding the exact 
mechanisms of drug action in non-histone proteins. Traditionally, HDACi and methyltransferase 
inhibitors have been studied in the realm of histone regulation (97),(103)–(106). However, it is 
becoming increasingly evident that PTMs are also capable of regulating non-histone proteins 
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(78),(79),(105). As such, PTMs may represent novel therapeutic opportunities in non-histone 















































Chapter 2. – HDACi treatment causes Ras acetylation, directing signaling through the 
MAPK pathway through a reordering of the Ras:Raf binding interface1 
Introduction 
Ras proteins are the most commonly mutated oncoproteins in cancer. They function as 
critical regulators of cellular growth by acting as molecular switches, cycling between active and 
inactive states (4),(17),(33). In their active form, two highly dynamic regions of Ras proteins, 
termed switch I and switch II, assume a conformation that confers high affinity binding to 
downstream effectors (15)–(17). Effector engagement then stimulates signaling through 
downstream pathways that regulate cellular growth, differentiation and apoptosis (17),(33). 
Oncogenic, gain-of-function mutations in Ras genes promote Ras protein hyper-activation and 
are present in approximately 30% of the most deadly human cancers, including melanoma, lung, 
pancreatic and colorectal cancers (5),(17). Mutationally activated Ras proteins have a well-
validated role in driving oncogenic cancer cell transformation (107), and mutations in Ras at 
position 12, 13 or 61 are particularly oncogenic, and are widely recognized as critical 
determinants of therapeutic response (107)–(109). Despite more than three decades of research, 
Ras has remained an elusive target for cancer therapy and is commonly considered undruggable 
(24). This has stimulated the search for comprehensive approaches to develop efficient 
therapeutic strategies to target mutant Ras proteins for cancer treatment. Early attempts to target 
Ras proteins (farnesyltransferase inhibitors, FTIs) were directed toward inhibiting a key carboxyl 
                                                 
1 Figures 2.1-2.4 and corresponding methods provided by Sylvia Ispasanie and Dr. Christine Sers, Charité 
Universitätsmedizin Berlin, Berlin, Germany. Figure 2.5 and corresponding method provided by Dr. Erik 
Soderblom, Duke Core Proteomics Facility. Figures 2.12-2.17 and corresponding methods were developed in 
collaboration with Dr. Konstantin Popov, UNC – Chapel Hill. 
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(C)-terminal lipid modification, crucial for proper Ras localization and function at the cellular 
membrane (4),(34),(60). Unfortunately, as NRas and KRas can undergo an alternative type of 
lipid modification (geranyl-geranylation), the use of FTIs as an anti-Ras targeted therapy was 
unsuccessful (60). Current approaches to target oncogenic Ras proteins are more focused on 
indirect strategies, including disruption of regulator or effector protein interactions and inhibiting 
downstream effector signaling pathways (83).  
Histone deacetylase inhibitors (HDACi) are a very promising emerging class of anti-
cancer drugs directed at targeting the frequent dysregulation of PTMs in cancers. Aberrant 
dysregulation of acetylation due to altered expression of HDACs or histone acetyl transferases 
(HATs) has been observed in several cancer types (110)–(112). Additionally, HDACi have 
shown multiple clinical successes in the treatment of a myriad of primarily non-solid tumor 
cancers (96). Historically, the effects of PTMs have been most extensively studied in histone 
regulation (113); however, acetylation of non-histone proteins is known to alter protein stability 
and localization as well as protein-protein interactions (105). While the role of acetylation in 
modulating protein activity in several cancer-related proteins such as p53 has been well 
established (79),(105),(114), the role of acetylation has not been thoroughly investigated in Ras-
driven cancers. Despite the early promise of HDACi, they have not proven to be a clinically 
viable monotherapy treatment option for Ras-driven solid tumors (106),(115). The rationale for 
this ineffectiveness is currently unknown. However, the use of an HDACi as part of a 
combination therapy has been reported as a successful therapeutic strategy, causing Ras-driven 
cancer cell death and tumor regression (100)–(102). In particular, when pancreatic cells were 
treated with a combination therapy of a MEK inhibitor (trametinib, GSK1120212)/ PI3K 
inhibitor (belinostat, BEZ-235)/ HDAC inhibitor (TSA,SAHA or PDX101), >99% of cellular 
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proliferation was inhibited and dramatic cellular apoptosis was induced (101). Further, belinostat 
(HDACi) combination therapy with a MEK inhibitor (trametinib) synergistically acted to 
decrease tumor formation in a mouse lung cancer xenograft model (102).  
Ras proteins have been reported to be acetylated within their core GTPase domain, but it 
is unclear exactly how acetylation modulates Ras activity (67)–(69),(116),(117). Acetylation of a 
receptor tyrosine kinase upstream of Ras, EGFR (epithelial growth factor receptor), causes 
enhanced signaling and sustained downstream activation, leading to resistance of tumor cells to 
HDACi treatment (118). Also, HDAC2 overexpression has also been identified in colorectal 
cancer (CRC) (96),(119)–(122) and it is correlated with poor survival (121). CRC is one of the 
leading causes of cancer deaths in the United States (123), and Ras proteins are mutated in 
approximately 52% of CRCs (5). These findings suggest that acetylation likely plays a role in 
regulating Ras-driven CRC, and therefore, HDACi may be an important and novel therapeutic 
option for Ras-driven cancers. Given the lack of clinical knowledge surrounding HDACi therapy 
in Ras-driven cancers, we have used cellular, biophysical and computational approaches to 
characterize the mechanism by which HDAC inhibitors display limited clinical utility as a 
monotherapy in Ras-driven CRC. This may lead to novel therapeutic approaches for the 
treatment of Ras-driven cancers.  
Herein, we have demonstrated that treatment of CRC cells with the class I HDACi, 
Entinostat resulted in acetylation of Ras at a novel site, lysine (K) 5. We were further able to 
demonstrate that K5 acetylation led to increased MAPK signaling, while not significantly 
affecting PI3K signaling. Increased MAPK signaling is likely caused by an increased affinity of 
the acetylated protein to the Raf RBD, which was verified in binding studies. Molecular dynamic 
studies demonstrated the formation of novel electrostatic contacts between acetylated Ras and 
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the Raf RBD and an overall restructuring of the highly electrostatic binding network, consistent 
with the increased affinity for Raf and subsequent increased signaling.  
Results 
Oncogenic Ras is an effective predictor of resistance to HDACi treatment. 
To gain insight into the limited clinical utilities of HDAC inhibitors as therapeutics in 
Ras-driven solid tumors the Sers lab conducted a drug sensitivity screen using a selection of 
HDACi on a panel of CRC cell lines that differ in their KRas or BRaf mutational status. 
Inhibitors that were chosen target either class I HDACs or both classes I and II, serving as pan-
HDAC inhibitors. Three of the selected inhibitors in the include the pan-HDAC inhibitors 
panobinostat (LBH589), belinostat (PXD101) and vorinostat (SAHA), all of which are US Food 
and Drug Administration (FDA)-approved for the treatment of multiple myeloma (MM), 
peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL), respectively 
(115),(124). Additionally included in the screen were the two narrow- spectrum, class I HDAC 
inhibitors, entinostat (MS-275) and the FDA-approved romidepsin (FK228) (115),(124). The 
CRC cell lines were treated with the HDACi for a total of 72 hours and the degree of cellular 
apoptosis was quantified as the percentage of cells that displayed cleaved caspase-3, a marker of 
cellular apoptosis, as analyzed by flow cytometry (Figure 2.1A). The extent of the apoptosis was 
further investigated based on the levels of cleaved PARP and visualized by immunoblotting 
(Figure 2.1B). Interestingly, upon treatment with the class I HDACi, MS-275 and FK228, they 
were able to observe two distinct cellular response profiles based on whether the CRC cells 
harbored KRas WT or oncogenic KRas. Cell lines that harbored KRas WT were unanimously 
more sensitive to HDACi treatment with more than 50% of the cells being apoptotic, while cells 
with oncogenic KRas exhibited a markedly more resistant phenotype with less than 20% of cells 
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being apoptotic (Figures 2.1A, B). They were further able to demonstrate that in the presence of 
the oncogenic BRaf V600E mutant, cells harboring KRas WT demonstrated no alterations in their 
sensitivity profiles. This suggested a mechanism dependent upon KRas and not the oncogenic 
BRaf V600E-mediated dysregulation of the downstream MAPK-signaling cascade. To confirm 
that oncogenic Ras is an adequate predictor of resistance to HDAC inhibitor treatment, in 
particular the class I HDACi MS-275 (Entinostat), an isogenic system using CaCO-2 cells 
transduced with either KRas G12V or KRas WT was employed to allow for conditional 
expression of the respective proteins. Upon expression of the oncogenic KRas G12V, a 
significant reduction in apoptotic cells and a subsequent dramatic shift towards a more resistant 
phenotype with close to a 5-fold increase in the IC50 was revealed. This phenomenon was not 
observed with an induced expression of KRas WT, which displayed a largely unchanged 
response profile. Taken together these results suggest that oncogenic KRas G12V is a predictor 







Figure 2.1. Oncogenic Ras is an effective predictor of resistance to HDAC inhibitors. 
A. Heatmap representing the degree of sensitivity to HDAC inhibitors. 15 CRC cell lines were treated with 
either DMSO (0.1% v/v), MS-275 (5 μM), FK228 (5 nM), SAHA (5 μM), PXD101 (1 μM) or LBH589 (750 
nM) for 72 hrs. The level of apoptosis was determined based on the percentage of cleaved capspase-3 positive 
cells as detected by flow cytometry. The white end of the spectrum denotes no detectable apoptosis (< 5%), 
while the blue end of the spectrum represents increasing to complete activation of apoptosis (100%). KRas 
and BRaf mutational status is indicated in left column. Data were compiled as mean ± standard deviation B. 
The mutational status of KRas determines the degree of MS-275-induced apoptosis as based on the level of 
cleaved PARP (poly ADP-ribose polymerase). 11 CRC cell lines from A, were treated with either DMSO 
(0.1% v/v) or MS-275 (5 μM) for a total of 72 hrs. Samples were immunoblotted with the indicated 
antibodies. C. A KRAS G12V-dependent decrease in sensitivity to MS-275 treatment. CaCO-2 KRAS WT and 
CaCO-2 KRAS G12V cells were treated with either DMSO (0.1% v/v), MS-275 (5 μM) (left) or increasing 
concentration of MS-275 (right) for 72 hrs. The ectopic expression of KRAS WT and KRAS G12V was 
initiated with doxycycline (2 μg/ml) 72 hrs prior and maintained for the full duration of the experiment. The 
level of apoptosis (left) was determined as in A, while growth inhibition was measured using XTT 
(tetrazolium salt) cell proliferation assay (colorimetric assay for quantification of cellular proliferation). For 
the latter, the IC50 values are indicated. *Data collected by the Sers lab. 
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KRas is acetylated at position K5 in response to MS-275 treatment.  
KRas has been reported to be regulated via post-translational acetylation at lysine 104 
(K104) and lysine 147 (K147), with HDAC6 and SIRT2 serving as the lysine deacetylases 
modulating these processes (67)–(69),(125),(126). In order to investigate whether the resistance 
to the HDACi MS-275 observed upon expression of oncogenic KRas G12V protein is a 
consequence of modulation of the acetylation state of Ras, the Sers lab assessed the overall 
acetyl-lysine levels of immunoprecipitated Ras from CaCO-2 cells ectopically expressing either 
KRas WT or KRas G12V. Immunoblotting data demonstrated that irrespective of the mutational 
status of KRas, treatment with MS-275 resulted in elevated levels of detected acetyl-lysine 
(Figure 2.2A). This data suggests that MS-275 induced therapeutic resistance via modulation of 
acetylation state in oncogenic KRas G12V proceeds via a mechanism unique or perpetuated by 
oncogenic Ras that is distinct from KRas WT. In order to determine which residue was being 
acetylated in Ras proteins independent immunoprecipitation followed by protein shotgun LC-
MS/MS analysis was conducted. Intriguingly, only one lysine residue, K5 where acetylation was 
detected as a consequence of treatment with MS-275 was identified (Figure 2.2B). To verify that 
acetylation of K5 was solely responsible for the observed increase in detectable levels of 
acetylated lysine identified in response to MS-275 treatment, substitution mutants were made at 
K5. K5 was substituted for either alanine (K5A) or arginine (K5R). This functioned to eliminate 
the detectable overall lysine acetylation, permanently locking KRas in a constitutively 
deacetylated state upon MS-275 treatment. This indicated that K5 is likely to be the only 
acetylated lysine residue in this context (Figure 2.2C). K5 has not been identified previously as 
a site of post-translational modification in Ras proteins. Here, the Sers lab has identified a novel, 
physiologic acetylation site in Ras proteins in response to MS-275 HDACi treatment. As this is a 
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previously unidentified acetylation site in Ras proteins, the functional consequence of acetylation 
at K5 are unknown. 
 
Figure 2.2. HDAC inhibition promotes KRas acetylation 
A. Detection of acetyl-lysine of immunoprecipitated KRAS. CaCO-2 KRas WT and CaCO-2 KRas G12V cells, 
with an induced ectopic expression of the respective proteins, were treated with either DMSO (0.1% v/v) or 
MS-275 (5 μM) for 72 hrs. Total Ras was immunoprecipitated and acetyl-lysines (AcK) on KRas were 
detected by immunoblotting. B. Identification of the acetylated lysine residue by LC/MS/MS analysis of 
immunoprecipitated KRas G12V. C. Effect of K5A and K5R substitution mutations on overall lysine 
acetylation of KRas G12V. Ectopically expressed KRas G12V, KRas G12V-K5A and KRas G12V-K5R were 
immunoprecipitated form CaCO-2 cells treated as in A. Acetylated lysine on KRas was detected by 
immunoblotting. *Data collected by the Sers lab. 
MS-275 induced acetylation of Ras increases the steady-state Ras-GTP levels in cells. 
 As the role of K5 acetylation has not been previously described in Ras proteins, we next 
assessed the impact that acetylation at K5 has on the biological function of KRas. We first 
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evaluated whether MS-275 treatment and Ras acetylation were capable of modulating the overall 
activation status of Ras in cells. As Ras proteins bind to their downstream effectors in a GTP-
dependent manner (15), Raf-RBD (Ras binding domain) pulldown assays can be used to evaluate 
the GTP-bound population of Ras proteins in cells (127). The Raf-RBD pull-down assay 
revealed an immediate and persistent increase in the steady-state GTP-bound levels of KRas 
following treatment with MS-275. This effect was observed independent of KRas mutational 
status (Figure 2.3A). Although the steady-state GTP-bound level of KRas is expectedly 
significantly higher in the context of oncogenic KRas G12V relative to KRas WT, the magnitude 
of the change that occurs due to MS-275 treatment exhibits an overall similar tendency. To 
confirm that acetylation at K5 is solely responsible for the increase in the level of KRas-GTP 
complexed with the Raf RBD, the Sers lab assessed whether K5A or K5R substitution mutations 
would restore the KRas WT-GTP population in cells. However, in K5A and K5R KRas mutants, 
moderate increases in the steady-state GTP levels in cells relative to wild-type protein were 
observed (Figure 2.3B). Interestingly, KRas germline mutations at K5 have been identified in 
several Ras-driven genetic disorders, and these mutations have been demonstrated to increase the 
GTP-bound population of Ras in cells leading to increased downstream MAPK signaling (128). 
However, the mechanism by which K5 mutations activate Ras proteins is unknown (128). It is 
therefore likely that K5A and K5R KRas mutants are altering the relative GTP-bound population 




Figure 2.3. HDAC inhibition increases the steady-state levels of KRas-GTP complexed with Raf-RBD 
A. MS-275-induced changes in steady-state GTP-bound KRas levels. Cells were treated with either DMSO 
(0.1% v/v) or MS-275 (5 μM) for 72 hrs. Changes in the levels of KRas G12V-GTP and KRas WT-GTP 
pulled-down with Raf1-RBD agarose beads were assayed in the absence and presence of an induced ectopic 
expression of the respective proteins and detected by immunoblotting analysis. B. Effect of K5A and K5R 
mutations on MS-275-induced changes in steady-state GTP-bound KRas levels. Changes in the levels of KRas 
G12V-GTP, KRas G12V-K5A-GTP and KRas G12V-K5R-GTP were assessed as described in A. 
 
MS-275 induced acetylation of Ras results in preferential signaling through the downstream Raf-
MAPK signaling cascade. 
 KRas K5 germline mutations are associated with increased GTP-levels in cells and 
potentiate signaling via the downstream Raf-MAPK signaling cascade in Ras-driven genetic 
disorders (128)–(130). In addition, K5 is also highly conserved in the Ras superfamily of 
proteins (4). Taken together, this suggests that K5 is an important site in regulating the function 
and activity of Ras proteins. Given this data and the identification of an increase in the GTP-
bound population of Ras in Raf RBD pulldown assays, we would expect that acetylation at K5 
would likely also lead to altered downstream signaling via Ras-mediated pathways. Therefore, 
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the Sers lab assessed whether MS-275 treatment and acetylation of Ras at K5 led to altered 
MAPK-mediated downstream signaling. They uncovered that only in the setting of an oncogenic 
KRas G12V were they able to observe hyper-activation of the downstream MAPK signaling 
cascade due to MS-275 treatment. This is marked by an increase in the phosphorylation of 
MEK1/2 and ERK1/2 (Figure 2.4A). In case of KRas WT, this remained largely unchanged. This 
identified disparity is not entirely unexpected as oncogenic KRas G12V is known to populate a 
constitutively activated phenotype primarily due to the lack of GAP-stimulated GTP hydrolysis 
(4),(5),(27),(33). In response to MS-275 treatment, acetylation of K5 in KRas G12V resulted in 
further increase in MAPK pathway activation. No observed defect was identified in PI3K 
signaling (data not shown).  
 
Figure 2.4. HDAC inhibitor treatment potentiates MAPK-mediated signaling 
MS-275-induced hyperactivation of MAPK-signaling in KRas G12V expressing cells. CaCO-2 KRas WT and 
CaCO-2 KRas G12V were treated with either DMSO (0.1% v/v) or MS-275 (5 μM) for 24, 48 and 72 hrs. 
Changes in the levels of MAPK-signaling components were assayed in the absence and presence of an induced 
ectopic expression of the respective proteins. Samples were immunoblotted with the indicated antibodies.  
In vitro acetylation of KRas results in mild GEF and GAP defects and thermal instability. 
Despite being a highly conserved residue in the core GTPase domain of Ras proteins 
(4),(34), the functional role of K5 has until now remained an uncertainty. Structurally, K5 is 
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located in the 1 sheet of Ras and extends into a region known to be important for GEF, GAP 
and effector protein recognition and binding (16),(53),(131).  To explore the possibility that 
acetylation of K5 is capable of altering Ras activity in vitro, we generated KRas protein 
containing acetyl-lysine at position K5 using an unnatural amino acid approach. Here, a cognate 
pair of tRNACUA/tRNA synthase was used to direct the installation of  Nε-acetyl-lysine into 
KRas in response to an amber codon at the genetic level, in a manner similar to as described 
previously (68),(132),(133). Incorporation of acetyl-lysine was verified by mass spectrometry to 
be greater than 95% (Figure 2.5A,B).  
Cellular studies conducted by the Sers lab demonstrate an equal increase in Ras-GTP 
levels as identified by Raf RBD pulldowns independent of mutational status due to MS-275 
treatment and therefore Ras acetylation (Figure 2.3A). This suggests that regulation of Ras 
activation due to K5 acetylation likely occurs via a similar mechanism in wild-type and 
oncogenic KRas G12V. This would hold true despite the propensity of oncogenic KRas G12V to 
remain in an activated phenotype due to significantly impaired GAP-mediated hydrolysis 
(4),(5),(27),(33). In order to assess the activation of Ras proteins in vitro we evaluated intrinsic 
and regulator-mediated nucleotide cycling and hydrolysis rates using fluorescence-based 
methods (134),(135). Alterations in the ability of Ras proteins to cycle their nucleotides could 
lead to the activated phenotype of acetylated Ras proteins in cells. We were able to identify no 
significant defects in the ability of KRas WT or KRas K5 acetylated proteins to intrinsically 
cycle GDP (4.23±1.07 x 10-4 s-1 vs. 3.67±0.691 x 10-4 s-1 for KRas WT and acetylated protein, 
respectively) or GMPPCP, a GTP analogue (40.7±0.278 x 10-4 s-1 vs. 42.3±0.404 x 10-4 s-1 for 
KRas WT and acetylated protein, respectively). We also demonstrated similar rates of intrinsic 
GTP hydrolysis in KRas WT and KRas K5 acetylated proteins (2.94±0.219 x 10-4 s-1 vs. 
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2.85±0.326 x 10-4 s-1 for KRas WT and acetylated protein, respectively) (Figure 2.7, A-D). 
Interestingly, we were able to identify mild defects in the ability of acetylated KRas protein to 
undergo regulator-mediated nucleotide exchange and hydrolysis, with larger defects observed in 
the activated form of Ras proteins. Slower GMPPCP nucleotide exchange (348±6.97 x 10-4 s-1 
vs. 182±1.83 x 10-4 s-1 for KRas WT and acetylated protein, respectively) and GTP hydrolysis 
rates (24.3±0.277 x 10-4 s-1 vs. 9.96±0.178 x 10-4 s-1 for KRas WT and acetylated protein, 
respectively) in the presence of GEFs and GAPs may demonstrate a propensity for acetylated 
Ras proteins to remain in the active, GTP-bound form (Figure 2.6, A-D), although the noted 
defects are small in nature. Compiled nucleotide exchange and hydrolysis rates can be seen in 
Table 2.1. SOS is known to coordinate nearly every sidechain of the SWII region of Ras 
proteins. At the core of these interactions is a hydrophobic network in Ras proteins containing 
Y71 (54). K5 is noted to pack against Y71 particularly in the GDP-bound form (128). 
Acetylation could lead to alteration of Y71 and further disruption of the critical hydrophobic 
network in Ras that is responsible for placing SWII in the proper conformation for SOS binding. 
A similar disruption of SWII could lead to altered ability of acetylated Ras protein to undergo 
GAP-mediated hydrolysis (136).  However, as the identified defects are small in nature, this 
suggests that SWII is largely unperturbed. K5 acetylation may therefore impact SWII very 




Figure 2.5. Mass spectrometry identification and characterization of acetylated KRas  
Full-MS spectra of intact KRas protein verifies acetylation. Unmodified wild-type Ras (top panel, 19230.74 
Da), acetylated wild-type Ras (middle panel, 19272.743 Da) and acetylated G12V Ras (bottom panel, 






Figure 2.6. GEF and GAP-mediated defects identified in acetylated KRas 
A. Fluorescence-based assays were used to determine the rates of nucleotide exchange and hydrolysis in the 
presence and absence of regulatory proteins. KRas WT and KRas K5 acetylaed proteins were loaded with 
Mant-GDP or Mant-GMPPCP and the rate of nucleotide dissociation was measured over time by the 
addition of excess non-labelled nucleotide in the absence or presence of a the catalytic domain of human SOS 
(Ras:SOScat = 1:1 molar ratio). Data were fit to an exponential dissociation curve using GraphPad Prism 5. 
Rates are reported as the mean ± S.E. (n = 3). Statistical analysis was conducted using the built-in one-way 
ANOVA analysis in GraphPad Prism 5 (p<0.0001) followed by a post hoc Tukey comparison to determine 
statistical significance. Results of Mant-GDP and Mant-GMPPCP dissociation can be seen in B and C, 
respectively. D. Intrinsic and p120 GAPcat-mediated (GAPcat/Ras = 1:200 molar ratio) GTP hydrolysis was 
determined using single-turnover hydrolysis assays for KRas WT and acetylated proteins. Ras proteins were 
loaded with GTP, and the addition Mg2+ stimulated GTP hydrolysis. The production of free phosphate was 
measured over time using the phosphate binding protein, Flippi 5U. Data was fit to a phosphate standard 
curve and GTP hydrolysis rates were calculated using the GraphPad Prism 5 one-phase exponential 




Table 2.1. KRas WT and KRas K5AcK rates of nucleotide exchange and hydrolysis 
Determination of thermal melting temperatures can also provide insight into the structural 
role of K5 acetylation in contributing to overall protein stability. Using circular dichroism, we 
were able to identify alterations in the thermal stability of GDP-bound acetylated KRas protein, 
where melting temperature is defined as the temperature at which 50% of the protein is unfolded 
(Figure 2.7, A-C). Slightly more than a 4C defect in the melting temperature of acetylated Ras 
protein was observed in the GDP-bound form relative to wild-type protein (63.5±0.055C vs. 
59.4±0.217C for KRas WT and acetylated protein, respectively). This defect was not observed 
in the GMPPCP-bound form of the acetylated protein, indicating that K5 may play a structural 
role in stabilizing the GDP-bound form of the protein more extensively. Compiled results of 
thermal analysis of Ras proteins can be seen in Table 2.2. Taken together, the results of GEF- 
and GAP-mediated nucleotide exchange defects in the GMPPCP bound form and decreased 
thermal stability of acetylated protein in the GDP-bound form suggest that acetylation is likely to 





Figure 2.7. Minor alterations in thermal melting temperature due to KRas acetylation 
A. Thermal melting temperature was determined using circular dichroism measurements for GDP- and 
GMPPCP-bound KRas WT and acetylated proteins. Protein unfolding was measured as a function of 
increasing temperature over time (20–95°C, 2°C per minute) at 222 nm of 30 M Ras protein. The thermal 
melting temperature was determined by fitting the curve to a Boltzmann’s sigmoidal equation in GraphPad 
Prism 5, where the V50 is indicative of the protein melting temperature. Results are reported as the mean ± 
S.E. (n = 3). Statistical analysis was conducted using the built-in one-way ANOVA analysis in GraphPad 
Prism 5 (p<0.0001) followed by a post hoc Tukey comparison to determine statistical significance. Results of 
GDP- and GMPPCP-bound thermal melts can be seen in B and C, respectively. 
 
Table 2.2. Thermal melting temperature for KRas WT and KRas acetylated protein 
Acetylation of KRas at K5 alters the binding affinity of Ras to the Raf RBDs 
 Ras proteins are highly dynamic and display distinct conformations in both their GDP- 
and GTP-bound forms dictated by the positioning of two highly flexible regions, namely 
switches I and II (SWI, SWII) (9),(41). In their GTP-bound form, SWI and SWII form additional 
contacts with the guanine nucleotide, stabilizing the active form of Ras proteins (41). Ras 
proteins display significantly tighter affinities to their downstream effector proteins in their GTP-
bound form, promoting signaling through downstream cell signaling cascades (15),(16). Cellular 
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and biochemical analyses of Ras proteins demonstrate that K5 acetylation leads to an increased 
GTP-bound population of protein as identified in Raf RBD pulldowns and enhanced signaling 
through the MAPK cascade. As the structural role of K5 in regulating Ras activity is unclear, we 
sought to determine if enhanced MAPK signaling was due to changes in the affinity of acetylated 
Ras protein to the Raf kinase RBD (Ras binding domain) or due solely to the increase in the 
GTP-bound population of the acetylated protein. Raf RBDs primarily interact with Ras proteins 
through SWI, whereas other effector proteins such as PI3K interact with Ras proteins using both 
SWI and SWII (16),(50),(55). To assess whether K5 acetylation is capable of altering 
interactions with downstream effector proteins, we used isothermal titration calorimetry (ITC) to 
determine the binding affinity of Ras proteins to the RBDs of Raf and PI3K. Consistent with 
literature (17), we were able to observe a weakened binding affinity of KRas G12V to both BRaf 
and CRaf RBD. Interestingly, acetylation at K5 was able to restore the weakened binding affinity 
of KRas G12V to wild-type values for both BRaf and CRaf (Figures 2.8, 2.9, 2.10). This would 
suggest that the increased MAPK signaling observed in cells as a result of MS-275 treatment and 
Ras acetylation is at least due in part to altered interactions with the Raf RBDs. Cellular analysis 
also indicated no change in PI3K-mediated signaling as a result of mutation or acetylation (data 
not shown). This was verified in further binding studies, where ITC analysis indicated no 
statistical differences in the binding affinities for KRas WT, KRas G12V or K5 acetylated KRas 





Figure 2.8. KRas G12V-K5AcK displays altered affinity to Raf-RBD 
Binding affinities of KRas WT (blue), KRas G12V (light green) and K5 acetylated (K5AcK) KRas G12V (dark 
green) were determined to BRaf, CRaf and PI3K RBDs using isothermal titration calorimetry (ITC). Ras 
proteins at either 150 or 200 M were titrated into effector proteins at molar ratios of 1:10 or 1:15 for Raf 
and PI3K RBDs, respectively. Heat of binding was measured at 25C. A controlled subtraction was used to 
normalize the isotherm to the heat of saturation. Data was analyzed using a nonlinear least square algorithm 
and fit to a one-site model provided in the MicroCal PEAQ-ITC Origin Software. Calculated affinities were 








Figure 2.9. ITC binding analysis of KRas WT, KRas G12V and KRas G12V-K5AcK to BRaf RBD displays 
altered affinities 
Representative isotherms of Ras:BRaf RBD binding experiments conducted using isothermal titration 
calorimetry (ITC). Either 150 μM or 200 μM Ras proteins were titrated into Raf RBDs at a starting molar 
ratio of 1:10. Isotherms are shown for A. KRas WT, B. KRas G12V and C. K5 acetylated KRas G12V binding 
to BRaf RBD. Experiments were conducted as described in Figure 2.8. Calculated affinities of 37.3 ± 5.7 nM, 
223 ± 21.94 nM and 49.2 ± 12.62 nM correspond to A. KRas WT, B. KRas G12V and C. K5 acetylated KRas 
G12V binding to BRaf RBD, respectively. Compiled data can be seen in Table 2.3 where data is represented 







Figure 2.10. ITC binding analysis of KRas WT, KRas G12V and KRas G12V-K5AcK to CRaf RBD displays 
altered affinities 
Representative isotherms of Ras:CRaf RBD binding experiments conducted using isothermal titration 
calorimetry (ITC). Either 150 μM or 200 μM Ras proteins were titrated into Raf RBDs at a starting molar 
ratio of 1:10. Isotherms are shown for A. KRas WT, B. KRas G12V and C. K5 acetylated KRas G12V binding 
to CRaf RBD. Experiments were conducted as described in Figure 2.8. Calculated affinities of 60.6 ± 6 nM, 
344 ± 38.58 nM and 21.75 ± 10.71 nM correspond to A. KRas WT, B. KRas G12V and C. K5 acetylated KRas 
G12V binding to CRaf RBD, respectively. Compiled data can be seen in Table 2.3 where data is represented 








Figure 2.11. ITC binding analysis of KRas WT, KRas G12V and KRas G12V-K5AcK displays no difference in 
affinity to PI3Kα RBD 
Representative isotherms of Ras:PI3K RBD binding experiments conducted using isothermal titration 
calorimetry (ITC). Either 150 μM or 200 μM Ras proteins were titrated into Raf RBDs at a starting molar 
ratio of 1:15. Isotherms are shown for A. KRas WT, B. KRas G12V and C. K5 acetylated KRas G12V binding 
to PI3K RBD. Experiments were conducted as described in Figure 2.8. Calculated affinities of 2.39 ± 0.010 
M, 2.0 ± 0.271 M and 2.6 M correspond to A. KRas WT, B. KRas G12V and C. K5 acetylated KRas G12V 
binding to PI3K RBD, respectively. Compiled data can be seen in Table 2.3 where data is represented in 
replicate ± standard error (N=2 for Ras WT and Ras G12V, acetylated protein is N=1). 
 
 
Table 2.3. Calculated binding affinities of KRas WT, KRas G12V and KRas G12V-K5AcK to BRaf RBD, CRaf 
RBD and PI3Kα RBD 
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Acetylation of K5 causes sidechain reorientation and altered dynamics in GDP- and GTP-bound 
protein 
While K5 of Ras extends into the binding interface for regulatory and effector proteins, it 
is not noted to make any direct contacts (128). In the GDP-bound form, the K5 sidechain has 
been suggested to interact with SWII residues T74 and Y71 (128). Acetylation of K5 would 
likely disrupt these contacts, as is indicated by the mild change in thermal stability identified in 
Figure 2.7. In order to understand how acetylation alters intrinsic Ras protein activity, we 
conducted 200 ns Molecular Dynamic (MD) simulations of Mg+2-GDP bound Ras proteins and 
Mg+2-GTP bound Ras WT, Ras G12V and K5 acetylated (K5AcK) Ras G12V. Trajectories were 
subjected to clustering analysis using Gromacs (137), and the centroids of the most populated, 
lowest energy clusters for each was examined using PyMol 2.1 (Schrödinger, LLC). Results 
from this analysis (Figure 2.12) indicate that acetylation causes reorientation of K5, altering 
contacts with residues in SWII and β2. Throughout the simulations, the lysine 5 backbone 
carboxyl oxygen and amide can be seen forming polar contacts with the backbone amides of 
Gly77 and Glu76 and the C oxygen of Glu76. Acetylation of Ras wild type results in the 
formation of a polar contact with Asp54 in both the GDP- and GTP- bound forms (Figure 
2.12B,F), where the Asp54 contact is only identified for Ras WT bound to GTP (Figure 2.12E). 
Similar to Ras wild type protein, lysine 5 in Ras G12V forms backbone contacts with the 
backbone amides of Gly77 and Glu76 in both GDP- and GTP-bound forms (Figure 2.12C,G). 
No contact is noted with Asp54 in Ras G12V. In acetylated Ras G12V protein, an additional 
polar contact is noted with Y71 in the GDP-bound form (Figure 2.12D). In the GTP-bound 
form, acetylated RasG12V only forms contacts with the backbone amide of E76 and the C 
oxygen (Figure2.12H). Contrary to previous speculations (128), no contacts are noted between 
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the lysine 5 sidechain and Thr74 in any models (polar contact distance cutoff of 3.6Å). Since the 
backbone of lysine 5 forms several contacts with the highly dynamic switch II region, it is 
possible that acetylation may result in altered protein dynamics.  
 
Figure 2.12 Lysine 5 acetylation causes reorientation of switch II and β2 contacts. 
Lysine 5 contacts as identified from the lowest energy structure resulting from MD simulations and clustering 
analysis. Sidechains are shown as sticks. Ras wild type K5 (grey), wild type acetylated K5 (green), Ras G12V 
K5 (blue) and acetylated Ras G12V K5 (orange) models are shown in both GDP-bound (A-D) and GTP-
bound (E-H) states. The backbone carboxyl oxygen and amide from backbone contacts with the switch II 
residues Gly77 and Glu76. Sidechain contacts are also note with Asp54 of β2. Mutation or acetylation results 
in reorientation of these contacts.          
 As Ras proteins are highly dynamic in nature, we also calculated the C residue RMSD 
fluctuations over time upon mutation or acetylation. By calculating the C residue RMSD 
throughout the MD simulations, we can gain insight into protein backbone dynamics. Results of 
these analyses for wild type and G12V Ras proteins are seen in Figure 2.13. In the GDP-bound 
form, acetylation in wild type protein greatly reduces the dynamic fluctuations in both SWI and 
SWII (Figure 2.13B,D). Ras G12V overall is more stable relative to wild type protein (Figure 
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2.13 E-H). In GDP-bound Ras G12V, increased dynamic fluctuations are identified immediately 
preceding SWI, in α1 helix. Acetylation dampened these fluctuations but increases were noted in 
the N-terminal portion of the α1 helix. The GTP-bound form of Ras G12V proteins display 
largely unchanged dynamics due to acetylation at K5, with only mild decreases of SWII 
fluctuations noted (Figure 2.13G,H). As we do not see large defects in protein stability, 
nucleotide binding or exchange (Figure 2.6, 2.7), it is likely that the slightly altered residue 












Figure 2.13 Cα backbone fluctuations calculated throughout the MD simulation demonstrate that acetylation 
stabilizes the Ras WT GDP- and GTP-bound structures  
Cα backbone fluctuations throughout the course of the MD trajectory are mapped onto the structure of GDP- 
or GTP-bound Ras proteins. Fluctuations are labeled from least to most severe by color and size. Ras wild 
type and Ras wild type acetylated K5 GDP-bound are show in A and B respectively. Ras G12V and Ras G12V 
acetylated K5 GDP-bound are show in C and D respectively. Ras wild type and Ras wild type acetylated K5 
GTP-bound are show in E and F respectively. Ras G12V and Ras G12V acetylated K5 GTP-bound are show 
in G and H respectively. In wild type Ras, acetylation (B and D vs A and C) appears to minimize dynamic 
fluctuations of SWII in particular.  RasG12V proteins display less dynamic fluctuations as a whole and 
changes due to acetylation are minimal (E-H). 
Acetylation of K5 in KRas fosters enhancement of the electrostatic network between Ras and Raf 
RBD 
In Raf RBD pulldown experiments an increased GTP-bound population of protein was 
identified post MS-275 treatment (Figure 2.3). As no significant changes were identified in the 
innate functionality of Ras proteins but an increased binding affinity of acetylated proteins to the 
Raf RBDs was identified (Figure 2.8), it is likely that acetylation alters the ability of Ras 
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proteins to interact with the Raf RBD. As Raf RBDs interact with Ras proteins primarily through 
SWI (16),(56), it is not immediately clear how acetylation could impact Raf RBD binding. The 
interaction interface between Ras and Raf is highly electrostatic in nature (16),(42),(51), and 
mutation to any of the critical binding residues significantly alters or ablates binding (43). To 
understand how acetylation at K5 is capable of altering the affinity of Ras proteins to Raf RBDs, 
we conducted 500 ns Molecular Dynamic (MD) simulations of Mg+2-GTP bound Ras WT, Ras 
G12V, K5 acetylated (K5AcK) Ras WT and K5 acetylated (K5AcK) Ras G12V in complex with 
CRaf RBD. Analysis of these simulations was completed as described previously. Initial findings 
demonstrated that the acetyl sidechain of K5 reorients toward the effector interface (Figure 
2.14), forming a novel electrostatic contact between the sidechain acetyl oxygen of K5AcK and 
the CRaf R67 guanidino NH sidechain. Mutation to either alanine or leucine at this site (R67) in 
the CRaf RBD dramatically alters binding to Ras proteins, indicating the importance of these 
electrostatic interactions in Ras:Raf RBD binding (43). Based on the analysis of all centroids, the 
distance (CRaf R67 NH to Ras K5 acetyl oxygen) is in the range of ~3 Å, which is indicative of 
an energetically favorable electrostatic interaction (138)–(140). The relative distance for Ras 
wild type is longer (~9 Å), possibly resulting from the repulsive nature of the positively charged 
lysine and arginine sidechains. This finding led us to further investigate the electrostatic network 
of binding interactions between Ras and the Raf RBD. Strikingly, we were able to identify a 
reordering and increased electrostatic network formation in Ras due to acetylation at K5 (Figure 
2.15A-D). Several new electrostatic contacts were able to be identified due to acetylation 
involving Ras residues AcK5, Glu31, Glu37 and Asp54, which appear to be largely 
interconnected (Figure 2.15). Acetylation of lysine 5 appears to indirectly stabilize the Ras:Raf 
complex through the favorable reorganization of the electrostatic network. In Ras G12V, a 
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similar trend is also observed (data not shown). Taken together, the formation of novel 
electrostatic contacts and larger electrostatic networks are consistent with the increased binding 
affinity of acetylated proteins to the Raf RBDs (Figure 2.10) and also the increased GTP-bound 
population identified using Raf RBD pulldowns (Figure 2.3). Consistent with this, we are also 
able to observe the reorganization of the critical Ras:Raf binding interface elements α1, SWI and 
β3 in Ras and β2 and α1 in the Raf RBD (Figure 2.16A,B). In acetylated protein, an increased 
number of hydrogen bonds is noted between the β-strand interaction interface between Ras and 
the Raf RBD. Further, we can see that SWI in Ras and α1 in the Raf RBD reorient to position the 





Figure 2.14. Representative models of MD simulations of Ras WT ,Ras G12Vand K5 acetylated Ras proteins 
in complex with Raf RBD demonstrating overall reorientation of the K5 sidechain in response to acetylation. 
A. Ribbon diagram representation of Ras WT (grey) and K5 acetylated Ras (green) in complex with CRaf 
RBD obtained from MD simulations highlights differences in the positioning of Ras K5. In both Ras WT and 
Ras G12V (grey and blue, respectively), the K5 sidechain tucks inward and away from the solvent exposed 
interface, B. In K5 acetylated simulations, the acetyl-lysine sidechain reorients itself into the effector interface 
(Ras WT and Ras G12V on green and orange, respectively) We can see concurrent reorientation of the R67 
sidechain in the Raf RBD, C. The lysine 5 acetyl oxygen forms an electrostatic contact with the guanidino NH 




Figure 2.15 Reordering and strengthening of the electrostatic network of the Ras:Raf binding interface due to 
lysine 5 acetylation. 
Novel electrostatic contacts and networks are identified due to acetylation at K5. Identified residues for Ras 
WT and acetylated Ras WT are noted in A and B, respectively. Distances noted are the minimum distance 
through the trajectory as calculated using VMD Software (141). Representative reorientation of residues is 
shown in C and D. The electrostatic network in acetylated protein is much more interconnected as is seen in 




Figure 2.16 Reorientation of critical α-helical and -strand pairing binding interfaces due to mutation or 
acetylation are identified in Molecular Dynamic simulations 
In final structural models of Ras:Raf RBD complexes, large structural rearrangements can be identified due 
to K5 acetylation. Relative to Ras WT protein (A, grey), K5 acetylation alters critical -helical and -strand 
pairing networks for Ras binding to the Raf RBD (B).  
 
 Dramatic rearrangement of the binding interface between Ras and the Raf RBD have 
been identified in our MD simulations. However, as these are static structures and Ras proteins 
are known to be highly dynamic in nature, we calculated the RMSF fluctuations of each Cα 
backbone carbon throughout each trajectory. This will provide insight into how protein dynamics 
may play a role in Raf RBD binding. Consistent with the structural perturbations identified in 
Figure 2.15, we can also observe alterations in protein dynamics due to acetylation and G12 
mutation. Ras G12V mutation increases the backbone conformational dynamics of α1, SWI, 
SWII and critical -helical binding residues in the CRaf RBD (Figure 2.16B).  Most striking are 
the overall dampening of backbone dynamics observed upon acetylation of Ras G12V (Figure 
2.16D). Here, we can see translated onto the complex structure an overall decrease in the number 
and intensity of C backbone fluctuations, likely due to the stabilization of the binding network 
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between Ras and Raf RBD. This is consistent with the formation of a very stable Ras:Raf RBD 
complex and is reflected in the increased binding affinity of acetylated Ras G12V to the Raf 
RBDs (Figure 2.8). Here, we have identified the formation of a larger and more interconnected 
electrostatic binding network due to protein acetylation, which would support the increased 
affinity observed for acetylated protein to the Raf RBDs and increased MAPK cellular signaling.  
 
Figure 2.17. Altered conformational dynamics in the Ras:Raf RBD complex due to mutation or acetylation 
identified in molecular dynamics simulations. 
Cα backbone fluctuations throughout the course of the MD trajectory are mapped onto the structure of Ras 
proteins in complex with the Raf RBD. Fluctuations are labeled from least to most severe by color and size. 
Relative to Ras WT protein (A), acetylation does not significantly affect the dynamics of critical α1, SWI and 
SWII regions (B). Ras G12V displays increased fluctuations in the Raf RBD, specifically in regions critical for 
binding, C. Acetylation of Ras G12V dampens dynamic fluctuations of the entire complex, consistent with the 




Ras proteins have remained elusive drug targets for more than 30 years (24). However, 
small molecules that target the mutational status of Ras proteins are currently in clinical trials for 
the treatment of Ras G12C specific cancers (clinical trial identifier: NCT03785249 and 
NCT03600883). As direct targeting strategies have been largely ineffective, new approaches to 
target Ras in cancers focus on using indirect strategies including inhibiting Ras association with 
effector proteins and inhibiting the ability of Ras proteins to associate with the cellular 
membrane (83). Drugs that target post-translational modifications are gaining much interest as 
novel anti-cancer therapeutics. Histone deacetylase inhibitors (HDACi) have demonstrated 
success in the treatment of many non-solid tumors (96),(110)–(112). However, as the class I 
HDACi, Entinostat and other pan-HDAC inhibitors have been primarily studied in the context of 
hematologic (blood) cancers (142), it is unclear why HDACi have not proven to be clinically 
viable monotherapies in Ras-driven solid tumors (106),(115). 
The class I HDACi Entinostat is known to disrupt cell cycle progression through the 
induction of p21WAF1/CIP1 transcriptional activation (143). p21WAF1/CIP1 binds and inhibits the 
activity of cyclin-dependent kinase complexes responsible for leading cells through cell cycle, a 
process that is often dysregulated in cancers (144). While the overexpression of HDACs has 
been linked to increased cancer cell proliferation in a p21WAF1/CIP1 dependent manner (145), 
HDAC overexpression is not linked to a poor prognosis in all cancer types (146). This is not the 
case for the Ras-driven colorectal cancer. Ras proteins are mutated in ~50% of colorectal cancers 
(5). High levels of HDAC2 expression have been identified in colorectal cancers (96),(119)–
(122) and HDAC2 specifically has been linked with poor patient survival (121). As HDAC2 is a 
target of the class I HDACi Entinostat, it is reasonable that Entinostat may present a novel 
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therapeutic strategy in Ras-driven CRC. Surprisingly, we were able to determine that Ras is a 
direct target of Entinostat treatment. In CRC cells Entinostat caused Ras acetylation and fostered 
protein hyper-activation and preferential signaling through the Ras/MAPK mediated pathway.  
 We were able to discover that Ras proteins are acetylated in colorectal cancer (CRC) cells 
at a novel location, K5 due to treatment with the class I HDACi, Entinostat (Figure 2.2). This 
data represents a novel finding that Ras is acetylated at a never-before described location, K5, 
due to HDACi treatment. Using a genetic code expansion technique to generate acetylated Ras 
proteins, we were able to determine that acetylation does not severely impact the innate functions 
of Ras proteins. The ability of Ras proteins to bind and cycle nucleotides intrinsically or in the 
presence of modulatory proteins was not significantly altered due to acetylation (Figure 2.6). 
This is not surprising as K5 is not noted to play any role in binding or coordinating nucleotides, 
nor is it noted to interact with the Ras modulatory proteins, GEFs and GAPs. However, in Raf 
RBD pulldown assays using colorectal cancer (CRC) cells, HDACi treatment led to an increase 
in the GTP-bound population of cells (Figure 2.3). Consistent with this, HDACi treatment in 
wild type and G12V oncogenic CRC cells caused increased MAPK signaling (Figure 2.4), while 
no changes in PI3K signaling were observed. This was supported by our findings of increased 
binding affinity of acetylated proteins to the Raf RBDs most striking in the case of oncogenic 
G12V, where complete restoration to wild-type affinity was observed (Figure 2.8). Mutation nor 
acetylation resulted in alterations in binding affinity to the PI3Kα RBD (Figure 2.8).  
Computational molecular dynamic simulations provided further confirmation of our 
biochemical and cellular findings. The Raf RBD interacts with Ras primarily through SWI (16), 
and as such it is not immediately clear how acetylation at K5 could alter Raf binding. Most 
importantly, the interface between Ras and Raf is highly electrostatic in nature and mutations in 
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critical binding residues have been demonstrated to significantly alter or even ablate binding of 
Ras to the Raf RBD (43),(51). Upon acetylation the acetyl-oxygen of the K5 sidechain forms a 
novel contact with Arg67 of the Raf RBD (Figure 2.14). Concurrent with this we also identified 
a complete rearrangement of the critical binding interface between Ras and the Raf RBD (Figure 
2.15) and a further enhancement of a strongly interconnected electrostatic network between Ras 
proteins and the Raf RBD in response to acetylation (Figure 2.15). A dampening of protein 
dynamics was also identified in acetylated proteins in complex with the Raf RBD, consistent 
with the formation of a very stable complex, most notably identified in the Ras G12V-
K5AcK:Raf RBD model (Figure 2.17). 
We present for the first time the direct regulation of Ras proteins by the class I HDACi 
Entinostat. Entinostat was granted ‘Breakthrough Therapy’ designation by the United States 
FDA in 2013 after promising clinical results were described in breast cancer (147). Since then, 
several clinical trials have been initiated using Entinostat as a monotherapy or part of a 
combination therapy strategy in a host of solid and hematologic cancers (clinicaltrials.gov). 
Recent studies have demonstrated that combination strategies using MEKi+HDACi and 
MEKi+HDACi+PI3Ki have resulted in favorable synergistic drug activities and increased 
cellular death in Ras-driven pancreatic cancer cells and murine lung cancer xenograft models 
(100)–(102). Therapeutic targeting of Ras-driven cancers is notoriously difficult in part because 
of the dramatic pathway cross-talk and paradoxical activation of Ras-specific signaling cascades 
observed upon drug treatment (83). Our data may initially seem to contradict these findings as 
acetylation led to more robust Raf RBD binding and increased MAPK-specific signaling. 
However, it may be possible that HDACi serve to alleviate the extensive pathway crosstalk in 
Ras CRC, and thereby allow for more efficient MAPK therapeutic targeting. Increased MAPK 
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signaling is known to upregulate the transcription of key cell cycle regulatory proteins (CDK4/6, 
cyclin D) crucial in G1/S cell cycle transition (148),(149). Specifically, activation of the 
Ras/Mek/Erk pathway has been demonstrated to induce cyclin D transcription (148). The cyclin 
dependent kinase inhibitor, p21 disrupts CDK4/6-cyclin D complex formation, and can serve as 
a negative regulator of cell cycle progression (148),(150). Given that Entinostat is known to 
induce cell cycle arrest through upregulation of p21 (143), HDACi may present a method to 
mitigate oncogenic cancer cell proliferation. Further, the Ras/MAPK transcription factor myc has 
also been suggested to play a role in p21 regulation both upstream and downstream of the critical 
G1 cell cycle checkpoint (148),(149), further linking the Ras/MAPK pathway to cell cycle 
control. Future work should focus on determining the underlying mechanism of Ras-specific cell 
cycle regulation by HDACi. Further, determining the underlying mechanism of therapeutic 
combinations with HDACi in regulating Ras-specific signaling and cell death will be crucial in 
understanding the clinical utility of HDACi as combination therapies in Ras-driven cancers. 
Materials and Methods 
Cell Culture 
The CRC cell lines were maintained in the appropriate cell culture medium supplemented 
with serum and antibiotics as specified by the suppliers. In the case of the CaCO-2, DLD-1 and 
SW837 cell lines containing conditional gene expression systems, cells were additionally 
cultured 72 hrs prior to experiment and further maintained for the full duration of the experiment 
in the presence of doxycycline (2 μg/ml). HEK-ER cells were additionally cultured 48 hrs prior 
to the experiment and further maintained for the full duration of the experiment in the presence 
of 4-Hydrotamoxifen (20 nM). All the cell lines were authenticated by short tandem repeat 
(STR) analysis (CLC Cell Line Service GmbH) and routinely checked for mycoplasma. 
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Retroviral and Lentiviral Constructs 
 All CRC cell lines in which conditional expression of either RAS isoforms, BRAF or c-
MYC was induced, were generated by initially infecting the cells with the lentiviral vector 
pRRL-SFFV-rtTA3- IRES-EcoRec-PGK-Puro, kindly gifted by Johannes Zuber (IMP, Vienna) in 
order to make the cells ecotropic and thereby allow transfection with the retrovirus produced by 






TRE3G-MYCWT-IRES_BFP-PGKHygro, pSIN-TRE3G-MYCT58A-IRES_BFP-PGK-Hygro and 
pSIN-TRE3G-MYCT58A/S62A-IRES_BFPPGK- 
Hygro.  
The retroviral vectors pSIN-TRE3G-KRASG12V-IRES_BFP-PGK-Hygro, pSIN-
TRE3GNRASQ61K- IRES_BFP-PGK-Hygro and pSIN-TRE3G-NRASWT-IRES_BFP-PGK-
Hygro were kindly provided by K.K-N, B.G and N.K. 
The cells already containing pSIN-TRE3G-KRASG12V-IRES_BFP-PGK-Hygro retroviral 
vector were in addition infected with the lentivirus pCDH-ELK-GFP for ELK-1 reporter 
expression. 
To generate pSIN-TRE3G-KRASWT-IRES_BFP-PGK-Hygro, KRASWT cDNA sequence 
was PCR amplified from pDONR221-KRASWT-KanR vector kindly provided by Lange B. (MPI 
für Molekulare Genetik, Germany), restriction digested with NotI and XhoI and ligated into the 
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pSINTRE3G -IRES_BFP-PGK-Hygro vector backbone. The following primers were used: 
forward, 5’- TGGATCCGCGGCCGCATGACTGAATATAAACTTGTGGT-3’ and reverse, 5’-
GTTAACCTCGAGAGATCCGTCGACTCACATAATTACACACTTTGTCT-3’. Vector was 
sequenced to confirm its sequence accuracy. 
To create pSIN-TRE3G-MYCWT-IRES_BFP-PGK-Hygro, pSIN-TRE3G-
MYCT58AIRES_BFP-PGK-Hygro and pSIN-TRE3G-MYCT58A/S62A-IRES_BFP-PGK-Hygro, 
MYCWT, MYCT58A and MYCT58A/S62A cDNA was PCR-amplified from vectors kindly 
provided by Martin Eilers (University of Würzburg, Germany), namely pBABE-MYCWT-Puro, 
pBABE-MYCT58A-Puro, and pBABEMYCT58A/S62A-Puro, respectively. The resultant PCR 
products were restriction digested with NotI and XhoI, then ligated into the pSIN-TRE3G -
IRES_BFP-PGK-Hygro vector backbone. The following primers were used to clone both 
MYCWT, MYCT58A and MYCT58A/S62A: forward, 5’- 
TAAGCAGCGGCCGCATGCCCCTCAACGTTAGCTTC-3’ and reverse, 5’- 
TGCTTACTCGAGTTACGCACAAGAGTTCCGTAG-3’. All vectors were sequenced to 
confirm their sequence accuracy. 
To generate the pSIN-TRE3G-KRASG12V-K5A-IRES_BFP-PGK-Hygro and pSIN-
TRE3GKRASG12V-K5R-IRES_BFP-PGK-Hygro, pSIN-TRE3G-KRAS-WT-K5A-IRES_BFP-
PGK-Hygro, pSINTRE3G-KRAS-WT-K5R-IRES_BFP-PGK-Hygro retroviral vectors, 
KRASG12V and KRASWT cDNA sequences were PCR-amplified to contain either K5A or 
K5R substitution mutations from the pSINTRE3G-KRASG12V-IRES_BFP-PGK-Hygro vector 
and the pSIN-TRE3G-KRASWT-IRES_BFP-PGKHygro vector respectively. The PCR product 
was restriction digested with NotI and XhoI, and subsequently ligated to the same pSIN-TRE3G-
IRES_BFP-PGK-Hygro vector backbone. The 
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following primers were used to clone KRASG12V-K5A and KRASWT-K5A: 
forward, 5’- TAAGCAGCGGCCGCATGACTGAATATGCACTTGTGGTAGTTGGAGCT-3’, 
reverse, 5’-TGCTTACTCGAGAGATCCGTCGACTTACATAATTACACACTTTGTC-3’, and 
to clone KRASG12V-K5R and KRASWT-K5R: 
forward, 5’-TAAGCAGCGGCCGCATGACTGAATATAGACTTGTGGTAGTTGGAGCT-3’, 
reverse, 5’- TGCTTACTCGAGAGATCCGTCGACTTACATAATTACACACTTTGTC-3’. All 
vectors were sequenced to confirm their sequence accuracy. 
Inhibitors 
All inhibitors used were dissolved in DMSO and further diluted to the indicated final 
concentration in cell culture medium at the time of treatment. 
Cell Apoptosis Assay 
Cells were plated and treated for a total of 72 hrs with the indicated agents. Cells were 
harvested for analysis by trypsinization and fixed in formaldehyde (2%) for 10 min at room 
temperature. Following a further incubation step on ice for 1min, the fixation solution was 
removed by centrifugation and cells were subsequently permeabilized in 90% ice-cold methanol 
and incubated again on ice for 30 min. Cells were thereafter washed by centrifugation with 
incubation buffer (PBS, 0.5% BSA) and probed with cleaved Caspase-3 Alexa Fluor® 647 
conjugated antibody according to manufacturer’s specification (Cell Signaling Tech., Cat# 
9602). Following additional washing by centrifugation, 1x104 cells per sample were analyzed 
with a BD AccuriTM C6 (BD Bioscience) Flow Cytometer. 
Immunoblot Analysis 
For fresh protein extraction, cells were washed twice with ice-cold PBS and subsequently 
lysed in MPER™ Mammalian Protein Extraction Reagent (ThermoFischer Scientific, Cat# 
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78501) supplemented with a protease and phosphatase inhibitor cocktail (Roche, Cat# 
04693132001, 04906837001) for 30 min on ice. Lysates were cleared by centrifugation at 13,000 
rpm for 15 min at 4°C, and protein concentrations were determined using Pierce™ BCA Protein 
Assay Kit (Thermo Scientific, Cat# 23225). Equal amounts of proteins were resolved on SDS-
PAGE with appropriate acrylamide percentage and transferred onto nitrocellulose membranes 
(Amersham™, GE Healthcare Life Sciences). The membranes were blocked with 5% non-fat dry 
milk in TBS-T (25 mM Tris, 150 mM NaCl, 2 mM KCl, pH 7.4 containing 0.1% Tween-20) for 
1 hr at room temperature and thereafter incubated overnight at 4°C with the indicated primary 
antibodies diluted in 5% non-fat dry milk with TBS-T. A washing step with TBS-T followed, 
and membranes were subsequently probed with secondary antibodies conjugated to either 
horseradish peroxidase (anti-rabbit/-mouse HRP-linked IgG antibody) (Cell Signaling Tech., 
Cat# 7074, 7076) or to a fluorophore (IRDye® 680RD anti-rabbit/- mouse IgG antibody) (Li-Cor 
Bioscience, Cat# 925-68071, 925-68071) for 1 hr at room temperature. The membranes were 
washed again as described above, and chemiluminescence was detected using GE Healthcare 
ECL (Ammersham ECL) western blotting detection reagents and imaged by Protein Simple 
FluorChem System, while fluorescence was detected using the Li-Cor Odyssey Infrared System. 
Cell Viability Assay 
Cells were seeded at densities between 1500-3000 cells/well (depending on pre-
determined growth properties) in a 96-well plate and allowed to adhere overnight. The cells were 
subsequently treated with the indicated drugs for a total of 72 hrs before XTT cell proliferation 
assay (Roche) was performed. The absorbance read-out (optical density, OD) was measured at a 
wavelength of 450- 500nm with a reference wavelength at 650nm using an ELISA plate reader 
(Synergy|2 Microplate Reader, BioTek). Negative control was subtracted from the OD values 
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and cell viability rate (%) was calculated according to the following formula: 
(ODTREATED/ODCONTROL) ´ 100. Untreated cells served as the indicator of 100% cell 
viability. Drug-response curves of single compounds and combinations were generated by 
Graphpad Prism 6 software (GraphPad Software, inc., La Jolla, CA). The IC50 values were 
calculated by concentration response curve non-linear fitting (log(inhibitor) vs response). 
LC/MS/MS Analysis 
Proteins eluted from the IP beads were digested using an automated sample-preparation 
workflow (Axel-Semrau Proteome Digest-O-r 140). Briefly, the samples were reduced by 1mM 
tris (2- carboxyethyl) phosphine (TCEP, Merck) and free sulfhydryl groups 
carbamidomethylated using 5.5 mM chloroacetamide (Sigma-Aldrich). Proteins were digested 
with 0.5 μg sequencing grade endopeptidase LysC (Wako) overnight at room temperature. The 
reaction was terminated by adding trifluoroacetic acid (TFA, Merck) to a final concentration of 
1% resulting in a final pH of 2. The peptides were purified using C18 stage-tips (Empore SPE 
disks, 3 M) 141 and measured on a QExactive plus mass spectrometer (Thermo-Fisher, 
Germany) coupled to a nano-LC system (easy-nLC, Thermo-Fisher, Germany). 2 μg of the 
peptide sample were injected and separated using a 3h gradient (4 to 76 % acetonitrile and 0.1 % 
formic acid in water) at a flow rate of 0.25 μl/min on an in-house prepared nano-LC column 
(0.075 mm x 250 mm, 3 μm Reprosil C18, Dr. Maisch GmbH). The separated peptides were 
ionized on a proxeon ion source and directly sprayed into the mass spectrometer (Q-Exactive 
Plus, Thermo Scientific). The MS1 acquisition was performed at a resolution of 70,000 in the 
scan range from 300 to 1700 m/z. The top 10 intense masses were selected for MS2 analysis. 
MS2 scans were carried out at a resolution of 15,500 with the isolation window of 2.0 m/z. 
Dynamic exclusion was set to 30 s and the normalized collision energy to 26 eV. For the 
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automatic interpretation of the recorded spectral data, the MaxQuant software package version 
1.6.016 was used 142. Carbamidomethylation was set as a fixed modification while oxidized 
methionine and acetylated lysine were set as variable modifications. An FDR of 1% was applied 
to peptide and protein level, and an Andromeda-based search was performed using a human 
Uniprot database (uniprot.HUMAN.2016-08.fasta, downloaded August 2016). 
Ras-GTP Pull-Down Assay 
The Ras-GTP bound level was studied on the basis of Ras-Ras interaction using the RBD 
agarose beads as per manufacturer’s specifications (Millipore Sigma, Cat# 17-218). Cells were 
washed twice with ice-cold PBS and subsequently lysed in MLB (25 mM HEPES, pH 7.5, 150 
nM NaCl, 1% IGEPAL CA-630, 10 mM MgCL2, 1 mM EDTA) for 30 min on ice. The protein 
lysates were additionally sonicated for 10 sec and debris was removed by centrifugation at 
13,000 rpm for 15 min at 4°C. The cleared lysates were incubated with RBD agarose beads for 
45min and thereafter washed twice with MLB by centrifugation prior to the following 
immunoblotting analysis. Ras pulled down by RBD agarose beads indicates the presence of 
active GTP-bound Ras capable of interacting with Raf1. 
Immunoprecipitation (IP) 
Cells were washed twice with ice-cold PBS and fresh protein extraction was prepared by 
lysis of cells in M-PER™ Mammalian Protein Extraction Reagent supplemented with a protease 
and phosphatase inhibitor cocktail for 30 min on ice. Debris were removed by centrifugation at 
13,000 rpm for 15 min at 4°C and protein concentrations were determined using Pierce™ BCA 
Protein Assay Kit. Lysates were pre-cleared with Dynabeads® Protein A/G (Invitrogen, Cat# 
10002D, 10004D) for 1 hr at 4°C and subsequently incubated with the appropriate isotype 
control or the indicate antibody overnight at 4°C under gentle agitation. The immune complexes 
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were then precipitated with the Dynabeads® Protein A/G for 4hrs at 4°C under gentle agitation, 
washed with M-PER™ lysis buffer and resuspended in sample loading buffer. Following SDS-
PAGE separation, proteins were transferred onto nitrocellulose membranes for immunoblot 
analysis.          
Protein Purification 
Acetylated KRAS-4B protein was generated and expressed using a duel vector system. 
The pUltra vector containing the coding regions for Methanosarcina mazei tRNACUA 
(MmtRNACUA) and the acetyl-lysyl-tRNA synthetase (AcKRS-3 ) (132) was co-expressed with 
a pET52 vector harboring a Nterminal 6-histidine tagged KRAS-4B (C118S, 1-169) with the 
amber stop codon at the desired site of acetyl-lysine incorporation and a TEV protease cleavage 
site. As described previously, acetyl-lysine incorporation is directed by the acetyl-lysyl 
synthetase and the cognate amber suppressor M. mazei tRNACUA in response to the amber 
codon in KRAS (133),(151). Briefly, E. coli BL21-Gold (DE3) cells (Novagen) were 
transformed with both pUltra and pET52 vectors harboring the MmtRNACUA, AcKRS-3 and 
KRAS-4B (C118S) with an amber codon at position 5, respectively. Cells were grown at 37°C in 
Luria-Bertani (LB) medium supplemented with ampicillin and spectinomycin. At A600 of ∼0.5 
the culture media was supplemented with 10 mM N-ε-acetyl-lysine (Sigma, Cat# A4021) and 20 
mM nicotinamide (Acros Organics, CAS 98-92-0) to inhibit the E. coli deacetylase, CobB 
(152),(153). The temperature was reduced to 18°C, and RAS expression was induced after 30 
min upon addition of 500 μM Isopropyl β-D-1-thiogalactopyranoside (IPTG). The culture was 
allowed to grow for 16 hrs at 18°C. The cells were harvested and pelleted at 4,000 rpm, 
resuspended in a lysis buffer containing 20 mM HEPES, 300 mM NaCl, 1 mM MgCl2, and 20 
mM imidazole (pH 7.75) and sonicated. The cell lysate was centrifuged at 15,000 rpm, and the 
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supernatant isolated. Acetylated KRAS-4B protein was purified using nickel-nitrilotriacetic acid-
agarose (Ni-NTA agarose) affinity chromatography (Qiagen). Cells were washed with a buffer 
containing 20 mM HEPES, 500 mM NaCl, 5 mM MgCl2, 40 mM imidazole, 5% glycerol, pH 
7.75. Proteins were eluted in the wash buffer with lower salt and higher imidazole, 50 mM NaCl 
and 250 mM imidazole, respectively. The histidine tag was cleaved during overnight dialysis 
into 10 mM HEPES, 50 mM NaCl, 5 mM MgCl2, 10 μM GDP (pH 7.75) using TEV protease. 
Acetylated K5 KRAS-4B was further purified by size exclusion chromatography using a 
Sephadex G-75 column. Acetylated protein was then submitted for mass spectrometric analysis 
to ensure acetyl-lysine incorporation >95%. KRAS-4B (C118S) wild type protein was expressed 
and purified as noted above. KRas G12V and the amber codon containing G12V constructs were 
generated using standard mutagenesis strategies. They were grown and purified as described 
above. 
The isolated RBD of human BRaf (residues 149-232) was subcloned into the pET28a 
bacterial expression vector encoding a N-terminal 6-histidine tag and TEV cleavage site (28). 
Briefly, BRaf RBD was expressed in BL21 (DE3) cells and were grown at 37°C in Luria-Bertani 
(LB) medium. At A600 of ∼0.5 the temperature was reduced to 18°C, and BRaf RBD expression 
was induced after 30 min upon addition of 500 μM Isopropyl β-D-1-thiogalactopyranoside 
(IPTG). The culture was allowed to grow for 16 hrs at 18°C. The cells were harvested and 
pelleted at 4,000 x g, resuspended in a lysis buffer containing 20 mM HEPES, 300 mM NaCl, 1 
mM MgCl2, 20 mM imidazole, and 5% glycerol (pH 7.75) and sonicated. The cell lysate was 
centrifuged at 15,000 x g, and the supernatant was isolated and purified using nickel-
nitrilotriacetic acid-agarose affinity (Ni-NTA agarose) chromatography (Qiagen). Briefly, the 
supernatant was added to the column and washed with buffer containing higher salt (500 mM 
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NaCl and 40 mM imidazole) and then again with the lysis buffer. The protein was eluted using a 
buffer containing 15 mM HEPES, 50 mM NaCl, 5 mM MgCl2, 250 mM imidazole, pH 7.75. 
The histidine tag was cleaved during overnight dialysis into 10 mM HEPES, 50 mM NaCl and 5 
mM MgCl2, pH 7.75 using TEV protease. BRaf RBD was further purified by size exclusion 
chromatography using a Sephadex G-75 column. Greater than 95% purity was achieved using 
size exclusion chromatography and verified using SDS-PAGE analysis. 
 The isolated RBD of human CRaf (residues 54-131) was subcloned into a pQlinkH 
bacterial expression vector, harboring a N-terminal 6-histidine tag with TEV protease cleavage 
site and purified as described previously (64). CRaf RBD was expressed in BL21 (DE3) cells 
and were grown at 37°C in Luria-Bertani (LB) medium. At A600 of ∼0.5 the temperature was 
reduced to 18°C, and CRaf RBD expression was induced after 30 minutes upon addition of 500 
μM Isopropyl β-D-1-thiogalactopyranoside (IPTG). The culture was allowed to grow for 16hrs at 
18°C. CRaf RBD was purified as described previously (64). CRaf RBD was further purified by 
size exclusion chromatography and > 95% purity verified using SDS-PAGE analysis. 
The catalytic domain of SOScat (residues 566 -1049) was purified as previously described 
(131). Briefly, SOScat was transformed into BL21 (DE3) RIPL E. coli cells and was grown at 37 
°C in Luria-Bertani (LB) medium until an A600 of ∼0.5. The temperature was then lowered to 18 
°C and the cells were induced with 0.5 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG). Cells 
were allowed to continue expression for 16 hours. Cells were pelleted by centrifugation at 4000 x 
g and resuspended in wash buffer (25 mM Tris-Cl, 500 mM NaCl, 20 mM imidazole (pH 7.5) 
with the protease inhibitor phenylmethanesulfonyl fluoride (ACROS Organics)). Cells were 
sonicated and then centrifuged at 14,000 x g for 30 minutes. The supernatant was isolated and 
purified using standard Qiagen nickel affinity purification procedures. Proteins were washed 
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with 10 column volumes of wash buffer and eluted in wash buffer with 500 mM imidazole. 
Tobacco Etch Virus was used to cleave the N-terminal histidine tag on SOScat through overnight 
dialysis. SOScat protein was further purified by size exclusion chromatography using a Sephadex 
G-100 column. Protein purity of >95% was obtained and verified by SDS-PAGE analysis 
The catalytic domain of p120GAP (GAP-334, residues 764-981) (13) in pQlinkH was 
expressed and purified as described for Ras proteins.  
The Ras binding domain (RBD) of human PI3K (residues 157-297) was synthesized 
and cloned by Twist Bioscience into the pCDB24 bacterial expression vector, which encodes for 
an N-terminal 10-histidine tag and a SUMO cleavage site. The PI3K RBD was expressed in 
BL21 (DE3) RIPL cells and was grown at 37°C in Luria-Bertani (LB) medium. The cells were 
grown to an A600 of ~ 0.5, the temperature was then reduced to 18°C for 30 minutes and the cells 
were induced with 500 μM Isopropyl β-D-1-thiogalactopyranoside (IPTG). Following growth for 
16 hours at 18°C, the cells were centrifuged at 4,000 x g, the pellet was resuspended in lysis 
buffer containing 50 mM HEPES, 500 mM NaCl, 20 mM imidazole, and 10% glycerol (pH 8.0) 
and then sonicated. The cell lysate was subsequently centrifuged at 15,000 x g for 25 minutes. 
The supernatant was purified using nickel-nitrotriacetic acid-agarose affinity (Ni-NTA agarose) 
chromatography. Briefly, the supernatant was applied to the Ni-NTA agarose column, washed 
with 5 column volumes (CV) lysis buffer, 5 CV buffer containing 1 M NaCl, 50 mM HEPES, 30 
mM imidazole and 10% glycerol (pH 8.0), again with 5 CV lysis buffer, and lastly with 2 CV 
buffer containing 50 mM HEPES, 500 mM NaCl, 100 mM imidazole and 10% glycerol (pH 8.0). 
The protein was eluted with buffer containing 50 mM HEPES, 500 mM NaCl, 500 mM 
imdiazole, and 10% glycerol (pH 8.0). The 10-histidine tag was cleaved with ULP1 protease 
during overnight dialysis into a buffer containing 50 mM HEPES, 500 mM NaCl, and 5 mM β-
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mercaptoethanol (BME) at 4°C. The PI3K RBD was further purified by size exclusion 
chromatography (SEC) using a Sephadex G-100 column. More than 95% purity was achieved 
using SEC and verified using SDS-PAGE analysis.  
Mass Spectrometry of Unmodified KRas and KRas K5AcK 
The ZipChip Interface (908 Devices) was coupled to an Orbitrap Fusion Lumos high 
resolution accurate mass tandem mass spectrometer (Thermo). A ZipChip HR microfluidic chip 
was used for the separations. Data was acquired at a resolution of 120K with an AGC target of 
4e5 ions or 50 ms max injection time, a scan range set at 200-2000, and a cycle time of 3 sec. 
The total run time was 5 min. Spectra were visualized using Freestyle 1.3 (Thermo Scientific) 
and deconvoluted using BioPharma Finder 3.0 (Thermo Scientific). Wild-type Ras, acetylated 
wild-type Ras and acetylated G12V Ras were identified as >95% purity in samples analyzed. 
Nucleotide exchange assays 
The rate of nucleotide dissociation was measured by using a well-established 
fluorescence-based assay (134),(135). Exchange assays were completed in both GDP and 
GMPPCP-bound forms. Proteins were loaded with Mant-labeled nucleotide using previously 
described methods (154) and loading was verified via HPLC. Nucleotide loaded Ras proteins 
were added to 1 ml of assay buffer (20 mM HEPES, 50 mM NaCl, 5 mM MgCl2, pH 7.4) to a 
final concentration of 1 μM and nucleotide exchange was initiated by the addition of 1 
mM unlabeled nucleotide. The rate of Mant-labeled nucleotide dissociation was measured as a 
change in fluorescence intensity over time (excitation, 365 nm; emission, 435 nm) (LS50B 
PerkinElmer Life Sciences luminescence spectrometer). Fluorescence data were fit using 
GraphPad Prism 5 software to a one-phase exponential decay curve. The minimal catalytic 
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domain of the Ras GEF, SOScat (131) was used to determine GEF-mediated nucleotide 
dissociation rates. For GEF-mediated dissociation, a 1:1 molar ratio of Ras to GEF was used. 
Hydrolysis Assay 
Single turnover GTP hydrolysis assays were performed as previously described (154). 
Intrinsic and GAP-mediated GTP hydrolysis rates were determined by monitoring the production 
of phosphate upon GTP hydrolysis using the phosphate binding protein Flippi 5U (155).  Flippi 
5U expression and purification have been previously reported (155). Briefly, all assays used 5 
µM FlipPi with 5 µM GTP-loaded Ras. GTP loading was performed as previously described 
(154) with desalting and removal of excess GTP completed using Zeba spin columns 
(ThermoFisher). Ras hydrolysis buffer consisted of 20 mM HEPES, 50 mM NaCl, 0.1 mM 
EDTA, 100 μM DTPA (diethylenetriaminepentaacetic acid), 0.5 mM inosine, pH 7.4. All buffers 
were made phosphate free using a ‘phosphate mop’ (156). The rate of GTP hydrolysis was 
measured using a SpectraMax 5M fluorimeter by taking the ratio of the 535- and 485- nm 
emission wavelengths (excitation: 435 nm; 25˚C) of kinetic runs. Hydrolysis was stimulated by 
the addition of 1 mM Mg. GAP-mediated hydrolysis assays included the addition of the minimal 
catalytic domain of p120GAP (Scheffzek et al., 1997) at a 1:200 molar ratio. Using GraphPad 
Prism 5, the data was fit to a one phase exponential association curve and normalized to a 
phosphate standard curve. Data is reported as percentage of GTP hydrolyzed and the GTP 
hydrolysis rate.  
Isothermal Titration Calorimetry (ITC) 
 The binding affinities of KRas-4B (C118S) wild type, KRas-4B (C118S) K5-acetylated, 
KRas-4B (C118S) G12V, and KRas-4B (C118S) K5-acetylated G12V to effector proteins were 
determined using a MicroCal PEAQ-ITC (Malvern Paranalytical). All ITC experiments were 
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performed in buffer containing 20 mM HEPES, 50 mM NaCl, 5 mM MgCl2, 1 mM 2-
mercaptoethanol (B-ME). Ras proteins at either 150 μM or 200 μM were titrated into effector 
proteins (BRaf RBD, CRaf RBD, PLCε, Ral GDS and PI3K-α). Starting effector to Ras molar 
ratios were 1:10 or 1:15. Heat of the binding event was measured at 25°C for 19 2-uL injections 
with a stirring speed of 650 rpm and an initial delay of 120 seconds. Injections were spaced at 
180 seconds. Heats released during the last few injections (when saturation had occurred) were 
averaged and subtracted from all the heat peaks (control subtraction). Data were analyzed using a 
nonlinear least square algorithm and fit to a one-site model provided in the MicroCal PEAQ-ITC 
software. 
Molecular Dynamic Simulations 
United-atom Molecular Dynamics (MD) simulations of Mg+2-GDP bound Ras proteins 
and Mg+2-GTP bound Ras WT, Ras G12V and K5 acetylated (K5AcK) Ras G12V  alone (200 ns) 
or in complex with the Raf RBD (500 ns). The Ras:Raf RBD complex was constructed using two 
high resolution X-ray structures from the protein data bank (PDB 4G0N (55) and 2C5L (157). 
Missing fragments of the 4G0N structures were constructed using corresponding fragments of 
the 2C5L structure, and mutations were corrected to wild type protein. Amino acid substitutions 
of the residues G12 using PyMol 2.1 (Schrödinger, LLC). Acetylation at position K5 was 
generated using Vienna-PTM 2.0 server (158)–(160). The structure of GTP was optimized using 
Maestro LigPrep tool (Schrödinger, LLC). Vienna-PTM and the Automated Topology Builder v 
3.0 (ATP) were used to generate system topology and parameter files for the GROMOS 54a7 
force field (158)–(162). Each protein or complex (Ras WT:Raf, Ras WT-K5AcK:Raf, Ras 
G12V:Raf and Ras G12V-K5AcK:Raf) was solvated using TIP3P water model with and sodium 
ions were added to neutralize the system. All MD simulations were performed using GROMACS 
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2018 package with the GROMOS 54a7 force field (163),(164) at a constant pressure and 
temperature of 1 atm and 298 K for 200 ns for single proteins and 500 ns for protein complexes. 
Trajectories were subjected to clustering analysis using Gromacs (137), and the centroids of the 
most populated, lowest energy clusters for each was examined using PyMol 2.1 (Schrödinger, 
LLC).  
Particle mesh Ewald (PME) (165),(166) was used for long-range electrostatic 
interactions, 10-Å cutoff were used for non-bonded interactions. Based on the analysis of the 
root-mean-square deviation (RMSD) of backbone Cα positions first 10 ns of the simulations 
were omitted for further analysis as to get simulations to reach equilibrium. To select 
representative models of the complex, clustering analysis was performed using a GROMACS 
clustering algorithm (137) on the simulation trajectories. The distance cut-off for clustering was 
chosen to be 1.5 Å, to correlate with distances from high-resolution of X-ray structure. The 
structures of the centroids representing the most populated clusters for each protein-protein 
complex were examined using PyMol 2.1 (Schrödinger, LLC).  
To study relative difference in binding between different complexes we used g_mmpbsa 
tool for the GROMACS (167),(168). Molecular mechanics Poisson–Boltzmann surface area 
(MM-PBSA) calculations are often used to estimate free energy of interaction between biological 
molecules as well as to provide energy-based scoring in computational drug discovery. Based on 
MD trajectory MM-PBSA calculations allow to estimate the following contributions to the 
binding energy: standard bonded interactions (bond, angle and dihedral), van der Waals and 
electrostatic interactions, polar and non-polar contributions to the energy of solvation. The polar 
contribution to the solvation energy is computed by solving the Poisson–Boltzmann equation, 
whereas the non-polar term is calculated using linear approximation to the solvent accessible 
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surface area (SASA). As some recent studies suggest (169) that the method not always provide 
an reliable value on absolute binding affinities we will use it only to estimate a relative 



























Chapter 3. The ‘Ras-opathy’ mutant KRas K5N potentiates protein activation through 
destabilization of the GDP-bound state 
 
Introduction 
Ras proteins are small GTPases that are critical for normal cellular function. Three Ras 
genes encode for four Ras proteins (H-, N- KRas-4A and KRas-4B). They utilize a molecular 
switching mechanism to cycle between active, GTP-bound and inactive, GDP-bound states. This 
process is further regulated by interactions with modulatory proteins (GEFs, guanine nucleotide 
exchange factors and GAPs, GTPase activating proteins) (41). In their active forms, Ras proteins 
bind to downstream effector proteins, mediating pathways that regulate cellular growth, 
differentiation and apoptosis (17),(33). Oncogenic, activated Ras proteins are mutated in 
approximately 30% of all human cancers, and they are known to be oncogenic drivers of some of 
the most aggressive cancers, such as lung, pancreatic and colorectal cancers (5).  
Mutant Ras proteins have also been identified in a subset of genetic diseases. ‘Ras-
opathies’ are rare genetic disorders that are known to be driven by the dysregulation of the 
Ras/Mitogen-activated protein kinase (MAPK) pathway (128),(170),(171). These diseases 
include Noonan’s syndrome (NS), cardio-facio cutaneous syndrome (CFC) and Costello 
syndrome (CS). The clinical features of CS, NS and CFC overlap greatly (130),(171). 
Interestingly, HRas has been reported to be mutated in high percentages (82.5-92%) in CS 
patients (130), whereas KRas germline mutations are identified in NS (128). This suggests that 
while Ras-opathies may all be characterized by overall defects in Ras/MAPK signaling, their 
mechanisms may be unique. Interestingly, the germline KRas mutations identified in NS are at 
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residues unique from those implicated as driving forces in human cancer (128), and are located 
within both the highly conserved effector domain and the sequence divergent allosteric lobe 
(46),(128),(172)–(177). Genetic analysis revealed that the major mutations identified in NS were 
those of KRas, SOS1 and PTPN11 (130),(178). These genes all play roles in fine-tuning the 
overall activation status of Ras in cells. PTPN11 is the gene responsible for the production of 
SHP-2 protein, which plays an essential role in the recruitment of the SOS protein (SOS1 gene) 
to the cellular membrane where it serves to activate Ras proteins (172),(179). While data 
quantifying actual disease prevalence is not available, NS is estimated to occur between 1 in 
1,000-2,500 births each year (178). As NS is a genetic disorder, treatment options focus on 
managing symptomatology. However, recent Ras-related drug approaches are being examined 
(180).  
Ras proteins have distinct conformations and dynamics as determined by their 
nucleotide-bound state (41). In NS patients, several KRas germline mutations have been 
identified at amino acid positions K5, V14, Q22, P34, I36, T58, G60, V152, D153 and F156 
(46),(128),(172)–(177). However, the functional role of these mutations in regulating Ras 
activity is not well understood. Residues that coordinate the guanine nucleotides or that are 
located in the dynamic ‘switch regions’ are highly conserved among the Ras isoforms and 
include V14, Q22, P34, I36, T58, G60 (4). Several of these residues also form contacts with the 
Ras modulatory proteins, GEFs (16),(53),(128),(131). Further, these mutations are located in the 
effector lobe of Ras, which is 100% conserved between the Ras isoforms (5), suggesting that 
these residues play important roles in Ras structure or activity. Although located within the 
allosteric lobe of Ras, V152, D153 are noted to further stabilize the guanine nucleotide binding 
pocket primarily through hydrophobic interactions (172). Since these mutations are located in 
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regions of Ras proteins that play crucial roles in binding guanine nucleotides and are at the 
interface of interactions with GAPs, GEFs or effector proteins (16),(53), it is not surprising that 
mutations at these residues would alter Ras activity.  
K5N is the one mutation that does not seem to have a clear role in mediating any of these 
processes. K5 is not noted to play a role in effector or modulatory protein recognition or binding, 
nor is it reported that K5 plays any role in nucleotide binding or exchange. It is therefore 
probable that the K5N mutation displays a unique mechanism to potentiate enhanced protein 
activation and MAPK signaling. Previous biochemical and cellular analysis of the K5N mutation 
revealed a modest increase in the GTP-bound population of Ras and a dramatically lowered GTP 
association rate as compared to wild type protein (128). However, a comprehensive mechanism 
of Ras regulation through K5N mutation was not able to be determined. As noted previously, K5 
may play an indirect role in stabilizing nucleotide binding in the GDP-bound form of the protein 
(128). It is suggested that mutation to asparagine would disrupt these contacts, leading to 
destabilization of GDP-bound Ras, which may serve to activate the protein (128). Further, 
K5R/E/N mutations are found in pancreatic, stomach, lung, and colon cancers and leukemia 
(181)–(185), but the mechanism by which they elicit an oncogenic role is unclear. In decades of 
research, Ras has remained an elusive target for therapeutic generation and is commonly 
considered undruggable (24). Here we report the results of biochemical, structural and 
computational analysis confirming that KRas K5N mutation destabilizes the inactive form of Ras 
proteins, while not significantly impacting the active form. This may lead to a mechanism in 
cells where Ras proteins are more likely to be GTP-bound and activated, leading to the increased 
cellular signaling characteristic of ‘Ras-opathies’. We provide further discussion as to how these 




KRas K5N mutation disrupts overall protein stability and alters nucleotide association and 
exchange in primarily the GDP-bound form 
 Ras proteins are GTPases (guanosine triphosphatases), meaning that they cycle the 
guanine nucleotides, GDP and GTP for their activity. In their inactive form, Ras proteins are 
bound to GDP, while their active form is characterized by a distinct conformational change upon 
GTP binding (4). Germline mutations have been identified in KRas at lysine (K) 5 in the Ras-
driven genetic disorder, Noonan syndrome (NS). These diseases are largely characterized by 
dysregulated Ras/MAPK downstream signaling and cellular hyper-activation (46),(128),(172)–
(177). Lysine 5 is highly conserved in the Ras superfamily (5), but the role of K5 mutation in 
regulating Ras activity is currently unknown. As described by Gremer et al, the lysine 5 
sidechain forms interactions with switch II, a highly dynamic region of the Ras protein, primarily 
in the GDP-bound form. It is suggested that the K5 sidechain directly interacts with T74 and 
packs against Y71 (128). These sidechain interactions are lost in the GTP-bound form of the 
protein. It is therefore reasonable that K5 mutations could activate Ras proteins in an indirect 
manner, stemming from a destabilization of the inactive, GDP-bound form of the protein. In 
order to investigate the role of K5 mutations in regulating Ras activity in NS, we mutated K5 to 
asparagine and first determined if mutation alone altered protein stability. As shown in Figure 
3.1 mutation to asparagine at lysine 5 caused a decrease in thermal stability of KRas in both 
GDP-bound and GTP-bound forms. A drop in the thermal melting temperature of approximately 
5 C is observed due to K5N mutation in both GDP- and GMPPCP-bound protein (Figure 3.1 
and Table 3.1) compared to KRas WT protein (60.64 ± 0.18 C for GDP-bound KRas and 49.26 
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± 0.12 C for GMPPCP-bound KRas protein). This data demonstrates that lysine 5 likely plays 
an essential role in contributing protein stability in both active and inactive forms of the protein.  
Lysine 5 has been implicated in contributing to the structural regulation of the critical 
switch II region in GDP-bound Ras. Ras proteins display distinct conformations in the highly 
dynamic switch I (SWI) and switch II (SWII) regions upon nucleotide binding (41). Disruption 
of the ability of Ras proteins to adopt these distinct conformations due to mutation could be one 
possible mechanism of Ras activation. In order to investigate the ability of the K5N mutation to 
regulate nucleotide-dependent Ras activity, we can first investigate the ability of Ras proteins to 
load and exchange GDP and GMPPCP. K5N mutation in GDP- nor GMPPCP-bound Ras protein 
was able to significantly alter intrinsic rates of nucleotide exchange (WT- GDP: 2.39±0.42 x 10-
4, s-1, WT GMPPCP: 10.23±0.62 x 10-4, s-1 vs. K5N-GDP: 3.92±0.32 x 10-4, s-1, K5N-GMPPCP: 
11.40±0.51 x 10-4, s-1) (Figure 3.2 and Table 3.2). However, an impaired SOS-mediated 
nucleotide exchange rate was identified in the GDP-bound K5N mutant. Here, we observe 
approximately a 2-fold increase in the rate of GDP-bound nucleotide exchange in the presence of 
the catalytic domain of the GEF, SOScat (WT- GDP: 37.3±0.63 x 10-4, s-1vs. K5N-GDP: 
59.2±0.88 x 10-4, s-1). This trend was not observed in GMPPCP-bound Ras proteins (Figure 3.2 
and Table 3.2). SOS is known to form several direct contacts with the Ras SWII region. At the 
core of these interactions is a hydrophobic network in Ras proteins containing Y71. The proper 
positioning of the hydrophobic core leads to the coordination of nearly every SWII sidechain by 
SOS upon complex formation (54). As K5 is noted to pack against Y71 in the GDP-bound form 
(128), mutation could lead to alteration of  Y71 and further disruption of the critical hydrophobic 
network in Ras that is responsible for placing SWII in the proper conformation for SOS binding. 
K5 is not noted to make contacts with Y71 in the active form of the protein, consistent with the 
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lack of observed differences in SOS-mediated nucleotide exchange in WT and K5N Ras proteins 
(Figure 3.2 and Table 3.2). The highly dynamic switch regions in Ras proteins are also 
recognized by GAP proteins, which facilitate the hydrolysis of GTP to GDP, thereby inactivating 
Ras proteins (136). Intrinsic nor GAP-mediated defects in hydrolysis rates were able to be 
identified in KRas K5N proteins (128). We further investigated the ability of Ras proteins to 
associate or load GDP and GMPPCP. Results from this analysis demonstrated that mutation to 
asparagine resulted in an increased rate of GDP association. An approximate 2-fold increase in 
GDP association was identified due to K5N mutation (WT- GDP: 8.17 ± 0.09 x 10-4, s-1 vs. K5N-
GDP: 18.9 ± 0.31x 10-4, s-1) (Figure 3.3 and Table 3.3). Taken together, the faster off-rate in 
SOS-mediated GDP exchange and faster on-rate for GDP in the asparagine mutant suggests a 
possible instability in the GDP-bound form of the protein. This could be due to a structural 
defect as is described by loss and re-orientation of SWII residues upon K5 mutation. As GTP is 







Figure 3.1. KRas K5N mutant is less thermostable in both active and inactive forms. 
A. Circular Dichroism measurements were used to determine thermal melting temperatures of KRas WT and 
KRas K5N proteins in GDP- and GMPPCP-bound forms. Protein unfolding was measured as a function of 
increasing temperature (20–95°C, 2°C per minute) at 222 nm of 15 M Ras protein. Data was fit to a 
Boltzmann’s sigmoidal equation in GraphPad Prism 5, where the V50 is indicative of the thermal melting 
temperature. Results are reported as the mean ± S.E. (n = 3). One-way ANOVA statistical analysis was 
conducted using GraphPad Prism 5 (p<0.0001) followed by a post hoc Tukey comparison test to determine 
statistical significance. Results of GDP- and GMPPCP-bound thermal melts can be seen in B and C, 
respectively. Thermal melting temperatures are noted in Table 5.1. 
 
 




Figure 3.2. KRas K5N has a GEF defect in the GDP-bound form. 
A. Nucleotide dissociation rates for GDP- and GMPPCP- bound KRas WT and KRas K5N were determined 
using fluorescence-based assays. Ras proteins were loaded with either Mant-GDP or Mant-GMPPCP and 
nucleotide dissociation was stimulated by the addition of excess non-labeled nucleotide in the absence or 
presence of a the catalytic domain of human SOS (Ras:SOS
cat
 = 1:1 molar ratio). Data was fit to an 
exponential dissociation curve using GraphPad Prism 5 to determine the nucleotide dissociation rate. Rates 
are reported as the mean ± S.E. (n = 3). One-way ANOVA statistical analysis was conducted using GraphPad 
Prism 5 (p<0.0001) followed by a post hoc Tukey comparison test to determine statistical significance. Results 
of Mant-GDP and Mant-GMPPCP dissociation can be seen in B and C, respectively. Nucleotide dissociation 
rates are noted in Table 5.2. 
 
 




Figure 3.3. KRas K5N mutant displays alterations in the ability to associate GDP 
A. The rates of GDP and GMPPCP nucleotide association were determined using fluorescence-based methods 
for KRas WT and KRas K5N proteins. Ras proteins were loaded with either GDP or GMPPCP and nucleotide 
association was stimulated by the addition of Mant-nucleotide in the presence of 1.25 molar excess EDTA to 
MgCl2, B and C. Data was fit to a one-phase exponential association curve using GraphPad Prism 5 software. 
Statistical analysis was conducted using the built-in one-way ANOVA in GraphPad Prism 5 (p<0.0017) 
followed by a post hoc Tukey comparison test to determine statistical significance. Data are reported as mean 
± S.E. (n = 4 for GDP, n=3 for GMPPCP). Nucleotide association rates are noted in Table 5.3.  
 
Table 3.3. Nucleotide association rates for KRas WT and KRas K5N 
K5N mutation does not alter protein binding to Raf RBDs 
 Noonan syndrome (NS) and the overarching class of the ‘Ras-opathies’ are rare genetic 
disorders known to be driven by the dysregulation of the Ras/Mitogen-activated kinase (MAPK) 
pathway (128). While K5 is not noted to make direct contacts with any Ras-effector proteins 
(16), it is possible that mutation may disrupt the ability of Ras proteins to bind or recognize their 
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effector proteins. In order to test this, we used isothermal titration calorimetry (ITC) to determine 
the binding affinity of Ras proteins to the Ras-binding domains (RBDs) of their effector proteins. 
As ‘Ras-opathies’ are primarily associated with defects in the MAPK pathway, binding analysis 
was conducted using the Raf-RBDs. Results from ITC analysis demonstrated that K5N mutation 
does not alter the binding affinity of Ras protein to the B- or CRaf RBD (KRas WT:BRaf RBD - 
28.35 ± 4.15 nM, KRas WT:CRaf RBD - 52.65 ± 7.35 nM versus KRas K5N:BRaf RBD - 23.70 
± 3.70 nM, KRas K5N:CRaf RBD - 74.40 ± 4.90 nM) (Figures 3.4 and 3.5, Table 3.4). This is 
consistent with literature where K5N mutation did not disrupt Raf1 (CRaf RBD) binding as 
determined using a fluorescence polarization assay (128). These results along with the GDP-
exchange defects would suggest that increased signaling through the downstream MAPK-
mediated pathway is likely due to an increase in the GTP-bound form of the protein potentiating 
increased signaling and not due to an increased preference to bind or signal through the Raf 
RBDs.  
 
Figure 3.4. KRas K5N does not alter binding to the Raf RBDs. 
Binding affinities of KRas WT and KRas K5N  were determined to B- and CRaf RBDs (white and blue, 
respectively), using isothermal titration calorimetry (ITC). Ras proteins at either 150 M were titrated into 
effector proteins at molar ratios of 1:10 Raf RBDs. Heat of binding was measured at 25C. A controlled 
subtraction was used to normalize the isotherm to the heat of saturation. Data was analyzed using a nonlinear 
least square algorithm and fit to a one-site model provided in the MicroCal PEAQ-ITC Origin Software. 




Figure 3.5. KRas K5N mutation does not disrupt binding to Raf RBDs 
A. KRas K5N mutation does not alter binding to BRaf or CRaf RBDs as indicated by isothermal titration 
calorimetry ITC. Representative isotherms of Ras:Raf RBD binding experiments conducted using isothermal 
titration calorimetry (ITC). 150 μM Ras proteins were titrated into Raf RBDs at a starting molar ratio of 
1:10. Isotherms are shown for KRas WT (A) and KRas K5N (B) binding to BRaf RBD and KRas WT (C) and 
KRas K5N (D) binding to CRaf RBD. No statistical differences in the affinity of the K5N mutant to BRaf or 




Table 3.4. Calculated binding affinities of KRas WT and KRas K5N to BRaf and CRaf RBDs 
NMR structural analysis reveals large structural perturbations in GDP-bound Ras due to K5N 
mutation 
 Lysine 5 is noted to make contacts with critical SWII residues primarily in the GDP-
bound form of Ras (128). While NS is characterized by defects in MAPK-mediated signaling, 
our ITC binding analysis demonstrates that the increased signaling is not due to an increased 
affinity to the Raf RBDs. Our biochemical data demonstrates a significant decrease in thermal 
stability of K5N mutant protein in both GDP- and GMPPCP-bound forms, suggesting a 
structural perturbation due to mutation. However, our nucleotide loading and exchange data 
suggest that the K5N mutation may impact the GDP-bound form of the protein more severely, 
which could be explained by disruption of K5 contacts with critical SWII residues exclusively in 
the GDP-bound form. To investigate whether a structural defect due to K5N mutation could be 
the causative factor in modulating protein activity we employed the use of nuclear magnetic 
resonance (NMR) to gain structural insight. 2D 1H-15N heteronuclear single quantum coherence 
(HSQC) spectral overlays of KRas WT and KRas K5N bound to GDP and GMPPCP are shown 
in Figure 3.6A and Figure 3.7A, respectively. Backbone assignments for KRas protein were 
obtained previously (69). 1H-15N HSQCs are capable of providing a ‘fingerprint’ of the protein 
backbone as NH resonances can be detected for every amino acid residue with the exception of 
proline (69). 156 and 153 peaks were able to be assigned in the GDP-bound KRas WT and KRas 
K5N proteins, respectively. In the active form of the protein, the switch regions are in 
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intermediate exchange on the NMR timescale, making them invisible in the spectrum. In the 
GMPPCP-bound form, 96 KRas WT peaks and 95 KRas K5N peaks were able to be confidently 
assigned. Chemical shift perturbations (CSPs) were calculated for both nucleotide-bound forms 
of Ras proteins. CSP analyses revealed a significant number of peak shifts in the GDP-bound 
form of KRas K5N protein (Figure 3.6B). Approximately 22% of peaks shifted > 0.05 ppm, 
with the largest perturbations corresponding to residues surrounding K5 (1), SWI, 3, SWII/2 
and 3. Results from the CSP analysis are mapped onto the structure of Ras (PDB 4OBE) 
(Figure 3.6C). These perturbations encompass nearly the entire effector lobe of Ras, suggesting 
a large change in the electrochemical environment in the GDP-bound form due to K5N mutation. 
This is largely consistent with the decreased thermal stability observed for GDP-bound KRas 
K5N (Figure 3.1 and Table 3.1) and may imply that K5N mutation destabilizes GDP-bound 
Ras. CSP analysis was additionally conducted for GMPPCP-bound proteins. Bearing in mind 
that several SWI and SWII residues are not visible in the NMR spectra in GMPPCP-bound KRas 
K5N, only approximately 4% of identifiable peaks demonstrated CSPs > 0.05 ppm (Figure 3.7). 
These changes are additionally mapped onto the GTP-bound Ras structure (PDB 5VQ6) (Figure 
3.7C), with the most severe CSPs surrounding the K5N mutation site (1). Results from this 













N 2D HSQC NMR spectral overlay of 
15
N-enriched KRas K5N (blue) and KRas WT (red). B. 
Chemical shift perturbation (CSP) resulting from the mutation reveal large chemical shift changes in β1- β3, 
switch I/II and  α2- α3. C. CSPs resulting from the K5N mutation were mapped onto KRas WT structure 
(PDB 4OBE). Results from this analysis demonstrate that K5N mutation alters the electrochemical 
environment significantly throughout the effector interface, potentially leading to disruption of GTPase 
regulation or downstream signaling. All NMR spectra were recorded on KRas (1-169) GDP using a Bruker 









N 2D HSQC NMR spectral overlay of 
15
N-enriched KRas K5N (blue) and KRas WT (red). B. 
Chemical shift perturbation (CSP) resulting from the mutation reveal modest changes throughout the 
protein, with prevalent shifts surrounding K5. Moderate shifts are identified near switch I and switch II 
regions. C. CSPs resulting from the K5N mutation were mapped onto KRas WT structure (PDB 5VQ6). 
Results from this analysis indicate minimal CSPs, primarily surrounding residue 5. This may indicate that 
K5N mutation may not severely impact the activity of GTP-Ras. NMR spectra were recorded on KRas (1-
169) GDP using a Bruker Avance III 850MHz. Data was processed using NMRFam Sparky (187). * Some 
switch I and switch II residues are not visible in the GMPPCP-bound form as they are in intermediate 
exchange on the NMR timescale. 
 
Molecular Dynamic (MD) simulations indicate Ras K5N reorganizes SWI and SWII contacts and 
results in larger scale structural changes primarily within the effector lobe of Ras.  
As the structural role of K5 is unclear, molecular dynamic (MD) simulations were 
conducted to provide insight into how K5N mutation could alter Ras activity. 100 ns MD 
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simulations of Mg2+ GDP-bound and GTP-bound Ras WT and Ras K5N were conducted (see 
Methods for details). The trajectories of the simulations were subjected to a clustering analysis 
(137), and the centroids of the most populated, lowest energy clusters for each protein was 
examined using PyMol 2.1 (Schrödinger, LLC) and UCSF Chimera 1.13.1 (188). K5 is noted to 
interact with the SWII region most extensively in the GDP-bound form of Ras (128), and 
disruption of this region could serve as a potential mechanism of activation through 
destabilization of the GDP-bound form. MD simulations demonstrate that K5 makes several 
SWII contact in both the GDP- and GTP-bound forms.  
The K5 backbone carboxyl oxygen and amide form contacts with the amide of G77 and 
the E76 C oxygen, respectively in both nucleotide-bound states (Figure 3.8A,C). The K5-NH 
sidechain forms a contact with T74-OH in the GDP-bound state, but not in the GTP-bound state 
where the K5 sidechain repositions away from the switch regions (Figure 3.8A,C). In the GDP-
bound form of the K5N mutant reorientation of the backbone contacts occur, where the N5 
backbone carboxyl oxygen makes contacts with the amides of E76 and G77 and the N5- NH 
sidechain amine creates an additional polar contact with the E76 C oxygen (Figure 3.8B). We 
can also note that the packing around this region has become much more electrostatic in nature 
relative to GDP-bound WT Ras with potentially unfavorable electrostatic packing identified 
between Y71:N5:T74 and between T74:E76. In the GTP-bound form, the K5 carboxyl oxygen 
forms a contact with the amide of E76 in addition to those previously mentioned (Figure 3.8C). 
Also noted is packing of K5 against the 2 residue D54 in both nucleotide-bound forms. In GTP-
bound Ras K5N, the backbone carboxyl oxygen and amide form contacts with the amide of E76 
and the C oxygen. We also note the formation of a 2 contact with the carboxyl oxygen of D54 
(Figure 3.8D). Overall, K5N mutation in the GDP-bound form may result in unfavorable 
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electrostatic packing due to the mutation, which may result in destabilization in the GDP-bound 
form. In the GTP-bound form, K5N may be further stabilized by an additional contact with D54 













Figure 3.8. Molecular dynamics simulations identify altered contacts in SWI and SWII due to K5N mutation.  
Results from molecular dynamic (MD) simulations identify several backbone and sidechain contacts made by 
K5 with Switch II residues in the GDP-bound (A) and GTP-bound (C) forms. The K5 carboxyl oxygen makes 
backbone contacts with the amides of E76 and G77 in both GDP and GTP-bound states. The backbone amide 
of K5 forms a polar contact with E76 C oxygen. K5-NH also creates an additional contact with T74-OH in 
the GDP-bound state (A). This contact is lost in GTP-bound WT Ras and reorientation of the K5 sidechain 
can be observed (C). K5N mutation in the GDP-bound form creates an additional contact between N5- NH 
sidechain amine and the E76 C oxygen. Also identified is the loss of the T74 contact (B). In the GTP-bound 
form (D) the Ras K5N carboxyl oxygen and backbone amide form contacts with the backbone amide and C 
oxygen of E76, respectively. Contact with G77 is lost relative to GTP-bound Ras WT protein. An additional 
contact is identified between the N5- NH sidechain amine and the 2 D54 sidechain carboxyl oxygen. 
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 We can also identify larger structural rearrangements as a result of K5N mutation in 
GDP- and GTP-bound forms of the protein isolated largely to the effector lobe. Consistent with 
our NMR analysis (Figure 3.6), in GDP-bound K5N protein, alterations in the overall 
conformation and secondary structure are identified in 3, SWII and 2 (Figure 3.9A). The 
binding of SOS to SWII causes the reorientation of backbone residues in 3 and 2, which is a 
crucial part of the mechanism of nucleotide exclusion (54). The large-scale disruptions in these 
regions as identified by MD simulations and NMR analysis could speak to the underlying 
mechanism behind the SOS-mediated defect in GDP exchange identified in Figure 3.2. In the 
GTP-bound form (Figure 3.9B), the K5N mutation appears to primarily disrupt the SWII/2 
helix of Ras. As SWII plays critical roles in binding and stabilizing the β- and γ- phosphates of 
GTP (41), the disruption of SWII could lead to destabilization of the protein, consistent with the 
decreased thermal stability identified (Figure 3.1A,C). In the GMPPCP- bound NMR studies in 
Figure 3.3, K5N mutation did not significantly alter CPSs relative to WT protein. However, as 
the switch regions are in intermediate exchange in the active form, they are not visible in the 
NMR spectra.  
 Ras proteins are highly dynamic in nature, and their ability to act as ‘molecular switches’ 
is critical for their activity. By calculating the C residue RMSF throughout the MD simulations, 
we can gain insight into protein backbone dynamics which may provide further insight into how 
K5N mutation is capable of regulating Ras activity. Results from these analyses were mapped 
onto the protein structure for both GDP- and GTP-bound forms (Figure 3.10). Upon K5N 
mutation in the GDP-bound form of the protein, we can identify several areas of the protein that 
display significantly increased dynamic fluctuations relative to Ras WT (Figure 3.10A,B). Of 
particular interest, SWII (residues 61-65) and the critical nucleotide binding NKXD motif both 
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display dramatic increases in conformational sampling and dynamics. We can also identify a loss 
in the N-terminal portion of the 2 helix, potentially as a result of the increased dynamics of 
SWII. The NKXD motif is a highly conserved structural motif in Ras proteins that is essential in 
coordinating the binding of and providing specificity for the guanine-nucleotide base. Mutations 
at these residues greatly destabilize Ras nucleotide binding, resulting in increased protein 
activation (1),(46),(47). In the GTP-bound form of the protein, no dramatic changes in the 
dynamic fluctuations are identifies as a result of K5N mutation (Figure 3.10C,D). Very modest 
fluctuations are noted in SWI, SWII and N-terminal portion of 3. Taken together, the analysis 
of the C backbone dynamics provides further evidence of mutation-induced instability in the 
GDP-bound form. This may potentiate GTP-binding which could lead to increased cellular 
signaling. We therefore propose that K5N mutation activates Ras in an indirect manner, by 









Figure 3.9. K5N mutation causes structural changes in the effector lobe of Ras.  
A. The effector lobes of Ras WT-GDP (grey), Ras K5N-GDP (light cyan) and B Ras WT-GTP (grey), Ras 
K5N GTP (light cyan) are overlayed and represented as cartoons. Residue 5 is shown as sticks. Results from 
molecular dynamic (MD) simulations indicate significant structural changes in both GDP-bound and GTP-
bound Ras K5N (teal and light cyan, respectively). There is loss in the secondary structure associated with β3 
in GDP-bound Ras K5N relative to wild type protein. Additionally, we can see SWII/α2 helix shifts in the Ras 
K5N mutant (A). B. There is a significant loss of the α2 helix in GTP-bound K5N mutant Ras relative to WT 
protein. β3 and α2 regions are important regions in Ras proteins as they flank two highly dynamic switches in 
Ras, switch I (SWI) and switch II (SWII). As these regions are highly disrupted primarily in the GDP-bound 




Figure 3.10 K5N mutant causes significant structural perturbations in GDP-bound form 
RMSF fluctuations of backbone C residues plotted onto the cartoon representation of Ras proteins. Ras 
proteins can be seen in both GDP- and GTP- bound forms. Fluctuations are gradated based on least to most 
severe with color and size.  Ras WT GDP-bound fluctuations are shown in A. Due to K5N mutation, in the 
GDP-bound form we calculate significant dynamic fluctuations of SWII (residues 61-65) and partial loss of 
the N-terminal portion of 2, B. Larger fluctuations are also calculated in the critical nucleotide binding 
NKXD motif. Disruptions in these regions would impact the ability of Ras K5N to properly coordinate 
nucleotide binding in the GDP-bound form and could lead to protein instability. Modest dynamic fluctuations 
also extend into the N-terminal portion of 3. Ras WT GTP-bound fluctuations are shown in C. Relative to 
WT protein, K5N mutation in the GTP-bound form displays modest fluctuations, with mild changes noted in 




 Germline mutations in KRas proteins have been identified in a subset of genetic diseases 
that are characterized by dysregulaton of the Ras/MAPK pathway (128),(130). Interestingly, 
these mutations are not at the common Ras ‘hotspot’ locations, which are known drivers of 
human cancers (5),(26). In Noonan’s syndrome, KRas mutations are identified that spread 
throughout the highly conserved effector lobe and the more divergent allosteric lobe 
(46),(128),(172)–(177). While several of these mutations occur at locations known to play 
critical roles in regulating nucleotide binding or protein activity (4),(16),(41),(53),(128),(131), 
this is not the case for lysine (K) 5 mutations. The functional role of K5 in regulating Ras protein 
activity is not well understood. K5 has been implicated in playing an indirect role in stabilizing 
nucleotide binding in the inactive, GDP-bound form of the protein, but not in the active form 
(128). Further, K5R/E/N mutations have been identified in pancreatic, stomach, lung, and colon 
cancers and leukemia (181)–(185). As such, K5 mutations may present novel mechanisms of 
activation in genetic disorders and cancers.  
Here, we show that K5N mutation causes a significant shift in the thermal stability of the 
protein in both GDP- and GTP-bound forms (~ 5 °C). This would likely be caused by a structural 
or conformation change in the protein due to mutation. Consistent with these findings, we are 
able to identify significant alterations in the NMR spectra of GDP-bound K5N protein, mapping 
predominately to the effector lobe. We identify significant CSPs in β1- β3, switch I/II and α2- α3 
due to K5N mutation. While the switch regions are in intermediate exchange on the NMR 
timescale in the GTP-bound form of the protein and therefore not visible in the spectrum, K5N 
mutation in the active form displays very few alterations relative to WT protein. This would 
suggest that the K5N mutation may impact the GDP-bound form of the protein more severely. In 
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support of this, computational analysis identified potentially unfavorable electrostatic packing 
and altered SWII contacts in Ras K5N GDP-bound protein. Significantly altered dynamics and 
structure were also identified in SWII/α2 (residues 61-65) and the critical nucleotide binding 
NKXD motif in the GDP-bound form upon K5N mutation. The highly conserved NKXD motif is 
essential in coordinating the binding of and providing specificity for the guanine-nucleotide base. 
Mutations at these residues greatly destabilize Ras nucleotide binding, resulting in increased 
protein activation (1),(46),(47). Taken together, these results may aid in providing support for the 
structural instability of GDP-bound Ras K5N.  
While K5 is not noted to make direct contacts with SOS, it is located very close to SOS 
residues Asp910 and His 911 (~ 5 Å) (36),(54). It is possible that the K5N plays a small role in 
disrupting these interactions. The switch regions are also critical locations for the interaction of 
Ras with SOScat (36),(54). In particular residues, Tyr64, Met67 and Tyr71 in Ras provide a 
hydrophobic anchor in the binding interface with SOS. The proper orientation of this core allows 
for the coordination of several sets of charged interactions, resulting in the binding of nearly 
every SWII residue by SOS (54). Gln61 forms interactions SOScat Thr935 in addition to packing 
against the Ras hydrophobic core residues. Glu62 in Ras forms a critical intra-molecular contact 
with the phosphate-binding (P-loop) lysine 16. Glu63 contacts Arg826 of SOScat. While Tyr64 is 
part of the hydrophobic core in the Ras:SOS interface, it also forms a contact with the SOScat 
residue 912. Structural changes are also noted in the Ras NKXD motif and extending through 
loop 8 in the Ras;SOS complex (residues 118-123) (54). Moderate dynamic fluctuations were 
also identified in this region due to K5N mutation in the GDP-bound form. Large dynamic 
fluctuations primarily in the Ras SWII residues responsible for SOScat interactions and 
unfavorable electrostatic packing of K5N with SWII along with moderately increased 
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fluctuations of the residues of the NKXD motif may support the slight SOS-defect identified in 
the GDP-bound form. Residues 61–64 are also highly implicated in binding interactions with Ras 
GAPs (13). However, K5N mutation displayed no defects in intrinsic or GAP-mediated 
hydrolysis (128). Contrary to previous literature, we were able to identify a mild defect in the 
ability of Ras K5N to associate GDP but not GMPPCP. These differences could potentially stem 
from the different methodology used for data collection (128). 
‘Ras-opathies’ are characterized by defects in Ras/MAPK signaling (128),(170),(171). 
We investigated whether this could be due to an altered affinity of the K5N mutant to bind BRaf 
or CRaf RBDs. As Raf RBDs interact with Ras primarily through the SWI region (16), it was not 
surprising that binding analysis revealed no changes in affinity due to K5N mutation. In the 
GTP-bound form, Ras K5N mutation displays very mild perturbations as noted in our 
biochemical, NMR and computational studies. Previously, small increases in MAPK-mediated 
signaling were identified in Ras K5N cells (128), but the overarching mechanism still remains 
unclear. Our data would suggest that K5N mutation causes protein instability in the GDP-bound 
form. This is demonstrated in the altered thermal stability of the protein and in NMR and 
computational studies. Given that physiologic levels of GTP are much higher in the cell, it is 
possible that K5N protein may be more GTP-bound. This may lead to increased signaling. 
Results from our analysis demonstrate that K5 plays an indirect role in stabilizing nucleotide 
binding, as noted previously (128). N5 mutation causes unfavorable packing in the GDP-bound 
form against SWII, which is reflected in the large dynamic fluctuations and alterations identified 
in the GDP-bound forms of the protein in NMR and MD analyses. As the increase in cellular 
signaling identified was minimal (128), it is possible that Ras K5N mutations would co-occur 
with either SOS1 or PTPN11 mutations that would further potentiate activation of the Ras-
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mediated MAPK signaling cascade. K5N mutation presents a unique mechanism of activation, 
through destabilization of the inactive form of the protein. As K5N/E/R mutations have been 
identified in cancers (181)–(185), our analysis may provide novel ways of K5 mutation-specific 
targeting.   
 
Materials and Methods 
Protein Purification 
Human KRas-4B (C118S) (residues 1–169) was subcloned into a pET21 vector with an 
N-terminal 6-histidine tag and a TEV protease cleavage site for expression in Escherichia coli 
BL21 (DE3) cells (Novagen). Standard site-directed mutagenesis techniques were used to 
generate the KRas K5N mutant. Briefly, E. coli BL21 (DE3) cells were grown at 37 °C in Luria-
Bertani (LB) medium supplemented with ampicillin and chloramphenicol until A600 of ∼0.5. The 
temperature was then lowered to 18 °C, and KRas expression was induced with 0.5 
mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) after 30 min. The cells were grown 15 hours 
at 18 °C and were then harvested. The cells were pelleted at 4000 x g, resuspended in a lysis 
buffer (20 mM HEPES, 300 mM NaCl, 1 mM MgCl2, 20 mM imidazole, 5% glycerol (pH 7.75) 
and sonicated. The cell lysate was centrifuged at 15,000 x g, and the supernatant was isolated. 
KRas proteins were purified using standard Qiagen nickel affinity purification procedures. 
Proteins were washed with a buffer containing 20 mM HEPES, 500 mM NaCl, 5 mM MgCl2, 40 
mM imidazole, 5% glycerol (pH 7.75). Proteins were then eluted in a buffer containing 20 
mM HEPES, 50 mM NaCl, 5 mM MgCl2, 250 mM imidazole (pH 7.75). The histidine tag was 
cleaved during overnight dialysis using TEV protease. Cleaved Ras proteins were further 
purified by size exclusion chromatography using a Sephadex G-75 column. Protein purity of 
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>95% was obtained and verified by SDS-PAGE analysis. Proteins were stored in a buffer 
containing 20 mM HEPES, 50 mM NaCl, 5 mM MgCl2, pH 8.0. 
The catalytic domain of SOScat (residues 566 -1049) was purified as previously described 
(131). Briefly, SOScat was transformed into BL21 (DE3) RIPL E. coli cells. Cells were grown at 
37 °C in Luria-Bertani (LB) medium supplemented with ampicillin and chloramphenicol 
until A600 of ∼0.5. The temperature was then lowered to 18 °C and the cells were induced with 
0.5 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG). Expression was continued for 16 hours. 
Cells were then pelleted by centrifugation at 4000 x g and resuspended in a buffer containing 25 
mM Tris-Cl, 500 mM NaCl, 20 mM imidazole (pH 7.5) and the protease inhibitor 
phenylmethanesulfonyl fluoride (ACROS Organics). Cells were sonicated followed by 
centrifugation at 14,000 x g. The supernatant was isolated and purified using standard Qiagen 
nickel affinity purification procedures. Proteins were washed with several column volumes of the 
buffer listed above and then eluted in this same buffer with 500 mM imidazole. SOScat was 
dialyzed overnight with Tobacco Etch Virus to cleave the N-terminal histidine tag.  SOScat 
protein was further purified by size exclusion chromatography using a Sephadex G-100 column. 
Protein purity of >95% was obtained and verified by SDS-PAGE analysis 
The RBD of human BRaf (residues 149-232) was subcloned into the pET28a bacterial 
expression vector encoding a N-terminal 6-histidine tag and TEV cleavage site and purified as 
described previously (28). BRaf RBD was expressed in BL21 (DE3) RIPL E. coli cells and was 
grown at 37°C in Luria-Bertani (LB) medium. At A600 of ∼0.5 the temperature was reduced to 
18°C, and protein expression was induced after 30 minutes upon addition of 500 μM Isopropyl 
β-D-1-thiogalactopyranoside (IPTG). The culture was allowed to grow for 16 hours. The cells 
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were then harvested and pelleted at 4,000 x g, resuspended in a lysis buffer containing 20 mM 
HEPES, 300 mM NaCl, 1 mM MgCl2, 20 mM imidazole, and 5% glycerol (pH 7.75) and 
sonicated. The cell lysate was centrifuged at 15,000 x g, and the supernatant was isolated. 
Protein was purified using standard Qiagen nickel affinity procedures. The supernatant was 
added to the column and washed with buffer containing 20 mM HEPES, 500 mM NaCl, 1 mM 
MgCl2 and 40 mM imidazole and then again with the lysis buffer. The protein was eluted using a 
buffer containing 15 mM HEPES, 50 mM NaCl, 5 mM MgCl2, 250 mM imidazole, pH 7.75. 
The N-terminal 6-histidine tag was cleaved during overnight dialysis into 10 mM HEPES, 50 
mM NaCl and 5 mM MgCl2, pH 7.75 using Tobacco Etch Virus protease. BRaf RBD was 
further purified by size exclusion chromatography using a Sephadex G-75 column. Greater than 
95% purity was achieved using size exclusion chromatography and verified using SDS-PAGE 
analysis. 
 The isolated RBD of human CRaf (residues 54-131) was subcloned into a pQlinkH 
bacterial expression vector, harboring a N-terminal 6-histidine tag with TEV protease cleavage 
site and purified as described previously (64). CRaf RBD was expressed in BL21 (DE3) RIPL E. 
Coli cells and was grown at 37°C in Luria-Bertani (LB) medium. At A600 of ∼0.5 the temperature 
was reduced to 18°C, and CRaf RBD expression was induced after 30 minutes upon addition of 
500 μM Isopropyl β-D-1-thiogalactopyranoside (IPTG). The culture was allowed to grow for 16 
hrs at 18°C. CRaf RBD was purified as described previously (64). Further purification was 
completed by size exclusion chromatography and > 95% purity verified using SDS-PAGE 
analysis. 
Nucleotide Dissociation Assay 
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Nucleotide dissociation was measured using a well-established fluorescence-based assay 
(189). Briefly, Ras proteins were loaded with either MANT-GDP ((2'-(or-3')-O-(N-
Methylanthraniloyl) Guanosine 5'-Diphosphate) or MANT-GMPPCP (2'/3'-O-(N-Methyl-
anthraniloyl)-guanosine-5'-[(β,γ)-methyleno]triphosphate), and loading was verified via HPLC to 
be >95%. 2 μM of loaded Ras protein was added to a final volume of 60 uL in assay buffer (20 
mM HEPES, 50 mM NaCl and 5 mM MgCl2, pH 7.4) and nucleotide exchange was initiated by 
the addition of 2 mM GDP or GMPPCP. Nucleotide dissociation was measured as a change in 
fluorescence over time (excitation, 360 nm; emission, 440 nm) using a SpectraMax M2 plate 
reader at 25°C. Fluorescence data was fit to a one-phase exponential decay curve using 
GraphPad Prism 5.  
Nucleotide Association Assay 
 Nucleotide association rates were determined using fluorescence-based assays (189). 
Briefly, Ras proteins were loaded with either GDP or GMPPCP and loading was verified using 
HPLC. Ras proteins were added to 1 ml of assay buffer (20 mM HEPES, 50 mM NaCl, 5 
mM MgCl2, pH 7.4) to a final concentration of 5 μM for GDP-bound association assays. EDTA 
was added in slight molar excess to the MgCl2 (1:1.25 molar ratio) to stimulate nucleotide 
loading. Mant-GDP was added to start the association reactions (0.25 μM). The rate of Mant-
labeled nucleotide association was measured as a change in fluorescence intensity over time 
(excitation, 365 nm; emission, 435 nm) (LS50B PerkinElmer Life Sciences luminescence 
spectrometer). Fluorescence data were fit using GraphPad Prism 5 software to a one-phase 
exponential association curve. GMPPCP association assays were conducted in a similar manner 
as described above (2.5 μM protein, 0.125 μM Mant-GMPPCP and no EDTA). 
Thermal Stability of Ras 
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CD (circular dichroism) data were collected on a Jasco J-815 CD spectrometer. UV CD 
scans were collected using a 1-mm cuvette at a concentration of 15 μM KRas protein and 15 uM 
nucleotide in a sparged buffer containing 10 mM KH2PO4
3−/K2HPO4
3−, 500 μM MgSO4, pH 7.2, 
at 20 °C. Thermal melts were obtained over a temperature range of 20–95 °C using a temperature 
increment of 2 °C per min. The CD signal was measured at 222 nm. Tm values were calculated 
by fitting the mean residue ellipticity to a Boltzmann sigmoidal equation, where V50 is 
representative of the melting temperature. Data calculations were completed using GraphPad 
Prism 5.  
NMR Analyses 
For NMR measurements, 1H-15N-enriched Ras proteins were produced using standard 
methods in M9 minimal media (190). Proteins were exchanged into NMR buffer (20 mM 
HEPES, 50 mM NaCl, 5 mM MgCl2, 5% D2O, 3% d6-DMSO, (pH 6.8)) with 1:1 molar ratio of 
protein to nucleotide. NMR spectra were acquired at 25 °C on a Bruker Avance III 850 NMR 
spectrometer. 2D 1H-15N HSQC experiments were recorded for KRasWT and KRasK5N in both 
GDP- (50 μM) and GMPPCP-bound (40 μM) forms. Data was collected as 2048 and 128 
complex points in the direct and indirect dimensions, respectively with 32 scans per increment. 
Spectral widths used were 11904.762 Hz (1H) and 3102.058 (15N) Hz. Spectra were processed 
using NMRFAM sparky (187). 1H-15N chemical shift perturbations (CSPs) were calculated using 
the square root of ((Δσ 1H)2 + (Δσ 15N)2/25), where Δσ 1H and Δσ 15N are the observed changes 
in 1H and 15N chemical shifts. 
Molecular Dynamic Simulations 
United-atom Molecular Dynamics (MD) simulations of Mg2+-GDP and GTP- bound Ras 
WT and Ras K5N were conducted in Gromacs 2018 using GROMOS 54a7 force field 
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parameters (163). An initial structure of GDP- or GTP-bound Ras was constructed using high 
resolution X-ray structures from the protein data bank (PDB ID 1CRP (48) and 4G0N (55)). The 
coordinates for the missing Ras WT residues in 4G0N were reconstructed using the Ras structure 
2C5L (157). Mutations were corrected to generate Ras WT using PyMol 2.1 (Schrödinger, LLC). 
The Ras K5N mutation was constructed using PyMol 2.1 (Schrödinger, LLC). GTP topology and 
parameters files for GROMOS 54a7 force field were generated using the Automated Topology 
Builder version 2.2 (161),(162). GTP charges were optimized using the Antechamber module 
from AmberTools package (191). To begin the simulations, Ras- Mg2+-GDP, Ras- Mg2+-GTP 
was solvated using a TIP3P water box. The system was neutralized by the addition of sodium 
ions, and the system was allowed to equilibrate at 300K. All simulations were run at constant 
temperature for a total of 200 ns. We determined that the system reached equilibrium by 2 ns by 
analyzing the root-mean-square deviation (RMSD) of backbone Cα position distribution during 
the simulations. The initial 2 ns simulations were omitted from the trajectories for the analysis. 
To select representative models of GDP- or GTP-bound Ras WT and Ras K5N, clustering 
analysis was performed using a GROMACS clustering algorithm (137). The distance cut-off for 
clustering was chosen to be 1.5 Å, to correlate with distances of high-resolution X-ray 
crystallographic structures. The structures of the lowest energy centroids associated with the 
most populated clusters for each protein or protein-protein complex were examined using PyMol 
2.1 (Schrödinger, LLC). Final models were constructed using UCSF Chimera 1.13.1 (188). 
Isothermal Titration Calorimetry (ITC) 
The binding affinities of KRas-4B (C118S) wild type, and KRas-4B (C118S) K5N to 
effector proteins were determined using a MicroCal PEAQ-ITC (Malvern Paranalytical). All ITC 
experiments were performed in a buffer containing 20 mM HEPES, 50 mM NaCl, 5 mM MgCl2, 
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1 mM 2-mercaptoethanol. Ras proteins (150 μM or 200 μM) were titrated into effector proteins 
(BRaf RBD, CRaf RBD and PI3K-α). Starting effector to Ras molar ratios were roughly 1:10 or 
1:15. The heat of the binding event was measured after an initial 120 second delay at 25°C for 19 
2-uL injections with a stirring speed of 650 rpm. Injections were spaced at 180 seconds. Heats 
released during the last few injections (when saturation had occurred) were averaged and 
subtracted from all the heat peaks (control subtraction). Data were analyzed using a nonlinear 



































Chapter 4. A KRas GTPase K104Q Mutant Retains Downstream Signaling by Offsetting 
Defects in Regulation2 
Introduction 
 RAS proteins function as molecular switches that cycle between active GTP- and inactive 
GDP-bound states to regulate signal transduction pathways that modulate cellular growth 
control. In the unstimulated cell, RAS proteins are populated in their inactive GDP-bound state. 
However, in response to growth-stimulatory signals, guanine nucleotide exchange factors (GEFs) 
(8) co-localize and up-regulate RAS by facilitating exchange of GDP for GTP. Inactivation of 
RAS is achieved through GTPase-activating proteins (GAPs) that bind to GTP-bound RAS and 
promote GTP hydrolysis (8),(53). Several point mutations in RAS have been identified that 
dysregulate RAS nucleotide exchange or hydrolysis, often leading to hyperactivation and 
promoting tumorigenesis. The most common RAS mutations identified in cancer occur at 
residues 12, 13, and 61 and render RAS GAP defective, thereby populating RAS in its active 
GTP-bound state (82). Constitutive hyperactivation of RAS promotes chronic stimulation of 
effector-mediated downstream pathways, causing deregulated growth and tumorigenic growth 
transformation. 
RAS contains two dynamic regions termed switch I (SWI; residues 30–37) and switch II 
(SWII; residues 60–76 with 66–74 corresponding to helix 2 (H2)) that populate distinct 
conformations when the protein is bound to GDP versus GTP. Effectors and GAP proteins 
                                                 
2 This chapter previously appeared as an article in the Journal of Biological Chemistry. This original citation is as 
follows: Yin, G.; Kistler, S.; George, S. D.; Kuhlmann, N.; Garvey, L.; Huynh, M.; Bagni, R. K.; Lammers, M.; Der, 
C. J.; Campbell, S. L. A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in 
Regulation. J. Biol. Chem. 2017, 292 (11), 4446–4456. https://doi.org/10.1074/jbc.M116.762435. 
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recognize specific conformations of the switch regions and bind with preferential affinity to the 
active GTP- bound state. Activated GTP-bound RAS can interact with multiple effectors 
(e.g. RAF kinase, RAL exchange factors, phosphoinositol 3-kinase (PI3K), the RAC-selective 
GEF TIAM1, phospholipase C, NORE1) to promote downstream signaling pathways that control 
cell growth, differentiation, and apoptosis (107). 
RAS proteins show high sequence conservation within their core guanine nucleotide 
binding domain (G domain) yet possess a hypervariable C terminus. The hypervariable region 
undergoes a variety of post-translational modifications (PTMs) that facilitate membrane 
association and drive differences in localization and activity (61). Additionally, several lysines 
within the core G domain of RAS undergo post-translational modifications, including 
acetylation, ubiquitylation, and methylation (61), but the role of these distinct modifications in 
regulating RAS function is still unclear. For example, KRAS monoubiquitylation at lysine 147 
up-regulates RAS activity, signaling, and tumorigenesis (62). Additionally, lysine 104 has been 
shown to be a minor site of ubiquitylation, and we have previously shown that ubiquitylation of 
KRAS at this position does not alter the intrinsic biochemical properties or regulation by GEFs 
and GAPs (65). In contrast, lysine 104 acetylation was reported to down-regulate KRAS G12V-
driven effector signaling and growth transformation in NIH 3T3 cells (67),(126). Whereas 
knockdown of two deacetylases, HDAC6 and SIRT2, reduced the viability of NIH 3T3 cells 
expressing the oncogenic KRAS G12V mutant (126), recent findings indicate that Ac-Lys104 is 
not a direct substrate for HDAC6 and SIRT2 under the conditions tested (68). A KRAS K104Q 
variant was used as an acetylation mimetic to evaluate how acetylation alters KRAS signaling. 
Molecular dynamics (MD) simulations indicated that the KRAS K104Q mutation completely 
disrupts the structural integrity of H2 (67), consistent with in vitro observations that SOS1-
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stimulated nucleotide exchange was impaired by 75%. However, the ability of KRAS K104Q to 
undergo GAP-stimulated GTP hydrolysis was not assessed (67). In NIH 3T3 cells, the K104Q 
mutation impaired KRAS G12V-driven effector signaling and growth transformation (67). 
To better understand how perturbations at position 104 of KRAS alter intrinsic 
biochemical properties, structure, and regulatory and effector interactions, we characterized 
mutations at this position, including a K104Q mutant that has previously been employed as an 
acetylation mimetic (67). We find that the K104Q mutation perturbed both GEF- and GAP-
stimulated guanine nucleotide exchange and GTP hydrolysis, respectively, yet did not alter either 
CRAF RAS binding domain (RBD) or PI3Kγ binding. However, in contrast to previous MD 
predictions, our NMR analyses indicated that KRAS K104Q does not fully disrupt SWII but 
rather causes a partial disruption of H2. Given these observations, we measured the thermal 
stability (melting temperature (Tm)) of WT, K104Q and Ac-Lys
104 KRAS using circular 
dichroism (CD). We found that both K104Q and Ac-Lys104 show a modest decrease in Tm of 1.5 
and 3.7 °C, respectively, relative to WT KRAS. Moreover, we found that K104Q did not 
significantly impair WT KRAS function, as measured by the ability to restore growth to Rasless 
mouse embryo fibroblasts (MEFs). In slight contrast to a previous study, we also found that 
K104Q did not significantly alter mutant KRAS G12V effector signaling and induction of 
morphologic transformation. Taken together, our data indicate that the KRAS K104Q impairs the 
structural integrity of H2 and RAS regulation by GEFs and GAPs in vitro but does not 
significantly alter the steady-state level of GTP-bound protein in NIH 3T3 cells. Consistent with 
our findings that KRAS K104Q retains effector engagement in vitro and GTP levels in cells, the 
K104Q substitution did not significantly alter either WT KRAS or G12V biological activity. We 
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postulate that the consequences of the K104Q substitution on GAP and GEF regulation probably 
offset each other to maintain the active GTP-bound state and effector signaling in cells. 
 
Results 
KRAS Lys104 Mutations Disrupt SOScat-mediated Nucleotide Exchange and p120 GAPcat-
mediated Hydrolysis 
RAS proteins cycle between inactive GDP- and active GTP-bound states to coordinate 
downstream signaling and cellular growth. Lysine 104 in KRAS undergoes multiple PTMs, yet 
the role of this residue in intrinsic RAS function has not been well characterized. In the X-ray 
structure of KRAS bound to GDP (PDB code 4LPK), the side chain of lysine 104 interacts with 
the backbone carbonyl group of Arg73 and Gly75contained within SWII. Disruption of these 
interactions has been proposed to perturb the structural integrity of SWII and alter interactions 
with regulatory proteins and effectors that interact with SWII (192),(193). Moreover, 
Arg102 and Val103, surrounding Lys104 in H3, interact directly with the SOS catalytic domain 
(PDB code INVW) (36). Hence, mutations or PTMs that perturb these interactions may prevent 
proper SOS-mediated up-regulation of RAS. Consistent with these observations, it has been 
shown previously that KRAS K104Q disrupts SOScat-mediated nucleotide exchange (67). KRAS 
K104Q has been dubbed an acetylation mimetic, yet how this mutation affects the structure of 
RAS, GAP-mediated GTP hydrolysis, and effector recognition has not been determined. To 
further investigate the role of non-conservative and conservative mutations at this key position, 
we mutated residue Lys104 to glutamine, arginine, and alanine and monitored the rate of 
MANT-GDP nucleotide dissociation in the absence and presence of SOScat. As shown in Figure 
4.1A, all three mutations impaired SOS-mediated nucleotide exchange. In particular, a reduction 
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in the rate of GDP dissociation by 78% for K104Q, 75% for K104R, and 50% for K104A was 
observed in comparison with WT KRAS (12.5 ± 0.2 × 10−4 s−1) (Figure 4.1A and Table 4.1). 
All three mutations, even the K104R variant that retains the side chain positive charge, impaired 
SOS-mediated exchange. Although KRAS K104R has previously been reported to retain GEF 
activity (67), we find that this conservative substitution (K104R) impaired SOS regulation of 
RAS nucleotide exchange. These findings indicate that Lys104 plays an essential role in SOScat-
mediated nucleotide exchange of KRAS. Because the K104Q variant was predicted to impair the 
structural integrity of SWII (67), which is also important for GAP-mediated down-regulation of 
RAS activity, we measured both the intrinsic and GAP-mediated rate of GTP hydrolysis (Table 
4.1). Although the intrinsic rate of GTP hydrolysis for KRAS K104Q is similar to that of WT 
KRAS, we found a significant reduction (53%) in the p120 GAPcat-stimulated rate of GTP 
hydrolysis (Figure 4.1B). Taken together, these data suggest that the K104Q mutation, which 
has been used as a RAS acetylation mimic, impairs regulation of GDP/GTP cycling by both 











Figure 4.1. The KRAS K104Q mutation impairs regulation by GEFs and GAPs yet retains effector binding 
interactions with RAF and PI3K RAS binding domains.  
A. E. coli-expressed and purified WT and mutant (K104Q, K104R, and K104A) were loaded with MANT-
GDP, and the rate of GDP dissociation was determined by monitoring the decrease in MANT-GDP 
fluorescence emission over time in the absence and presence of an SOS (Ras/SOS = 1:1). Data were fit to an 
exponential dissociation curve. Rates are reported as the mean ± S.E. (error bars) (n = 2). B. p120 GAP-
mediated GTP hydrolysis, as determined using single-turnover GTP hydrolysis for KRAS WT and K104Q in 
the absence or presence of p120 GAP (GAP/Ras = 1:200). Hydrolysis was initiated by the addition of Mg2+ 
and monitored by the change in fluorescence of the protein, Flippi, upon binding free phosphate. Data were 
converted to phosphate concentration using a standard curve. Results are the mean ± S.E. (n = 2). C. The 
binding affinity of KRAS WT and K104Q to CRAF RBD, BRAF RBD, and PI3Kγ K802T was determined by 
loading KRAS proteins with MANT-GMPPCP and measuring nucleotide release rates as a function of 
effector protein concentration. To determine the affinity (KD) for the KRAS-effector complex, the data were 
fitted to a standard curve. Relative binding affinity to KRAS WT is shown with original values included in 
Table 1. Results are reported as the mean ± S.E. (n = 2). All of the original values are listed in Table 1. 
 
Table 4.1.  Biochemical Properties of KRas WT and K104 mutant proteins. 
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Upon GEF-mediated GDP exchange for GTP, RAS-GTP undergoes a conformational 
change in both the SWI and SWII regions. This in turn promotes binding to downstream 
effectors (16). Although SWI is a primary binding site for a subset of RBDs (i.e. RAF and 
RALGEFs), some effectors (i.e. PI3K, PLCϵ, and NORE1) bind to RAS using both SWI and 
SWII regions (16). To assess whether the K104Q mutation alters KRAS effector interactions, we 
determined the binding affinity of KRAS K104Q to the RAS RBDs of CRAF and BRAF as well 
as PI3Kγ, by monitoring the dissociation rate of MANT-GMPPCP as function of RAS effector 
concentration (Table 4.1). Results from these analyses indicate that KRAS K104Q retains 
binding to RAF RBDs and PI3Kγ relative to WT RAS (Figure 4.1C). 
The KRAS K104Q and Ac-Lys104 Decrease Thermal Stability 
To evaluate the effects of side chain modification at Lys104 on thermal stability, we 
measured the Tm for His6-WT KRAS, K104Q, and Ac-Lys
104 by CD, by monitoring the thermal 
transition as a function of temperature, as shown in Figure 4.2A. We found that K104Q and Ac-
Lys104 KRAS showed similar cooperative unfolding transitions but possessed a lower Tm (K104Q 
(64.2 ± 0.1 °C), Ac-Lys104 (62.0 ± 0.5 °C)) in comparison with WT KRAS (65.8 ± 0.4 °C). The 
small Tm changes shown in Figure 4.2B indicate that acetylation or mutation of the Lys
104 side 







Figure 4.2. Ac-Lys104 and K104Q KRAS show decreased thermal stability relative to WT KRAS.  
A. the CD signal at 222 nm was monitored as a function of temperature (20–95 °C) for His6-WT KRAS, 
K104Q, and Ac-Lys104 (20 μM) bound to GDP. B. the midpoint of the thermal transition (Tm) was determined 
by fitting the temperature dependence in A. Results are reported as the mean ± S.E. (error bars) (n = 3). 
The KRAS K104Q Mutation Perturbs the Conformation of Helix 2 and Helix 3 
Given the decrease in protein stability observed for KRAS K104Q, we conducted NMR 
studies to investigate whether the mutation alters KRAS structure. The RAS switch regions 
undergo distinct conformations when bound to either GDP or GTP. These conformational 
changes are key to recognition of GAPs and effector proteins as well as GTP-dependent SOS 
allosteric regulation (194). Based on the crystal structure of KRAS bound to GDP (PDB code 
4LPK), the Lys104 amino side chain interacts with the backbone carbonyls of Arg-73 and Gly-75 
located at the end of SWII (Figure 4.5A). These interactions were previously predicted to play a 
key role in the structural integrity of SWII, because MD simulations suggested that both the 
KRAS K104Q mutation and Lys104 acetylation cause complete disruption of H2 within SWII 
(67). However, given our findings that KRAS K104Q retains the ability to hydrolyze GTP 
(Figure 4.1B), it is unlikely that helix 2 undergoes a full helix-coil transition upon mutation or 
acetylation. To better address this apparent discrepancy, we employed NMR spectroscopy to 
characterize structural and dynamic changes in KRAS upon mutation of lysine 104 to a 
glutamine. We first assigned the backbone resonances of WT and KRAS K104Q bound to 
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Mg2+ and GDP by acquiring a series of triple resonance NMR experiments on 13C,15N-enriched 
KRAS 1–169 (195). We were able to assign 159 and 161 of 167 non-proline backbone NH, Cα, 
and Cβ resonances for WT and KRAS K104Q, respectively. A 2D 1H-15N heteronuclear single 
quantum coherence (HSQC) spectral overlay of K104Q and WT KRAS bound to GDP is shown 
in Fig. 3. 1H-15N HSQC spectra allow for the detection of protons directly bonded to a 15N, 
including both backbone and side chain NH resonances. Because an NH resonance can be 
detected for every residue with the exception of proline, the spectrum contains a “fingerprint” of 
the protein backbone. Inspection of chemical shift differences between KRAS WT and K104Q 
bound to GDP show that ∼30% of the backbone NH peaks undergo changes in peak position. 
Using chemical shift perturbation (CSP) analyses (Figure 4.4A), we found that the largest CSPs 
(>0.2 ppm) corresponded to residues proximal to the site of the mutation (positions 102–110) 
and within SWII. Smaller (<0.2 ppm) CSPs were observed for residues within the first β-sheet. 
In contrast, residues in SWI do not show significant CSPs. These findings are consistent with 
perturbation of contacts between Lys104, Arg73, and Gly75at the end of SWII due to mutation of 




Figure 4.3. 2D 1H-15N HSQC NMR spectral overlay of 15N-enriched KRAS K104Q (red) and WT (blue). 
Residues that show significant chemical shift perturbations (CSP > 0.15) are marked. Spectra were recorded 




Figure 4.4. K104Q causes structural and dynamic perturbations primarily in helix 2 and helix 3.  
A. NMR analyses of peak shifts reveal that the K104Q mutation causes large CSPs in switch II and residues 
102–110 in helix 3 but minor changes in β1 and switch I. CSP was calculated based on weighted average 
chemical shift (square root of ((Δσ 1H)2 + (Δσ 15N)2/25)) of WT and K104Q KRAS NH peaks in 1H-15N 2D 
HSQC NMR spectra. B. differences in secondary structure were determined from Cα and Cβ chemical shift 
indexing. C. the difference in chemical shift indexing between K104Q and WT KRAS indicates that the 
KRAS K104Q mutation perturbs the local conformation surrounding 104 in H3 and the later part of the α2 
helix (residues 71–74) in switch II. D, NH RDCs were obtained from alignment in Pf1 bacteriophage with 
deuterium splitting of ∼15 Hz. Switch I, switch II, and H3 are highlighted in pink (ribbon). NMR spectra were 




Because a comparison of Cα and Cβ chemical shifts can be used to evaluate differences 
in secondary structure (196), we employed chemical shift indexing (CSI) to compare secondary 
structural differences between K104Q and WT KRAS (Figure 4.4B). We found that overall, the 
secondary structure of WT KRAS is similar to K104Q with the exception of H2 and H3. In 
contrast to MD predictions that KRAS K104Q completely disrupts the structural integrity of the 
SWII region, CSI analyses (Figure 4.4C) indicate loss of secondary structure for residues 70–74 
at the C-terminal end of H2 and loss of helical content for residues 102–103 in helix 3 (H3) near 
the mutation site (Figure 4.4B), which is consistent with the Tm decrease observed for K104Q. 
These secondary structural changes correlate with the large CSP observed for these residues 
(Figure 4.4A). The perturbed regions revealed by NMR are highlighted in the 3D structure 
(Figure 4.5B). Small distortions in secondary structure were also observed for the first half of 
SWII, β1, and the loop between SWI and SWII. However, SWI is unperturbed, consistent with 
our findings that binding of K104Q to effector RBDs is retained (Figure 4.1C). We also 
collected backbone NH residual dipolar coupling (RDC) data to generate long range distance 
constraints and evaluate changes in tertiary structure. As shown in Fig. 4D, comparison of the 
RDC profile for WT and KRAS K104Q indicates that the K104Q mutation does not significantly 






Figure 4.5. The side chain of Lys104 in helix 3 interacts with helix 2 in switch II.  
A. expanded region illustrating interactions between H3 and H2, derived from the X-ray structure of KRAS-
GDP (PDB 4LPK, resolution 1.5 Å). Hydrogen atoms were added to structure using XLeap (Amber). The 
Lys104 amino side chain is in close proximity to backbone carbonyl oxygens of Arg73 (H2) and Gly75 in switch 
II. B. structural perturbations revealed by NMR are mapped on the 3D structure (PDB code 4LPK). Switch I 
and switch II are colored with pink and purple, respectively. Lys104 is represented by spheres. The perturbed 
regions, as determined by NMR-derived CSP and chemical indexing, are highlighted in red for the latter part 
of the H2 and the α2-β4 loop (residues 71–76) and yellow for residues 102–103 in H3. 
The KRAS K104Q Shows Backbone Dynamics Similar to Those of WT KRAS 
The switch regions of RAS have been shown to sample multiple conformations in both 
the GDP- and GTP-bound states, as revealed by NMR (48),(197),(198). Conformational dynamic 
properties of these key regions are important for recognition of regulatory and effector proteins. 
Given the disruption in secondary structure within SWII, we evaluated whether the K104Q 
mutation alters backbone dynamic properties of KRAS, in the absence of regulatory proteins or 
effectors. We collected spin relaxation parameters R1 (Figure 4.6A), R2 (Figure 4.6B), and 
15N-
(1H) NOE (Figure 4.6C) and fit them to spectral density functions for obtaining order 
parameters (199). The order parameter S2provides a measure of restriction of motion over the 
picosecond to nanosecond range; whereas S2 = 1 suggests that the NH vector is rigidly fixed in 
the molecular frame, S2 = 0 is indicative of high mobility. Consistent with an increase in 
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backbone motion due to structural perturbations at residues proximal to the site of mutation and 
the C-terminal end of H2, reduced S2 values were observed in the loop (positions 104–107) 
between H3 and β5 (Figure 4.6D) as well as for residues 72–73 in SWII. A smaller decrease 
in S2 is observed for residues in SWI. We also observed that the K104Q mutation slightly 
enhances fast time scale backbone motions for the loop preceding H2 and residues 94–96 in H3. 
Taken together, these observations are consistent with our findings that H2 and H3 undergo 
small scale structural distortions and that the altered GEF and GAP activities observed for KRAS 








Figure 4.6. Backbone 15N relaxation parameters for K104Q KRAS (red) and WT KRAS (blue).  
Shown from top to bottom, plotted against residue number, are longitudinal relaxation R1 (A), transverse 
relaxation R2 (B), (1H)-15N steady state heteronuclear NOE (Isaturated/Iunsaturated) (C), and order parameter S2 
(D). Switch I, switch II, and H3 are highlighted in pink (ribbon) with secondary structure content represented 
at the top. Residue 104 at the end of H3 is labeled in red. All measurements were performed on KRAS WT 
and K104Q bound to GDP. NMR data were collected at 25 °C on 0.2 mm KRAS WT and K104Q samples 
using a Bruker Avance III 700 NMR spectrometer. 
KRAS K104Q Does Not Affect Growth in MEFs 
Because the KRAS K104Q mutation is impaired in GEF/GAP-mediated nucleotide 
cycling yet retains the ability to bind the RAF RBDs and PI3Kγ, we conducted studies in cell 
culture to determine the role of the K104Q mutation in KRAS-driven cellular growth. For these 
studies, we employed the use of Rasless MEFs, which lack endogenous Hras and Nras, and a 
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conditional Kras allele that can be ablated by activation of a knocked-in 4-hydroxytamoxifen-
inducible CreERT2 recombinase (200). 4-Hydroxytamoxifen treatment was done to induce Cre-
mediated disruption of the Krasallele with blotting analyses to verify loss of endogenous Kras 
protein expression (Fig. 7A). These viable but non-proliferating cells were then used to assess 
the ability of either WT KRAS or KRAS K104Q to rescue loss of endogenous Kras and restore 
proliferation. We found that both K104Q and WT KRAS were equally capable of promoting 
MEF proliferation, as assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) growth assays (Figures 4.7, B and C). These results suggest that KRAS acetylation may 
not impair the ability of KRAS to drive growth in a KRAS-dependent system. Based on our 
findings that K104Q is impaired in both GEF and GAP regulation, the disruption in GEF-
mediated up-regulation by the K104Q mutation may be partially offset by a defect in GAP-
mediated down-regulation of KRAS. Our findings that KRAS K104Q supports the growth of 
Rasless MEFs indicate that this mutant can still efficiently activate the RAF-MEK-ERK 










Figure 4.7. Exogenous KRAS K104Q expression supports the growth of Rasless MEFs.  
A. the anchorage-dependent growth rate was determined for MEFs deficient for all Ras isoforms with 
ectopically expressed KRAS WT or K104Q. B. cells were plated, and growth was monitored at days 1, 4, and 
7 using the MTT viability assay. Data shown are representative of two independent experiments. Data are the 
mean ± S.D. (error bars) (n = 48). Student's t test determined that the difference was not significant (NS). C. 
quantitation of the average ± S.D. of three independent experiments for day 7. Data shown are the average of 
three independent experiments. 
The KRAS K104Q Variant Retains RAS Activity, Downstream Signaling to Critical KRAS 
Effectors, and KRAS-driven Transformation in NIH 3T3 Cells 
We next assessed the consequences of the K104Q substitution for the cellular activity of 
WT and G12V KRAS when transiently expressed in NIH 3T3 mouse fibroblasts. First, we 
performed a RAF-RBD pull-down analysis to assess the relative steady-state levels of activated 
GTP-bound KRAS protein. The K104Q substitution did not significantly alter the low level of 
GTP-bound protein for WT KRAS or the elevated level for KRAS G12V (Figure 4.8). 
Similarly, KRAS G12V- and KRAS G12V/K104Q-expressing cells exhibited comparable levels 
of effector signaling, with equivalent levels of phosphorylated and activated ERK and AKT 
(Figure 4.9) and morphologic transformation (Figure 4.10). We conclude that mutation of 




Figure 4.8. The K104Q mutation does not alter the levels of GTP-bound KRAS.  
CRAF RBD pull-down analyses were done using cell lysates from NIH 3T3 cells transiently expressing (72 h 
post-infection) the indicated HA epitope-tagged KRAS WT or mutant proteins. GST-CRAF RBD was used to 
monitor the level of GTP-bound KRAS protein, with total expression determined by anti-HA blot of total 
cellular lysates. Data shown are representative of three independent experiments. Quantitation of three 
experiments done in A (n = 3), with KRAS-GTP levels normalized to total HA-tagged KRAS levels. Error 
bars, S.E. Student's t test determined that the difference was not significant (NS). 
 
Figure 4.9. The K104Q mutation does not alter KRAS effector signaling in NIH 3T3 cells.  
Shown is Western blotting analysis of total cell lysates from mass populations of NIH 3T3 cells transiently 
infected (72 h) with retrovirus expression vectors encoding the indicated KRAS proteins. Blotting analyses 
with antibodies for total or phosphorylated and activated AKT and ERK (pAKT and pERK, respectively) 




Figure 4.10. The K104Q mutation does not alter wild type or activated KRAS morphologic transforming 
activity.  
Shown is a photomicrograph of mass populations of NIH 3T3 cells transiently (24 h) infected with pBabe-
puro retrovirus expression vectors encoding the indicated KRAS proteins. 
Discussion 
Whereas GEF and GAP proteins play a critical role in regulating the activation state of 
RAS proteins, post-translational modifications within the G domain of RAS add another level of 
complexity. Lysine 104 in KRAS undergoes multiple PTMs, including acetylation (67) and 
ubiquitylation (62). Because oncogenic mutations at this position have not been identified in H-, 
N-, or KRAS, the role of this key residue has not been well characterized. Here, we show that 
both conservative and non-conservative mutations at KRAS lysine 104 (Gln, Arg, and Ala) 
impair SOScat-mediated nucleotide exchange. The K104Q mutant also impairs p120 RASGAPcat-
mediated GTP hydrolysis. Consistent with these observations and our findings that KRAS 
K104Q shows a small decrease in thermal stability (1.5 °C), NMR structural analysis indicates 
that the K104Q mutation perturbs protein conformation proximal to the site of mutation in H3 as 
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well as the end of H2 in SWII. Both of these regions are part of the RAS/SOScat binding interface 
(36). Residues 61–64 and 67 in SWII also form binding interactions with RAS GAPcat (13). 
Residues within H2 and H3 of RAS form multiple interactions with SOS1cat in crystal 
structures of RAS proteins bound to SOS1 (PDB codes iBKD, 1NVW, and 1XD2) 
(36),(54),(131). In particular, Arg102 in H3, next to the mutation site, forms contacts with 
Phe1010and Asp1007 in SOScat. Valine 103 in H3 interacts with Ser881 in SOScat. Moreover, 
residues Gln70, Tyr71, and Arg73 at the end of H2 in RAS form multiple binding interactions 
with SOScat (201). Specifically, Tyr71 forms a hydrogen bond with Tyr912 of SOScat. 
Additionally, the side chain of Arg73 forms a hydrogen bond with the carboxyl oxygen of 
Asn879, and its aliphatic side chain forms additional interactions with the aromatic ring of 
Tyr884 in SOScat. Thus, structural distortions due to either mutation or PTM in H2 could 
potentially impair binding interactions to SOScat. Given the structural distortions observed for 
residues in SWII and H3, it is not surprising that binding to and subsequent nucleotide exchange 
ability of SOScat is impaired by the K104Q mutation (36),(201). In addition to SOS, residues in 
SWII, including Glu63 and Tyr64, make multiple contacts with RAS GAP proteins (PDB 
code1WQ1) (13). Structural distortions at the end of SWII may cause more subtle changes in 
these key residues, resulting in the partial disruption of GAP-mediated GTP hydrolysis, observed 
for KRAS K104Q. 
Consistent with our findings that the structure of the KRAS SWI region is not perturbed 
by the K104Q mutation, the KRAS K104Q mutant shows similar binding to isolated RAS 
effector RBDs, such as CRAF and BRAF, which bind exclusively through SWI (PDB code 
4GON). A distinct effector, PI3Kγ, interacts with RAS primarily at SWI but also forms 
additional contacts with Tyr64 and Arg73 in SWII (PDB code 1HE8). Despite the structural 
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perturbations induced by the KRAS K104Q mutation in the SWII region, KRAS K104Q retains 
binding to PI3Kγ. Whereas RAS interacts with a number of downstream effectors to regulate 
cellular growth, our analyses in Rasless MEFs indicate that the K104Q substitution does not 
prevent KRAS WT from driving proliferation in this biological context. Furthermore, our 
analyses in NIH 3T3 cells indicate that K104Q did not significantly alter the steady-state GTP-
bound state or effector signaling and activation of ERK or AKT. These studies also indicate that 
KRAS G12V/K104Q is equally capable of driving morphologic transformation in NIH 3T3 cells. 
Hence, if K104Q functions as an acetylation mimetic, our studies indicate that this PTM may not 
significantly impair mutant RAS oncogenic function in these cells. Our findings differ from 
those described previously (67), where K104Q did reduce KRAS G12V stimulation of NIH 3T3 
cell proliferation. Because these analyses evaluated morphologic and not growth transformation, 
our results cannot be directly compared with those of the previous study. One possible 
explanation for our different conclusions is that there exist multiple strains of NIH 3T3 cells and 
there are strain-specific differences in the mechanisms by which RAS drives growth 
transformation (202). 
In summary, we found that the K104Q mutation in KRAS impaired GEF and GAP 
regulation but retained interactions with RAF and PI3Kγ RBDs. Our observations that signaling 
and cellular growth properties of K104Q are similar to those of WT KRAS suggest that the 
partial defect in GEF is at least partially offset by a defect in GAP regulation to retain RAS 
signaling. It is unclear whether the K104Q mutation or acetylation at this position perturbs 
interactions with all RAS GEFs. Whereas the CDC25 domains associated with RASGRP and 
RASGRF proteins show high homology (35),(203), allosteric regulation of these GEFs is quite 
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distinct from that of SOS1. Moreover, crystal structures of these GEFs in complex with RAS are 
lacking. 
Given the difficulties in preparation of various protein PTMs, mutations are often used as 
reagents to either mimic the desired modification or prevent the PTM. Although K104Q has been 
employed as an acetylation mimetic, this has yet to be truly validated (70). In fact, 
Lys104 acetylation has recently been reported to retain SOS activity (68). Computational analysis 
of the Ku protein revealed that acetylation of the Ku may not alter DNA interaction, yet a K-to-Q 
mutation decreased the binding compared with the WT protein (70). Indeed, the side chain of 
glutamine is quite distinct from an acetylated lysine in both size and composition, and it is 
unlikely that the K104Q mutant will be recognized by acetylation readers or deacetylases, such 
as SIRT2 and HDAC6, in a similar manner to native acetylated RAS (117). Although emerging 
data indicate that Lys-to-Gln mutations may not fully mimic acetylation, our studies do indicate 
that Lys104, a hot spot for RAS PTMs, plays a key role in maintaining the structural integrity of 
H3 and H2. Given the proposed role of H3 in RAS-mediated dimerization at the membrane, it is 
possible that KRAS acetylation may alter RAS dimerization (204). It will be important to 
evaluate each PTM (acetylation, ubiquitylation) separately to determine how the PTM may 
directly alter RAS activity as well as protein-protein interactions. 
Materials and Methods 
Protein Expression and Purification 
The human KRAS4B (C118S) cDNA sequence encoding the G domain (residues 1–169) 
was subcloned into a pET21 vector that adds an N-terminal 6-histidine tag and a TEV protease 
cleavage site for expression of recombinant protein in Escherichia coli BL21(DE3) cells 
(Novagen). Standard site-directed mutagenesis techniques were used to generate KRAS cDNA 
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sequences encoding K104Q, K104A, and K104R missense mutants. The mutations were 
subsequently verified by DNA sequencing. E. coli BL21 (DE3) cells were grown at 37 °C in 
Luria-Bertani (LB) medium supplemented with ampicillin and chloramphenicol until A600 of 
∼0.5. The temperature was then lowered to 18 °C, and KRAS expression was induced with 0.5 
mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) after 30 min. The cells were grown for an 
additional 15 h at 18 °C. The cells were then harvested and pelleted at 4000 rpm, resuspended in 
a lysis buffer (20 mM HEPES, 500 mM NaCl, 1 mM MgCl2, 20 mM imidazole, 5% glycerol (pH 
7.75), and protease inhibitor phenylmethanesulfonyl fluoride (ACROS Organics)), and 
sonicated. The cell lysate was centrifuged at 15,000 rpm, and the supernatant was isolated. 
KRAS proteins were purified using nickel-nitrilotriacetic acid-agarose affinity chromatography 
(Qiagen), and the histidine tag was cleaved during overnight dialysis using TEV protease. If 
needed, KRAS proteins were further purified by size exclusion chromatography using a 
Sephadex G-75 column. Protein purity of >95% was obtained and verified by SDS-PAGE 
analysis. 
The catalytic domains of human SOS1 (SOScat, residues 566–1049) (131) and p120-
RASGAP (GAPcat, residues 764–981) were expressed in a pQlinkH vector (Addgene) and 
purified as described previously (63). cDNA sequences encoding the isolated RBDs of human 
BRAF (amino acids 149–232) and CRAF (amino acids 51–132) were subcloned in a pET28a 
bacterial expression vector encoding an N-terminal 6-histidine tag and TEV cleavage sites and 
subsequently expressed in BL21 (DE3) cells. The RBDs were purified using nickel-
nitrilotriacetic acid affinity chromatography. The N-terminal tags were cleaved overnight with 
TEV protease. The tagless BRAF RBD was further purified using size exclusion 
chromatography (Sephadex G-75) and verified to be >95% pure by SDS-PAGE analysis. 
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Purified PI3Kγ protein (amino acids 144–1102) containing a K802T substitution was kindly 
provided by Genentech. 
Expression and Purification of His6-WT KRAS, K104Q, and Ac-Lys
104 Proteins 
His6-WT KRAS (residues 1–169, containing a 12-amino acid N-terminal non-cleavable 
His6 tag) and K104Q were expressed in LB medium as His6-tagged fusion proteins (pRSF-Duet, 
Merck Biosciences) in E. coli BL21 (DE3) cells as described (68). The E. coliculture was grown 
to an A600 of 0.6 (37 °C; 160 rpm), and protein expression was subsequently induced by the 
addition of 300 μM IPTG and further incubated overnight for 16 h (18 °C, 160 rpm). KRAS 
containing an amber stop codon at Lys104, was co-expressed with a pRSF-Duet-1 vector 
containing the synthetically evolved Methanosarcina barkeri MS 
tRNACUA (MbtRNACUA)/acetyl-lysyl-tRNA-synthetase (pAcKRS3) pair in Terrific broth 
medium. The E. coli BL21 (DE3) KRAS Ac-Lys104 culture was grown to an A600 of 0.6 at 37 °C 
at 160 rpm and then supplemented with 10 mM N-(ϵ)-acetyl-lysine (Chem-Impex International 
Inc.) and 20 mM nicotinamide to inhibit the E. coli deacetylase CobB. The temperature was then 
reduced to 18 °C. After 30 min, protein expression was induced by the addition of 300 μM IPTG. 
The cells were then grown for 16 h at 20 °C. After expression, the cells were harvested (4000 
× g, 20 min) and resuspended in a buffer containing 50 mM Tris/HCl, pH 7.4, 100 mM NaCl, 5 
mM MgCl2, 2 mM β-mercaptoethanol, and 200 μM Pefabloc protease inhibitor mixture for His6-
WT KRAS and K104Q. For His6-KRAS Ac-Lys
104, a buffer containing 50 
mM K2HPO4/KH2PO4, pH 6.4, was used. The cells were lysed by sonication, and the soluble 
fraction (20,000 × g, 45 min) was applied to an equilibrated Ni2+-nitrilotriacetic acid affinity 
chromatography column. The column was washed with a buffer containing 10 mMimidazole and 
1 M NaCl, pH 6.4. The His6-KRAS proteins were eluted with an imidazole gradient of ∼10 
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column volumes covering 10–500 mM imidazole. The protein was concentrated by ultrafiltration 
and applied to a HiLoad 16/600 Superdex 75 pg size exclusion chromatography column (GE 
Healthcare). 
RAS Nucleotide Dissociation and Hydrolysis Assays 
The rate of nucleotide dissociation was measured by a fluorescence-based assay using 
MANT-GDP (BioLog, San Diego, CA) as reported previously (134),(135). Briefly, MANT-
GDP-bound RAS was added to 1 ml of assay buffer (20 mM HEPES, 50 mM NaCl, 5 
mM MgCl2, and 100 μM diethylenetriaminepentaacetic acid (DTPA), pH 7.4) to a final 
concentration of 1 μM, and nucleotide exchange was initiated by the addition of 1 mM GDP. 
MANT-GDP dissociation was measured as a change in fluorescence intensity over time 
(excitation, 365 nm; emission, 435 nm) (LS50B PerkinElmer Life Sciences luminescence 
spectrometer). Fluorescence data were fit in GraphPad Prism (GraphPad Software, La Jolla, CA) 
to a one-phase exponential decay curve. For GEF-mediated dissociation, 1 μM RAS and 1 
μM SOScat were used. Results are plotted as the mean ± S.E. (n = 3). 
Single-turnover GTP hydrolysis assays were performed as described previously (154) 
using the phosphate-binding protein Flippi 5U (Addgene) to detect inorganic phosphate released 
upon GTP hydrolysis (155). Flippi 5U was purified as described previously (155). All buffers 
were made phosphate-free by dialysis with 1 unit of nucleoside phosphorylase (Sigma) and 2 
mM inosine (Sigma). For GAP-mediated hydrolysis, 10 μM RAS was used with 0.05 μM p120-
RASGAPcat (1:200). The ratio of fluorescence emission was measured at 485 and 530 nm with 
an excitation of 420 nm on a SpectraMax M5 microplate reader (Molecular Devices). Hydrolysis 
curves were fit in GraphPad Prism to a one-phase exponential association curve. Results are 
plotted as the mean ± S.E. (n = 2). 
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Effector Binding Assay 
KRAS was preloaded with MANT-GMPPCP using methods described previously (28). 
For quantitative binding to CRAF and BRAF RBDs and PI3Kγ (amino acids 144–1102, 
containing a K802T substitution), MANT-GMPPCP-bound KRAS was incubated with the 
desired effector at a range of concentrations, in a buffer containing 50 mM HEPES, 50 
mM NaCl, and 5 mM MgCl2 at pH 7.4. Nucleotide dissociation was initiated by the addition of a 
1000-fold molar excess of unlabeled nucleotide, and the rate of dissociation was determined by 
monitoring the change in fluorescence of the MANT-GMPPCP-loaded protein (excitation and 
emission wavelengths of 335 and 485 nm, respectively) using a SpectraMax M2 plate reader 
(134). Each nucleotide dissociation curve was fit to a one-phase single exponential to 
determine kobs. The dissociation rates were plotted against the effector concentrations and fit as 
described previously (205) to determine the equilibrium dissociation constant (KD). 
Tm Measurements Using CD 
CD data were collected on a Jasco J-815 CD spectrometer. Far-UV CD scans were 
collected using a 1-mm cuvette at a concentration of 20 μM KRAS protein in a buffer containing 
10 mM KH2PO4
3−/K2HPO4
3−, 500 μM MgSO4, pH 7.2, at 20 °C. Thermal melts were obtained 
over a temperature range of 20–95 °C using a temperature increment of 2 °C/min. The CD signal 
was measured at 222 nm. Tm values were calculated by fitting the thermal denaturation data 
using non-linear fitting. Results are plotted as the mean ± S.D. (n = 3). 
NMR Analyses 
For NMR measurements, 13C,15N-enriched KRAS proteins were exchanged into NMR 
buffer (20 mM Tris-maleate (pH 6.5), 40 mM NaCl, 5 mM MgCl2, and 20 μM GDP, 5% D2O). 
NMR spectra were acquired at 25 °C on a Bruker Avance III 700 NMR spectrometer. 2D 1H-15N 
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HSQC experiments were recorded for both WT and K104Q KRAS bound to GDP, with 1024 
and 256 complex points in the direct and indirect dimensions, respectively, 32 scans/increment, 
and a recovery delay of 1.0 s. Spectral widths used were 9803.992 Hz (1H) and 2553.626 (15N) 
Hz. Average 1H-15N chemical shift perturbations were calculated according to the square root of 
((Δσ 1H)2 + (Δσ 15N)2/25), where Δσ 1H and Δσ 15N are the observed changes in 1H and 15N 
chemical shifts. Backbone resonance assignments of WT KRAS were obtained by analysis of 3D 
HNCA, HNCACB, CBCA(CO)NH, HNCO, and HN(CO)CA spectra recorded on 13C,15N-
labeled WT KRAS bound to GDP. The assignment of Cα, Cβ, CO, N, and HN chemical shifts 
was obtained by an iterative procedure using the program MARS (206) and manual inspection. 
Backbone assignment of 13C,15N-enriched K104Q KRAS (0.8 mM) was obtained by collecting 
3D HNCA and HNCACB data and using WT KRAS assignments. For CSI, ΔCα and ΔCβ values 
were calculated by subtracting experimental chemical shifts of Cα and Cβ from random coil 
values obtained from the ncIDP server (207). The value of ΔCα-ΔCβ was calculated to cancel 
the systematic offset contained in ΔCα and ΔCβ and then used to predict RAS secondary 
structure. For 15N-based backbone relaxation experiments, 15N longitudinal (R1) and transverse 
relaxation (R2) rates and 
1H-15N steady-state NOE were measured on 200 μM 15N WT and 
K104Q KRAS-GDP samples in NMR buffer at 700 MHz. Relaxation delays were as 
follows: R1measurements, 0.01, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1.0, 1.2, and 1.4 s; R2 experiments, 
15.01, 45, 165.11, 30.02, 135.09, 60.04, 105.07, 75.05, and 90.06 ms. The 15N-(1H) NOE and 
reference spectra were recorded in an interleaved manner with a 5.5-s 1H saturation time and the 
equivalent recovery time for the reference experiment. Order parameters (S2) were calculated by 
fitting relaxation parameters R1, R2, and 
15N-(1H) NOE using the programs FAST ModelFree 
(208) and ModelFree (209). Backbone NH RDCs were measured using Pf1 bacteriophage (20 
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mg/ml) (ASLA Biotech) with deuterium splitting of 15 Hz. The 1JNH constant was measured 
using an interleaved HSQC-TROSY. Spectra were processed and analyzed using NMRPipe 
(NIDDK, National Institutes of Health) and Sparky (University of California, San Francisco). 
Cell Lines 
NIH 3T3 mouse fibroblasts were obtained originally from Dr. Geoffrey Cooper (Boston 
University) and were maintained in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% calf serum (Colorado Calf Serum). Mouse embryonic fibroblasts devoid 
of endogenous Ras alleles (Rasless MEFs) were obtained from Dr. Mariano Barbacid (CNIO 
Madrid) and were maintained in DMEM supplemented with 10% calf serum (200). 
Rasless MEF Growth 
Primary mouse embryonic fibroblast (MEFs; DU315) devoid of all endogenous RAS 
protein expression (Hras−/−; Nras−/−; Kraslox/lox; RERTert/ert) were generated and characterized 
previously (200) and were obtained from Dr. Mariano Barbacid (CNIO, Madrid, Spain). In brief, 
DU315 cells were treated with 600 nM 4-hydroxytamoxifen to activate translocation of the 
estrogen receptor-fused Cre to the nucleus for removal of the endogenous (floxed) Kras. Cells 
were arrested in the G1 phase after 9–11 days. Blot analyses were done to verify loss of 
endogenous KRAS protein expression. Cell proliferation resumed after the delivery of 
a KRAS transgene to the cells using lentiviral transduction. Transduced cells were selected using 
blasticidin and expanded to generate cell line pools dependent on expression of the exogenous 
transgene for continuous proliferation. 
Anchorage-dependent Growth Assays 
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To monitor proliferation rates, cells were plated onto a 96-well plate at a density of 2000 
cells/well. After 24, 96, and 168 h, cell proliferation was monitored using the MTT colorimetric 
viability assay, and absorbance was measured at 550 nm to quantify cell number. 
NIH 3T3 Infection 
NIH 3T3 cells were infected with the pBabe-puro retrovirus expression vectors 
containing cDNA sequences encoding human KRAS4B (WT, K104Q, 12V, and 12V/K104Q). 
Post-infection, the cultures were maintained in complete growth medium supplemented with 
puromycin to select for stably infected cells. Samples were collected immediately after 72 h 
post-selection and analyzed for signaling via Western blotting. The drug-resistant cells were 
further passaged and maintained in puromycin-containing growth medium. Light microscopy 
images were collected at 24 h (Nikon Eclipse TS100) post-selection to monitor transformation. 
RAS-GTP Pull-down Assays 
NIH-3T3 cells were infected with retrovirus containing cDNA for KRAS (WT, K104Q, 
12V, 12V/K104Q), followed by selection in puromycin-containing growth medium, to establish 
mass populations of drug-resistant cells. Determination of the steady-state GTP-bound levels of 
each KRAS protein was performed using standard pull-down analyses as described by us 
previously (210). Briefly, drug-resistant mass populations of cells maintained in complete calf 
serum-containing growth medium were collected 72 h post-infection for analyses. The cultures 
were lysed in detergent buffer, and the total cell lysates were then incubated with recombinant 
glutathione S-transferase (GST)-tagged CRAF RBD protein, followed by Protein G-Sepharose 
beads, to isolate the bound KRAS-GTP. After separation by SDS-PAGE, the level of KRAS-
GTP was determined by blot analyses with anti-KRAS antibody. Total FLAG epitope-tagged 




Retrovirus was produced in HEK-293T cells via transfection of pBABE-puro target 
vector and pCL-10A1 packaging vector with calcium chloride. Cells were allowed to produce 
retrovirus for 24 h. Retrovirus was then harvested and placed on target cells in the presence of 2 
μg/ml Polybrene. Cells were incubated with retrovirus for 8 h. Fresh medium was then placed on 
the cells, and antibiotic selection was applied 24 h later (2 μg/ml puromycin). 
Western Blotting 
Cells maintained in complete growth medium were lysed in 1% Nonidet P-40 buffer (50 
mM Tris, 150 mM NaCl, 10 mM MgCl2, 10% glycerol, 1% Nonidet P-40, 0.25% sodium 
deoxycholate, pH 7.4) and resolved using SDS-PAGE analysis. To determine the levels of 
effector signaling, Western blotting analyses were done using phospho-specific antibodies to 
ERK1/2(Thr202/Tyr204) and AKT(Ser473), with antibodies recognizing total ERK1/2 and AKT to 
control for total protein expression (Cell Signaling Technologies). Antibodies for KRAS (OP24, 
EMD Millipore) and anti-HA epitope (16B12, Covance) were used to determine the expression 
levels of endogenous and exogenous KRAS, respectively. An antibody for vinculin (Sigma-













Chapter 5. A Tool for Site-Specific Methyl-Lysine Generation and Selective Enrichment in 
Intact Proteins3 
Introduction 
 Historically, canonical amino acid mutations have been used to study post-translational 
modifications (PTMs) in intact proteins. It is becoming increasingly evident that canonical amino 
acids are not capable of truly mimicking their PTM counterparts (68)–(70). Current strategies to 
generate native post-translationally modified intact proteins are limited. This is especially true 
for methylation. Several methods have been proposed such as chemical ligation reactions and the 
use of unnatural amino acids, but these approaches have exhibited limited success to date (211). 
In a physiologic setting, a methyl group would be transferred from a cofactor, such as S-
adenosyl-L-methionine (SAM), in an SN2 fashion where the ε-amine of the lysine would carry 
out nucleophilic attack on SAM to transfer the methyl group to the recipient (212). This can 
occur multiple times, generating mono-, di- or trimethylated lysine (212). Simon et al. have 
described an approach using an alkylation reaction to install methyl-lysine analogs (MLAs) in 
fully denatured histone tails (213),(214). Unfortunately, the harsh reducing and denaturing 
conditions required in this method are not suitable for some functionally intact, folded proteins.  
 Methylation status is highly regulated in the cellular milieu, and aberrant methylation 
signaling has been identified in several cancers (76),(80). As such, it is a reasonable assumption 
that lysine methyltransferases, KMTs and lysine demethylases, KDMs may be novel therapeutic 
targets (97). However, given the limited methods to generate methylated proteins, this field 
                                                 
3 Mass spectrometry analysis and associated methods were provided by Dr. Laura Herring of the UNC Michael 
Hooker Proteomics Center 
 
 136 
remains largely unstudied. While MLAs are highly similar to native methyl-lysine residues, they 
are incorporated into the protein using a chemically reactive thiol as a linker (213),(214). As 
such, the final product contains a carbon-sulfur bond rather than a native carbon-carbon bond, 
which will differ in bond length and angle (215). It is not well understood if MLAs are capable 
of truly mimicking native lysine methylation. Experimental studies quantifying the ability of 
MLAs to bind to methyl-binding domains from several families have demonstrated varying 
conclusions to this question depending upon several factors such as sequence length, 
modification and binding partner (215). However, as with any non-native modification, caution 
should be used in experimental design and interpretation. There is no experimental evidence 
either in support of or against the use of MLAs in functional, intact proteins. To date MLAs 
represent the most feasible option to study lysine methylation in functional proteins. 
Methylation has been primarily studied in the context of histone regulation; however, it is 
a critical PTM that has been demonstrated to modulate the activity of several non-histone 
proteins (78),(80). Methylation (and acetylation) of the tumor suppressor protein p53 are known 
to modulate protein activity (78),(79). Recently, altered lysine methylation patterns have been 
identified in pancreatic cancer (PDAC) (76),(77). Clinically, PDAC is one of the most 
challenging cancers to therapeutically treat and is one of the deadliest cancers in the U.S. 
annually (123). Pancreatic ductal adenocarcinoma (PDAC) is known to be driven by oncogenic 
KRas proteins, where approximately 98% of PDAC contains activating KRas mutations (5). 
Interestingly, several KMTs have been identified as upregulated in PDAC, and subsequent 
analysis verified that methylation of key players of the Ras/MAPK pathway enhanced Ras-
mediated oncogenic signaling (76),(77). In particular, knockdown of the KMT SMYD3 inhibited 
Ras-mediated tumorigenesis in mouse models of PDAC and lung cancer by inhibiting MAP3K2 
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methylation (77). Despite decades of research, no clinically effective anti-Ras therapeutics have 
been developed (24),(82),(107). Taken together, this may suggest that methylation plays a 
dynamic role in regulating the Ras/MAPK signaling cascade. As such, methylation may 
represent an untapped potential therapeutic target in Ras-driven cancers.  To date, the current 
methods to generate methylated proteins have not been successful with intact, functional Ras 
proteins. Here, we present a method to site-specifically modify intact, functional Ras proteins 
with methyl-lysine analogues to generate a product structurally similar to natively methylated 
proteins. Given that reaction efficiency can vary greatly with the accessibility of the residue to be 
modified, we further provide a method using ‘methyl reader’ proteins and competitive small 
molecules to isolate and enrich for methylated populations of proteins in a variably modified 
sample.     
Site-specific methyl-lysine analogue alkylation reaction 
Immediately following cysteine-mutant KRas protein purification, proteins are prepared for 
methyl-lysine alkylation reactions.  
1. An alkylation buffer (100mM HEPES, 50mM NaCl, 5mM MgCl2, 10 mM DTT, 30 uM 
GDP (pH 7.8)) is chilled and sparged with N2 for 45 minutes while stirring.  
2. Ras proteins are then exchanged into this buffer and concentrated to ~ 1 mg/mL. The pH 
is maintained at 7.8 to mitigate multiple reactivities with methyl-lysine substrates.  
a. To install methyl-lysine analogues at buried sites in intact proteins, the addition of 
250 mM GnHCl can help increase the reaction efficiency.  
3. Once intact proteins are prepared in alkylation buffer, 1000x molar ratio of the 
methylation substrate is added to the reaction mixture.  
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a. Protein should be delicately pipetted up and down to ensure that methylation 
substrates were adequately solubilized.  
b. Mono- and dimethyl substrates are commercially available (2-chloro-N-
methylethanamine hydrochloride and 2-Chloro-N,N-dimethylethylamine 
hydrochloride, respectively).  
c. Mono- and di-methyl-lysine alkylation reactions were conducted at KRas K5C, 
K117C and K147C.  
4. Fresh, 1M DTT was made with the prepared alkylation buffer and added to the reaction at 
5 mM final concentration.  
5. This reaction was allowed to continue for 2 days at 4 C.  
6. Ras proteins were then desalted using PD-10 columns per manufacturer protocol (GE 
Healthcare) to remove excess unreacted methyl-lysine substrate and further purified via 
size exclusion chromatography using a Sephadex G-75 column. 
Methyl-binding domain enrichment of methylated Ras 
 Methylated KRas proteins were further isolated and enriched using the methyl-binding 
domains of L3MBTL1 or L3MBTL3 (malignant brain tumor family of methyl readers, MBT) 
and the cognate small molecule competitive binders UNC-669 or UNC-1215, respectively (The 
University of North Carolina, Chapel Hill Structural Genomics Consortium, Dr. Stephen Frye) 
(216),(217). An on-bead enrichment strategy was used with Ni-NTA agarose beads and His-
tagged methyl binding domain proteins.  
1. Methylated KRas and His-tagged MBT proteins were dialyzed overnight into a buffer 
containing 20 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 10 M GDP (pH 7.4).  
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2. The His-tagged methyl binding domain of either L3MBTL1 or L3MBTL3 (~ 5 mg/mL) 
was added to a nickel column and allowed to incubate on beads while nutating for 30 min 
at 4 C.  
a. A five-fold higher molar ratio of His-MBT was used relative to KRas 
concentration to ensure binding of all alkylated protein and was maintained 
throughout these steps.  
3. The column was then washed with the buffer above to remove any unbound His-MBT.  
4. Alkylated KRas proteins (~ 1 mg/mL) were added to the column and allowed to nutate 
for 1 hour at 4 C to ensure binding to the His-MBT domain.  
5. The column was again washed with 20 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 10 
M GDP (pH 7.4) to remove unbound, non-alkylated Ras protein.  
a. This flow-through and wash step were verified as containing non-alkylated Ras 
protein via intact mass spectrometry.  
6. To release the alkylated Ras protein from the His-MBT protein, the competitive small 
molecules UNC-669 and UNC-1215 were used (216),(217).  
a. Small molecules were added to a methyl elution buffer (20 mM HEPES, 500 mM 
NaCl, 5 mM MgCl2 (pH 7.4)) at 100 uM final concentration (in slight excess of 
the methylated protein).  
7. This solution was added to the column and allowed to nutate for 2 hours at 4 C.  
8. The column was subsequently washed with the same methyl elution buffer with small 
molecules present.  
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a. The flow-through from this incubation and wash was collected, concentrated, 
estimated pure via SDS-PAGE gel and verified via mass spectrometry as enriched 
alkylated Ras protein.  
9. The His-MBT domain protein was further eluted from the beads using a buffer 20mM 
HEPES, 150 mM NaCl, 250mM imidazole, 5mM MgCl2 (pH 7.4). 
Results 
 
Figure 5.1 Ras methylation has been identified at several sites within the core GTPase domain 
Methyl-lysine analogues are installed in Ras proteins at three locations: K5, K117 and K147. Mono- and di-
methyl lysine analogues are installed at exposed and semi-buried sites within the Ras protein. K5, K117 and 
K147 are highly conserved in the Ras superfamily and are the sites of previously identified post-translational 
modifications. While K5 is more solvent exposed, K147 is known to play roles in nucleotide binding and 
stability. K117 mutants have been characterized as ‘fast-exchange’ mutants given the role of K117 in 
stabilizing the nucleotide base. K117 and K147 have been previously identified as sites of monoubiquitination 




Figure 5.2 Methyl-lysine analogues are able to be installed in a site-specific manner in intact Ras protein 
A. The reaction mechanism to generate a dimethyl-lysine analogue in intact protein. A reactive thiol is used to 
link the dimethyl-lysine analogue, generating a product that is structurally very similar to natively di-
methylated lysine. B. LC-MS/MS peptide analysis of trypsin digested KRas K147C protein that has been 
reacted with the di-methyl lysine analogue. MS/MS spectrum of di-methylated peptide SYGIPFIETSACTR 
of KRAS verifies that di-methylation is identified at K147 (CID induced ions are labeled, b ions are labeled in 




Figure 5.3 Dimethyl-lysine reaction optimization at K147 and K117 in intact KRas protein. 
Intact KRas proteins were di-methylated at either K147 (A) or K117 (B). Initial reaction efficiency can be 
seen for each site-specific alkylation. A matrix-like reaction optimization procedure was used varying 
temperature, pH and concentration of GnHCl to generate final reaction methods. Di-methylation at exposed 
sites (K147) yields populations of protein that are fully modified. Alkylation of less exposed sites yields a 







Figure 5.4 A methyl-enrichment strategy for intact methylated proteins 
A methyl-enrichment strategy is presented for subsequent methylated protein isolation. The protein is first 
reacted with the methylated-lysine analogue. If a mixed methylated population is identified via mass 
spectrometry, protein can be further isolated using ‘methyl reader’ proteins. The MBT domains of 
L3MBTL1/3 can be used to selectively bind methylated lysine residues. Methylated protein can be selectively 
eluted with the introduction of small molecule competitive binders UNC669 and UNC1215. 
 
Discussion 
KMTs and KDMs have been identified as potential therapeutic targets in several cancers 
(97). Given that aberrant methylation patterns have been identified in a multitude of cancers 
(76),(97), there is a pressing need to understand how methylation is capable of regulating protein 
activity. While methylation has been primarily studied in the context of histone regulation, there 
is increasing evidence that methylation can also regulate cancer-related proteins. p53 methylation 
(or acetylation) is known to fine-tune its overall activation status in cancers (78),(114). Further, 
the Ras/MAPK pathway has also been implicated in dynamic methylation regulation by the 
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KMT SYMD3. MAP3K2 methylation by SMYD3 was demonstrated to increase MAPK-
mediated signaling and Ras-mediated tumorigenesis in mouse models of PDAC and lung cancer 
(73),(77). Aberrant methylation patterns have also been identified in the Ras-driven pancreatic 
ductal adenocarcinoma (76). Novel methylation sites have also been identified in Ras proteins 
(data not shown). Given the current limitations in the field of understanding how methylation 
regulates the activity of non-histone proteins, we sought to develop a strategy to generate site-
specifically methylated intact proteins. The current strategies to generate methylated intact 
proteins are limited. Unlike acetylation, genetic code expansion techniques to generate 
methylated intact proteins have not been overarchingly successful. This is due in part to the 
inability to develop orthogonal tRNA/amino-acyl tRNA synthetase pairs that recognize 
methylated lysine exclusively (211). As such, genetic code expansion techniques have been used 
most successfully to install precursor molecules, and then methylated lysines are recovered 
through various chemical reactions (211). These methods incorporate UV exposure or acidic 
conditions to generate the final product (218)–(220), rendering them not useful for a multitude of 
intact proteins.  
 In a method similar to Simon et al (213),(214), we used methyl-lysine analogues to 
generate methylated intact proteins that are highly similar to natively methylated proteins. Our 
method is unique in that we present a strategy suitable for use in intact, functional protein. While 
we are in the analysis phase of our research, preliminary results have demonstrated the ability to 
generate mono- and di-methylated intact Ras proteins at three different locations in intact KRas 
protein: K5, K117 and K147. Reactions have been optimized to temperature, pH and 
guanidinium hydrochloride concentration to facilitate the highest reaction efficiency while 
assuring the intact protein remain functional. However, it is important to note that these factors 
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may vary slightly with each protein tested. While altering the temperature and pH increases 
reaction efficiency significantly (data not shown), this is often met with an altered reactivity. The 
primary or secondary amines generated in the final product are susceptible for additional methyl-
lysine linkage if the pH is increased. Increasing temperature also facilitates this process (data not 
shown). As such, these reactions were completed at pH no greater than 7.8 and 4 C.  For 
exposed sites, a reaction time of a few hours completed at 25 C was adequate to generate 
methylated product. However, methylation at sites that were less exposed or more integral to 
protein stability required longer times and lower temperatures. The method presented here 
reflects these sites. Of note, this method uses the reactive thiol of a cysteine to link the methyl-
lysine analogue. Therefore, exposed cysteines would be a concern for reactivity. In this example, 
we have used a cysteine-light version of KRas protein, where the exposed cysteines have been 
mutated to limit alternative reactivity (90). 
One limitation of our method is due to the accessibility of the site to be modified. We saw 
significant differences in the reaction efficiency depending on how ‘exposed’ the residue is and 
how accessible it is to modification. As such, we generated a subsequent enrichment strategy 
harnessing ‘methyl reader’ proteins and competitive small molecules to selectively enrich for 
methylated lysines. As the family of ‘methyl reader’ proteins used in this method bind 
methylated lysines in a relatively promiscuous manner, this method should be highly translatable 
for use with any methylated protein. The ‘methyl reader’ proteins used in this method are from 
the MBT (malignant brain tumor) family, L3MBTL1 and L3MBTL3. They recognize mono- and 
di-methyl lysines in a sequence-independent manner, where the protonated amine of the methyl-
lysine is coordinated in a deep pocket through hydrogen bonding and a cation- interaction (221) 
(also seen in Figure 5.4). The small molecules used in this method, UNC669 and UNC1215 
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(UNC structural genomics consortium) have low micromolar to nanomolar affinities for the 
‘methyl reader’ proteins (216),(217) and are capable of competitively eluting the methylated Ras 
protein from the ‘methyl reader’ protein. We have completed each reaction in replicate so as to 
provide statistical relevance to our data. We also plan to extend the enrichment strategy to 
whole-cell lysates to identify the methylation site(s) in endogenous Ras proteins. In this manner, 
we hope the investigate the role of methylation in regulating Ras protein activity.  
 
Materials and Methods 
Cysteine-light KRas WT and cysteine mutant purification 
A cysteine-light version of human KRas-4B (G12C/C51S/C80L/C118S) (residues 1–169) 
in a pET21 vector with an N-terminal 6-histidine tag and a TEV protease cleavage site was 
provided by the Shokat lab (90). In brief, the exposed cysteines in Ras were mutated to reduce 
sensitivity to oxidants and reactivity to methyl-lysine analogue substrates in this study. This 
construct has been structurally and biochemically characterized as functionally similar to KRas 
wild type protein (90). Standard mutagenesis techniques were used to generate KRas K5C, 
K117C and K147C constructs, and construct sequences were verified. For expression 
in Escherichia coli BL21 (DE3) cells (Novagen), cells were transformed and grown at 37 °C in 
Luria-Bertani (LB) medium until A600 of ∼0.5. At this point the temperature was lowered to 18 
°C, and KRas expression was induced with 0.5 mM isopropyl-β-D-1-thiogalactopyranoside 
(IPTG) after 30 min. Expression was continued for 16 hours. To harvest cells, the growths were 
pelleted at 4000 x g. They were then resuspended in a buffer containing 20 mM HEPES, 300 
mM NaCl, 1 mM MgCl2, 20 mM imidazole, 0.5 mM TCEP (tris(2-carboxyethyl)phosphine 
hydrochloride), 5% glycerol (pH 7.75), sonicated and pelleted again by centrifugation at 15,000 
x g for 25 minutes. The supernatant was isolated and KRas proteins were purified using standard 
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Qiagen nickel affinity purification procedures. Proteins were washed with a buffer containing 20 
mM HEPES, 500 mM NaCl, 5 mM MgCl2, 40 mM imidazole, 0.5 mM TCEP, 5% glycerol (pH 
7.75). Proteins were then eluted in a buffer containing 20 mM HEPES, 50 mM NaCl, 5 
mM MgCl2, 250 mM imidazole, 0.5 mM TCEP (pH 7.75). The histidine tag was cleaved during 
overnight dialysis at 4C in reducing buffer (100 mM HEPES, 50 mM NaCl, 5 mM MgCl2, 0.5 
mM TCEP, 10 M GDP (pH 7.8)) using TEV protease. Proteins were used immediately for 
methyl-lysine analogue reactions to reduce opportunity for cysteine oxidation. Following 
methyl-lysine reactions, Ras proteins were further purified by size exclusion chromatography 
using a Sephadex G-75 column. Protein purity of >95% was obtained and verified by SDS-
PAGE analysis. 
Methyl binding domain purification  
 The methyl binding domains of L3MBTL1 (residues 268-590) and L3MBTL3 (residues 
225-555) (malignant brain tumor family proteins, MBT) were obtained from the Structural 
Genomics Consortium at the University of North Carolina, Chapel Hill courtesy of Dr. Stephen 
Frye. Briefly, the constructs are transformed for expression into Escherichia coli BL21 (DE3) 
cells (Novagen). They are grown at 37 °C in Luria-Bertani (LB) medium until A600 of ∼0.5, at 
which point the temperature is lowered to 18 °C. Cells are induced with 0.5 mM isopropyl-β-D-
1-thiogalactopyranoside (IPTG) after 30 min, and the expression was continued for 16 hours. 
Cells are pelleted at 4000 x g for 30 minutes, resuspended in wash buffer (50 mM sodium 
phosphate, 500 mM NaCl, 30 mM imidazole, cOmplete ULTRA protease inhibitor cocktail 
tablets (Roche) (pH 7.75)) and sonicated. Cells are pelleted at 15000 x g for 25 minutes and the 
supernatant is isolated. Proteins are purified using standard Ni-NTA agarose purification 
procedures (Qiagen). The supernatant is applied to the column and washed with the buffer above. 
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Elution if the protein is achieved through the addition of 500 mM imidazole to the wash buffer. 
Proteins were further purified by size exclusion chromatography using a Superdex 200 column in 
25 mM Tris, 250 mM NaCl, 2 mM DTT, 5% glycerol (pH 7.5). Protein purity of >95% was 
obtained and verified by SDS-PAGE analysis. Proteins are flash frozen with 10% glycerol at 5 
mg/mL. 
Mass Spectrometry 
 All samples were analyzed by nanoLC-MS using a Waters nanoAcquity coupled to a 
Thermo Orbitrap Velos. The samples were injected onto a PepMap C18 (5 um particle size, 5 
cm), trapping column (Thermo) then separated by in-line gradient elution onto a PepMap C18 (3 
um particle size, 15 cm). Samples were eluted over a 10 min gradient from 5-90% mobile phase 
B, where mobile A was H20 in 0.1% formic acid and mobile phase B was ACN in 0.1% formic 
acid. The Orbitrap Velos was operated in full scan mode and the resolution for the precursor scan 
(400-2000 m/z) was set to 100,000 at 400 m/z. Data were processed in Thermo Xcalibur and 

















Chapter 6. Conclusions and Future Directions 
 While our work has largely contributed to the field of understanding how PTMs in the 
core Ras domain can modulate its activity, the questions remain of the exact molecular and 
cellular mechanisms behind these processes. It is clear that PTMs are capable of regulating Ras 
activity (61), and therefore present novel therapeutic opportunities in Ras-driven cancers. In 
particular, acetylation has been previously identified in the core G-domain in Ras proteins at 
K104 and K147 (67)–(69). However, there is some disagreement in the field as to whether 
canonical amino acids are capable of mimicking true PTMs. As such, when canonical amino 
acids were used as acetylation mimetics, much more severe alterations in Ras behavior were seen 
versus when Ras was natively acetylated (67)–(69).  
In collaboration with the Sers lab (Charité Universitätsmedizin Berlin), we were able to 
identify a novel acetylation site in Ras (K5) that was identified in CRC cell lines after treatment 
with the class I HDACi, Entinostat. Their work demonstrated that drug treatment primarily 
served to activate the protein through increased Ras-GTP bound to Raf RBDs in pulldown assays 
and increased signaling through the downstream MAPK pathway. Interestingly, oncogenic Ras 
displayed a much more resistant phenotype, exacerbating the above-mentioned behaviors. In 
vitro, we were able to generate acetylated Ras proteins using a genetic code expansion technique. 
We were able to determine that K5 acetylation played little role in modulating the intrinsic 
ability of Ras proteins to exchange or hydrolyze nucleotides. However, in the presence of the 
modulatory proteins, GEFs and GAPs, small defects were identified. While K5 is not noted to 
make direct contacts with GEFs or GAPs, it does sit very close (~5 Å) to several SOS GEF 
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residues (54),(131), where the closest residues in p120GAP are about 10 Å away (13). It is 
possible that K5 acetylation is slightly affecting the ability of GEFs or GAPs to bind Ras and 
stimulate activity either through disruption of direct contacts or through disruptions in the critical 
switch regions that bind directly to GEFs and GAPs. We are also able to demonstrate that K5 
acetylated oncogenic proteins (G12V) are able to restore the weakened affinity of G12V to the 
Raf RBDs, consistent with the increased signaling through the MAPK pathway identified by the 
Sers lab. To gain structural insight into how K5 is capable of regulating Ras activity, we 
conducted united atom molecular dynamic (MD) simulations of Ras in complex with the Raf 
RBD. In collaboration with Dr. Konstantin Popov at UNC, we were able to see that in complex 
with the Raf RBDs, acetylated K5 causes a significant rearrangement of the critical electrostatic 
binding interface between Ras and the Raf RBD. In this manner, it facilitates a much more 
interconnected network, which explains the tighter binding affinity observed to the Raf RBDs. 
One huge enigma that remains in the field is why Ras oncogenic mutants display decreased 
affinities to the Raf RBDs yet significantly increase MAPK signaling relative to WT protein. In 
this sense, a much more thorough cellular, structural and dynamic evaluation should be 
completed to try to understand how oncogenic mutants function to increase Ras activity. Our 
work focused on the class I HDACi, Entinostat. In the future, this evaluation should be extended 
to include selective class I or class II and pan-class HDACi to identify if a similar mechanism of 
Ras regulation exists. There are several studies that demonstrate that combination therapies with 
MEKi+HDACi or MEKi+PI3Ki+HDACi yield increased oncogenic cellular apoptosis, decreased 
proliferation and slowed tumor formation (101),(102). HDACi could serve as novel therapeutic 
drugs in Ras-driven cancers, and as such, combination therapeutic studies should be extensively 
evaluated. Further work should also include understanding the underlying mechanism of cell 
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cycle arrest facilitated by Entinostat and how increased MAPK signaling is capable of driving or 
mitigating this process. In this manner, we may then understand better how combination 
therapies increase drug sensitivity in cells and xenograft models. 
While K5 was identified as a novel acetylation site, it is also mutated in several ‘Ras-
opathies’ and cancers. ‘Ras-opathies’ are often characterized by their ability to activate Ras as 
seen through increased, dysregulated MAPK signaling (128),(170),(171). However, previous 
studies of the Noonan’s syndrome KRas germline mutant, K5N were not able to determine the 
mechanism leading to dysregulated MAPK signaling. Cellular studies indicated a mild, at best, 
increase in MAPK signaling while no other changes were noted in the biochemical function of 
the protein. Interestingly, they did briefly describe a potential structural role for Ras activation 
due to K5N mutation (128). In this study, I was able to determine that K5N mutation likely 
destabilizes the protein more predominately in the GDP-bound form. We were able to identify 
only small changes in the ability of the protein to exchange nucleotide in the presence of a GEF 
and in the ability of the protein to load nucleotides, primarily in the GDP-bound form. However, 
NMR and computational analysis demonstrated significant alterations in the GDP-bound form of 
the K5N mutant. 1H-15N NMR HSQCs identified significant chemical shift perturbations in the 
GDP-bound form of the protein, relative to WT. These mapped entirely to the effector lobe of the 
protein and the critical switch regions. In the active form, the K5N mutant displayed a much 
more similar NMR mapping to WT protein. MD simulations indicated that the K5N mutation 
likely disrupts the protein in the GDP-bound form primarily through causing a very 
electrostatically unfavorable packing network around the mutation. In dynamic evaluations of 
K5N, the MD simulations showed a dramatic increase in the fluctuations of SWII in the GDP-
bound form, while the GTP-bound form is highly similar between the Ras proteins. Taken 
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together these data support the previously mentioned structural role for K5N instability in the 
GDP-bound form, primarily through an indirect role in disrupting nucleotide binding. Of note, 
we are not able to identify any differences in the ability if the K5N mutant to bind the Raf RBDs, 
which is a hallmark of ‘Ras-opathies’ (178). This suggests that there is likely a defect in the 
protein due to K5N mutation that does not affect effector binding. If K5N mutation causes 
instability in the GDP-bound form, it is possible that this mutant would be more GTP-bound in 
the cell. By altering steady-state GTP levels in cells, the K5N mutant could potentiate signaling 
in Ras-mediated cascades such as the MAPK cascade. What is left unanswered is exactly how 
K5 regulates Ras activity. It is highly conserved, yet it is not noted to play critical roles in 
nucleotide binding or effector/modulatory protein binding or recognition. It is only by 
understanding this that we will be able to gain insight into how the K5N mutant alters protein 
behavior. Consistent with literature, K5 does seem to play an indirect role in coordinating and 
stabilizing nucleotide binding (128). More extensive structural and dynamic studies will be 
needed to understand how mutation disruptes these processes. 
 As previously mentioned, acetylation has been identified in several sites in the Ras core 
G-domain at K104 and K147 (67)–(69). In this study, we sought to determine the effect of 
acetylation at K104 in regulating protein activity. We were able to demonstrate that K104 is 
important for GEF recognition, as any mutation at this position resulted in impaired GEF-
mediated nucleotide exchange. Using the acetylation mimetic, glutamine, Q we found that the 
K104Q displayed both GEF and GAP defects. This was consistent with NMR structural 
perturbations that were identified in α2 helix in Ras, which is a critical interface for GEFs and 
GAPs (13),(54). In cells, KRas K104Q mutation was not able of altering steady state GTP-levels 
in RBD pulldown assays, nor was K104Q able to cause cellular transformation in NIH 3T3 cells 
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or efficiently rescue cells. We concluded that the GEF and GAP defects displayed in K104Q 
likely balanced one another, which overall did not change Ras activity. What remains unclear is 
whether glutamine is an adequate acetylation mimetic. When we used natively acetylated protein 
and again investigated the GEF activity, a much less severe defect was identified. It is becoming 
evident that canonical amino acids are not suitable mimetics of PTMs and as such, further studies 
should include natively acetylated Ras proteins. 
 Work in my lab and others has also identified novel methylation sites in the Ras core 
domain (unpublished). However, dissimilar to acetylation, there are no reliable methods to 
produce fully methylated, intact proteins in vitro (211). A previous method to methylate histone 
tails has been described by Simon and Shokat (214), but is not suitable for intact proteins due to 
the severe denaturing and reducing conditions needed. In this work, I have generated a novel 
method to methylate intact proteins in a site-specific manner using methyl-lysine analogues. The 
method involves the use of a reactive thiol to link the methyl lysine analogue to generate a 
product with high structural similarity to natively methylated protein. Additionally, as residue 
reactivity is highly dependent upon the accessibility of the site, I generated a subsequent method 
for methylation enrichment. This method involves the use of methyl binding domains, which 
bind the methylated intact protein. Subsequent exposure to competitive small molecules of the 
‘methyl reader’ protein can cause the ‘release’ and of methylated protein. I will also be using this 
tool to probe whole-cell lysates to see if I can ‘capture’ methylated Ras proteins in order to 
identify physiological sites of methylation. Several Ras-driven cancers such as pancreatic cancer 
have dramatically altered methylation patterns (76). With methyltransferase inhibitors on the 
market for the treatment of several cancers (104),(222),(223), understanding how methylation 




 Herein, we have discussed the importance of G-domain PTMs in modulating Ras activity. 
Our data adds to a growing body of literature suggesting that Ras GTPases are particularly 
sensitive to modulation by PTMs and these may provide novel Ras therapeutic targeting 
opportunities. With HDACi and methyltransferase inhibitors currently on the market for the 
treatment of several cancers (97),(104),(106),(115),(222),(223), it is reasonable to believe that 
these drugs may be applicable in Ras-driven cancers as well. In order to answer these questions, 
more thorough mechanistic insight is needed into how acetylation (HDACi) and methylation 
(methyltransferase inhibitors) modulate Ras activity. As such, future work should include 
detailed in vivo an in vitro work aiming to characterize the mechanisms behind acetylation and 
methylation regulation of Ras activity. We would further suggest cell-based drug screens with 
combination therapy approaches, as stronger anti-tumorigenic properties have been described in 
the contact of HDACi treatment when combined with MEK and PI3K inhibitors (101),(102). 
This could then be extended to organoid and mouse models. Interestingly, upon Entinostat 
treatment (class I HDACi), only K5 was identified as being acetylated (Chapter 2). This suggests 
that K5 may be the physiologic site of acetylation. While it is highly conserved in the Ras 
superfamily, the role of K5 is modulating Ras activity is not well understood. In addition, the 
role of K5 mutations found in cancers and ‘Ras-opathies’ should be more thoroughly 
characterized in cellular and structural experiments as they may also provide novel mechanisms 
of activation and hence novel therapeutic targeting opportunities (Chapter 3). The role of 
methylation is largely unknown in Ras proteins. Using the methylation and enrichment strategy 
developed, it may be possible for the first time to provide insight in how methylation regulates 
Ras activity (Chapter 5). As pancreatic cancer has displayed aberrantly dysregulated methylation 
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patterns (76), and it is nearly 100% driven by oncogenic Ras (5), it is possible that 
methyltransferase inhibitors may also be successful in Ras-driven cancers. Future work should 
therefore include the biochemical and biophysical characterization of methylated Ras proteins 
(mono- and di-methyl at the 3 sites described in Chapter 5. As the physiologic sites of 
methylation in Ras remain unknown, the methylation enrichment strategy described in Chapter 5 
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